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ABSTRACT
The progression from normal to neoplastic cells takes place over an undefined period 
under the combined influence of several factors, including genetic susceptibility. The MHC 
system (HLA in humans) is composed of genes that control a variety of immune functions and 
influence the susceptibility for more than 40 diseases, including cancer. This study was to 
investigate the relationship among cytokine related genetic loci on chromosome 6 that might 
be involved in Barrett’s oesophagus and in gastric cancer that involves a major “environmental 
factor” Helicobacter Pylori infection. The genetic loci investigated were the HLA-DQB1 
locus, the HSP-70-2 locus and D6S273 marker and compared with TNFa 1-14 microsatellites, 
on chromosome 6, in region 2, band 1, sub-band 3. The subjects taking part in this 
investigation were patients with Barrett’s oesophagus, patients with gastric cancer and a 
cancer free population, all originated from the West of Scotland. The protocols used were PCR 
based and radioactive PCR microsatellite analysis, performed in order to refine the genetic 
contribution of the three loci that were investigated, in gastric cancer and in Barrett’s 
oesophagus conditions and to fine map the relationship of the TNF locus with adjacent genetic 
loci that span from the HLA class-II region to HLA-B locus.
The results obtained suggest that there is a significant difference in genotype and 
allelotype distribution in certain loci. Significant associations were discovered in the DQpi 
locus for the DQ 3 serotype (gastric cancer Vs controls; P = 0.0421), in the HSP 70-2 locus 
genotype 1 * 2 (malignant Barrett’s Vs controls; P = 0.0194), in the D6S273 locus genotype 
132-134 (malignant Barrett’s Vs controls; P = 0.0337) and the allelotype (serotype) DQ 6 
(total Barrett’s population Vs controls; P= 0.0252). Also there are significant differences in 
allelotype distribution among certain loci where significant association was discovered 
between the DQpl locus and the HSP 70-2 locus (DQ 2 - HSP (936bp) alleles in gastric 
population Vs controls; P= 0.0487). Additionally, there is not a defined difference in 
genotype-allelotype distribution and no significant association was discovered among the three 
loci tested compared with the TNFa 1-14 microsatellites.
Our study leads to the conclusion that the HLA-DQpi, HSP-70-2 and D6S273 loci are 
associated with gastric cancer and Barrett’s oesophagus and that the HLA-DQpl and the HSP- 
70-2 loci are in linkage with each other for the genotype (DQ 2 - HSP (936bp). In addition 
none of the three loci tested are in close linkage with the TNF locus.
Encouraging results were obtained, and there could be a possibility that new 
immunogenetic therapeutic procedures for Barrett’s oesophagus and gastric cancer could be 
based on these specific immunogenetic targets (i.e. HLA-DQpi, HSP-70-2, and D6S273), 
their protein products and relative cytokines.
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INTRODUCTION
INTRODUCTION
1. CHARACTERISATION OF CANCER
Cells within our bodies have the ability to adapt in response to environmental 
changes. This is accomplished by altering their growth mechanism or their metabolism. A 
key feature of such alterations is that if the stimulus is removed, cells revert to their normal 
growth, function or metabolic activity. There are certain environmental stimuli that can 
cause drastic alterations to the genetic material of a cell, such as chemical substances or 
UV radiation that may result in permanent modification to cellular growth. This process is 
known as metaplasia. There are also many factors that may influence such modifications 
although a person’s “lifestyle” could be one of the main influences (such as food, drink or 
tobacco consumption for example). If these stimuli are combined, uncontrolled division 
and cell invasion occurs, which is otherwise known as neoplasia. They proliferate 
excessively forming a lump or a tissue mass known as a neoplasm. A mass of neoplastic 
cells is commonly known as tumour, derived from the Latin “tumere” meaning to swell.
Despite all these generalisations, cancer is now known to be a multifactorial 
disease. The term “lifestyle” accommodates numerous factors that are known to be 
associated with susceptibility to the disease such as diet, smoking and exposure to synthetic 
and natural agents. Diseases that are derived from viruses, bacteria, mutations in 
suppressor genes and oncogenes are known also to play a crucial role in the development 
of cancer. Thus, an acceptable definition of cancer would be: a set of diseases, 
characterised by unregulated cell growth leading to invasion of surrounding tissues and 
metastasising to other parts of the body (Stevens & Lowe, 1995; King, 1996).
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CLASSIFICATION OF NEOPLASMS
There are two main types of neoplastic growth. A tumour that is well defined and 
grows only locally is termed benign. In contrast, when the neoplastic cells are growing into 
and destroying the surrounding tissues the neoplasm is termed malignant. The main 
difference between benign and malignant tumours is that the malignant tumours are 
invasive and metastasising. Benign tumours have a much better prognosis than malignant. 
They normally grow very slowly, remain localised and do not show a highly abnormal 
deregulation. The main feature of such tumours is that they cause compression of adjacent 
tissues. Such abnormal growth and lack of full differentiation of benign neoplastic cells 
reflects the abnormal function and morphology of tissues or organs. Malignant neoplastic 
cells represent variable degrees of differentiation. When tumour cells present only a small 
resemblance to the original tissue, then the neoplasm is termed “a poorly-differentiated” 
malignant neoplasm. In the case of complete failure of differentiation, where it is not 
possible to identify the precursor cell, then the growth is termed “anaplastic” malignant 
neoplasm. Finally when the tumour cells resemble the original tissue then the tumour is 
termed “a well-differentiated” malignant neoplasm. Generally, poorly differentiated 
neoplasms tend to be more aggressive than well differentiated. Morphological variations 
such as size and shape of cells or nucleus are commonly seen in both types of neoplasms. 
This is known as atypical cytology (Stevens & Lowe, 1995; King, 1996).
INVASION AND METASTASIS
Invasion and metastasis are key features of malignant neoplasms. It is an inefficient
process as most cells are destroyed in transportation to other parts of the body but efficient
in the sense that most human cancers metastasise successfully. The control of cell growth
in primary tumours becomes so abnormal that cells grow into adjacent tissues, a process
known as invasion. Metastasis is the escape of cancer cells from primary sites and their
localisation at secondary sites. Metastasising cells continue to grow abnormally
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constructing a new tumour at the new site, known as a secondary tumour. Treatment of 
such malignant metaplastic conditions is very difficult due to the fact that systemic 
eradication is required. Metastasis requires a disruption of local cell -  cell interactions, 
invasion, and penetration into blood or lymphatic vessels, escape from these vessels, 
migration and growth. The organ that the transporting vessels first pass through is usually 
the first organ in which the metastases occur. Adhesion molecules, endothelial function 
and extra cellular matrix composition all contribute to metastatic process. Individual 
metastasis can be of clonal origin. Invasion and migration requires proteolytic enzymes and 
polypeptide mobility factors. Arrest of cancer cells within vessels is possible as a result of 
passive entrapment from lymphocytes, platelets and endothelial cells. Growth of 
metaplastic tumours and primary tumours require the development of blood vessels this 
process is known as angiogenesis. Angiogenesis requires angiogenic factors, the most 
characteristic of which is heparin binding fibroblast growth factors (Stevens & Lowe,
1995; King, 1996).
CANCER AND GENE CHARACTERIZATION
Most of the fundamental ideas on causes of cancer were originated around the turn
of last century. The distinguished British surgeon Percival Potts, 200 years ago identified
the first occupational cause of cancer, among chimney sweeps due to their exposure to
soot. Thus, the first type of cancer described to a specific cause was cancer of the scrotum.
Later other causes were described such as abnormalities of differentiation, viruses, defects
of the immune system, chromosomal abnormalities, such as that of the tpr-met (Soman et
al., 1991) gene translocation in gastric cancer. All these causes of cancer can now be
combined into one main concept that cancer arises from a series of changes in the
expression of genes. Today, evidence suggests that specific genetic changes occur in cancer
cells from a clonal origin. Such evidence originated from studies on X-linked genes in
females showing that only genes from X-chromosome were expressed in a tumour
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(Bodmer, 1994). However mutations can occur not only at the stem cell level but also at 
the somatic cell level. Each mutation that occurs at the somatic cell level is an independent 
evolutionary process, making each tumour distinct. Because many other mutations may 
occur within a developing tumour, each one has a potential selective advantage for 
inheritance (Bodmer, 1994). Many studies until now have given clear-cut evidence of 
specific mutations and translocations in genes leading to cancer. The work of Varmus and 
Bishop initially and others at a later stage showed that the transforming ability was 
determined by genes homologous to normal nuclear genes. Such work has led to the 
discovery of dominant oncogenes (Bodmer, 1994).
There are two categories of genes and the proteins they encode describe the 
functional features that drive carcinogenesis at molecular level. These are, oncogenes and 
suppressor genes. Oncogenes are normal, regulatory genes whose activity is increased as a 
consequence of genetic alterations. Oncogenes can be activated by mutations e.g. in a 
coding sequence (a codon) that generates an altered product. Alternatively chromosomal 
rearrangement can result in increased production of a normal protein or fusion protein 
altering its biological activity. An example of such chromosomal rearrangements specific 
for a disease is the formation of the tpr-met oncogene in gastric cancer (Sasajima et ah, 
1979, Soman et al., 1991; Liang et al., 1996). In 1984 Cooper et al., detected a new 
oncogene in a human osteosarcoma cell line (MNNG-HOS). This oncogene has been 
shown to result from a rearrangement between the 5’ part of the tpr gene located on 
chromosome 1 and the 3’ region of a gene located on chromosome 7, the c-met proto­
oncogene. This new oncogene has been denominated as the tpr-met oncogene. The most 
characteristic feature of the tpr-met gene is its ability to activate through rearrangement, 
proto-oncogenes from the TK (tyrosine kinase) receptor family. The c-met proto­
oncogene, codes for the hepatocyte growth factor- scatter factor (HGF-SF), transmembrane 
TK receptor. HGS-SF is a multifactorial cytokine, which when binding to its receptor on 
epithelial and endothelial cells induces TK transduction pathways, which affects cell
motility, cell proliferation, morphogenesis, tissue invasion and angiogenesis (Wicker et al, 
1995). The oncogenic tpr-met RNA is 5.0Kb hybrid transcript encoding a 65 KDa fusion 
protein. The Tpr-met hybrid protein has tyrosine kinase activity and is constantly 
phosphorylated. It has been shown by Kamikura et al., 1995 that the most highly 
phosphorylated tyrosine residue is the (Y489) in the carboxy terminus of the tpr-met 
oncoprotein and that this residue is essential for biological activity of the tpr-met 
oncoprotein. Other residues are involved but not to the same degree. The potential tyrosine 
phosphorylated sites contained in the met receptor which is a 190kD heterodimer 
consisting of a 45kDa extracellular a  subunit and a 140kDa P subunit that spans the 
membrane. The tpr domain contains a leucine zipper that mediates dimerization and 
activation of the Met receptor tyrosine kinase, following ligation with HGF-SF, leading to 
activation of oncogenes (Kamikura et al, 1995). The tpr-met oncogene has been reported 
to be involved in tumourogenesis. Liang et al, demonstrated that the expresion of tpr-met 
leads to the development of mammary tumours in transgenic mice and suggested that tpr- 
met expresion may be involved in the development of human tumours. Indeed in 1991 
Soman et al, observed amplification and over-expression of the c-met gene in human 
gastric cell line GLT-16, suggesting a possible role of met oncogene in gastric 
tumourogenesis. The tpr -met RNA expresion was frequently found in gastric carcinoma 
and in pre-neoplastic tissues.
Helicobacter pylori infection it has been established as a possible factor for
development of gastric cancer. Correlation of tpr-met and Helicobacter pylori infection has
not yet been established. In different cases of gastric cancer studied by Soman et al,
including superficial gastritis (SG) and carcinoma (CA), tissues showed elevated
expression of tpr-met RNA but an absence of Helicobacter pylori. In other cases studied,
the Helicobacter pylori infection was present but an absence of tpr-met rearrangement (Fox
et al., 1989; Correa et aL, 1989). It is believed that tpr-met gene is expressed in early
stages of gastric cancer in superficial gastritis where one of the early morphological
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changes observed is inflammation, followed by atrophy or gland loss and involving 
regenerative hyperplasia (Fox et al., 1989; Correa et al., 1989, Soman et al., 1991). Thus, 
tpr-met may be expressed in early stages as a consequence of inflammation where tpr-met 
RNA expression continues through the later stages including chronic atrophic gastritis 
(CAG), intestinal metaplasia and carcinoma. However, in a Japanese study examination of 
tpr-met RNA expresion by RT-nested PCR in similar cell lines demonstrated lack of 
rearranged tpr-met mRNA (Osaki, 1996). Therefore the issue of tpr-met and gastric cancer 
is still controversial. Other studies have reported similar rearrangements leading to the 
activation of BCR-ABL in the Philadelphia chromosome translocation in CML 
(Haisterkamp et al., 1986) and the TRK gene (Martin et al, 1986). The function of many 
metabolic pathways may be affected as a result of oncogene activation. These include 
membrane receptors, signal transduction, and apoptosis and gene transcription. Some other 
examples of oncogenes are the ras, erb-B2, and myc genes, but there are many others.
The other types of genes involved in carcinogenesis are the suppressor genes.
Suppressor genes encode for inhibitory proteins whose function is lost in cancers. Both
genes copies must usually be lost in a diploid cell before an effect is to take place. This
type of suppressor is recessive. Examples of known suppressor genes are the Bcl-2 and the
rb genes. An exception to this rule is the p53 suppressor gene in that mutation in one allele
generates an abnormal p53 protein that inactivates the normal product of the other allele.
This type of mutation is defined as dominant negative. Suppressor proteins may be
inactivated by binding to other proteins or by phosporylation or mutation. RNA viruses
carry an oncogene coding for proteins responsible for causing cancers. Carcinogenic RNA
viruses such as (HIV) influence the host genes by insertional mutagenesis. Carcinogenic
DNA viruses such as (EBV) carry suppressor genes that code for suppressor binding
proteins (i.e. LMP1) that bind to host proteins (Rugge & Genta, 1999). Cell proliferation
and death pathways can be affected by suppressor genes, which lead to uncontrollable
proliferation and formation of tumours (Steel, 1994). Oncogenes and suppressor genes co-
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operate in the genesis of cancers but the exact contribution of each of the known 
susceptibility genes to cancer is unclear. However it seems that the high risk genes in some 
common cancers have been identified. Examples are hMSH2 and hMSHl genes in colon 
cancer and in endometrial cancer (Easton, 1994; Stanbridge, 1990).
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2. ANATOMICAL ASPECTS
ANATOMY OF THE OESOPHAGUS
The oesophagus can be found between the pharynx and the stomach. It is 
approximately 25 cm long and lies just behind the trachea. The oesophagus ends at the 
stomach passing through an opening in the diaphragm. This is known as the oesophageal 
hiatus. The main function of the oesophagus is to transport food from the pharynx to the 
stomach. The oesophageal wall is thick consisting of four layers mucosa, submucosa, 
muscularis and adventitia, common to the digestive tract (Fig 1). Like most parts of the 
digestive tract, the oesophageal muscle has an outer longitudinal layer and an inner circular 
layer but it differs from the other parts of the digestive tract in that it consists of skeletal 
muscle in the superior portion and smooth muscle in the inferior portion of the oesophagus. 
The regulation of movement of material into and out of the oesophagus involves 
coordination by the upper oesophageal sphincter and lower oesophageal sphincter. The 
mucosal lining of the oesophagus is made up of moist, stratified, non-keratinising 
squamous epithelium, and numerous mucus glands produce thick lubricating mucus.
HISTOLOGY OF THE OESOPHAGUS 
Mucosa
The mucosa is the inner most layer that consists of three layers.
• The mucous epithelium, which is moist, non-keratinising, stratified squamus 
epithelium
• The lamina propria, a loose connective tissue
• The muscularis mucosa, a thin smooth muscle layer
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Submucosa
The submucosa is a thick connective tissue layer that contains nerves, blood vessels 
and small glands. It lies beneath the mucosa. The submucosal plexus is formed from the 
nerves of the submucosa.
The muscularis
The muscularis is the third layer that consists of an inner layer of circular smooth 
muscle and an outer layer of longitudinal smooth muscle except in the upper oesophagus 
where the muscles are striated and in the stomach where there are three layers of smooth 
muscle. A nerve plexus known as the myenteric plexus, consisting of nerve fibres, and 
parasympathetic cell bodies, lies between the two layers. The submucosal and myenteric 
plexuses comprise the intramural plexus that is extremely important in the control of 
movement and secretion.
Serosa or adventitia
Serosa or adventitia is the fourth layer consisting of connective tissue. The term 
Serosa applies when a portion of the digestive truck protrudes into the peritoneal cavity, 
whereas the layer is called “adventitia” if the outer layer of the digestive tract is derived 
from adjacent connective tissue. Adventitia is present in the oesophagus and the 
retroperitonial organs. The key feature is that the oesophagus lacks a serosal covering 
(Seeley et al., 1992; Sherwood, 1993).
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Fig. 1. The layers of the digestive tract wall.
The digestive tract wall consists of four tunics, the mucosa, submucosa, muscularis 
and serosa or adventitia (Sherwood, 1993).
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ANATOMY OF THE STOMACH
The lower part of the oesophagus, which opens into the stomach, is known as the 
gastro-oesophageal junction opening (Fig 2). The region of the stomach below the gastro- 
oesophageal junction is known as the cardia. The portion of the stomach left and superior 
to the cardia is known as the “fimdus” whereas the largest portion of the stomach is the 
“body”. The body turns to the right forming a greater curvature and a lesser curvature. The 
lower part of the body narrows to form the antrum, which is leads to the pylorus. The 
“pyloric opening” is the opening between the stomach and the duodenum, and is 
surrounded by a thick ring of the smooth muscle known as the pyloric sphincter.
HISTOLOGY OF THE STOMACH
Unlike the oesophagus the outer layer of the stomach is the serosa. It consists of an 
inner layer of connective tissue and an outer layer of mesothelium. The muscularis propria 
of the stomach consists of three sub-layers: an outer longitudinal followed by a middle 
circular layer and an inner oblique layer. The mucosa and submucosa form folds known as 
“rugae”, when the stomach is empty. Rugae are elastic allowing the mucosa and 
submucosa to stretch when the stomach is filled. Columnar epithelium lines the stomach 
where the mucosal surface forms tube-like pits. Gastric pits form the opening where the 
gastric glands lie. Five groups of the epithelial cells exist:
• The surface mucus cells that produce mucus, located on the surface of the lines and
gastric pits. The remaining four are the glands.
• The mucus neck cells that produce mucus,
• The parietal cells that produce hydrochloric acid and the intrinsic factor,
• The chief (zymogenic) cells that produce pepsinogen,
• The endocrine cells that produce regulatory hormones (Seeley et al., 1992;
Sherwood, 1993).
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Fig. 2. Diagrammatic representation of the stomach anatomy.
A: The muscular layers and the internal anatomy are revealed.
B: This is a section of the stomach wall that illustrates its histology, including 
several gastric pits and glands (Seeley et al., 1992).
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3. BARRETT’S OESOPHAGUS
The first description of Barrett’s oesophagus was from Norman Barrett in 1950 
(Barrett, 1950). Ulcers in the distal part of the oesophagus lined by columnar epithelium 
were observed. It was believed that the ulcerated columnar lined tissue was a kind of 
tubular segment of the upper-stomach, a characteristic of patients with congenitally short 
squamous lined oesophagus. It was not until 1953 that Allison and Johnston reported the 
confirmation that columnar epithelium lines the distal oesophagus and suggested that 
Gastro-Oesophageal Reflux Disease (GORD) was involved in the pathogenesis 
(Navaratnam & Winslet, 1998). Since 1970 the incidence of adenocarcinoma of the 
oesophagus has increased in western countries at a vigorous rate (Bytzer et ah, 1999; Blot 
et al., 1991). Barrett’s oesophagus represents the replacement of >3 cm squamous 
epithelium of the distal tubular oesophagus by metaplastic columnar epithelium. Three 
types of columnar epithelium are known:
a) Specialised columnar epithelium that exhibits a villiform surface, mucus glands and 
intestinal type goblet cells.
b) An atrophic gastric fundic type of epithelium involving chief and parietal cells.
c) A junctional type epithelium similar to that of the gastric cardia.
In theory, the junction between the squamous epithelium and the columnar 
epithelium is located at the anatomic junction of the oesophagus and stomach. The exact 
location of the end of the oesophagus and stomach cannot be identified precisely therefore 
the proximal margins of the gastric mucosal folds are used as an indication for the 
oesophagus gastric junction. In almost 100% of the cases the columnar Barrett’s mucosa 
consists of specialised epithelium with incomplete intestinal metaplasia. It has been 
observed that columnar epithelium with intestinal metaplasia will predispose to 
adenocarcinoma (Hameeteman et al., 1989). The origin of such change is not precise.
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AETIOLOGY & PATHOPHYSIOLOGY OF BARRETT*S OESOPHAGUS
The main aetiological factor is GORD. The lower oesophageal sphincter relaxes 
abnormally due to dysfunction, causing reflux of gastric acid (Gastro-Oesophageal Reflux). 
Other contributory factors in Barrett’s oesophagus could be the presence of a hiatus hernia 
or ulcerations or the oesophageal epithelium’s ability to resist refluxate. A long period of 
exposure to gastric acid reflux or to bile induces abnormal changes to the epithelium lining 
of the oesophagus. However, not all patients with GORD develop Barrett’s oesophagus and 
exhibit complications that leading to adenocarcinoma (Navaratnam et al., 1998). The 
sequential progression of change is from normal stratified squamous epithelium, to 
metaplastic columnar epithelium, then to dysplasia, which leads to carcinoma in situ and 
eventually invasive carcinomas, although this process is not solely due to GORD. 
Environmental risk factors such as smoking and ageing have been identified to a play role 
in the development of the disease (Van den Boogert et al., 1998).
However, free radical generation such as super oxide anions, hydrogen peroxide and 
hydroxyl radicals is now known to play a role in the development of such cancers 
(Navaratnam et al., 1998).
MOLECULAR ASPECTS OF BARRETT’S OESOPHAGUS
Multiple genetic alterations affect both cellular and proto-oncogenes and tumour
suppressor genes, during the sequential development and progression of Barrett’s
oesophagus. Different histological forms of oesophageal carcinomas suggest that a
spectrum of genetic alterations are involved in different tumour types. The abnormalities
that result in the p53 gene are the most frequently occurring. p53 is located on
chromosome 17. Inactivation through mutation or allelic deletion, contributes to the onset
of tumours. The p53 protein is closely linked with tumourogenesis. Loss of heterozygosity
(LOH) that occurs in tumour types, and following mutations in the gene, produces an
aberrant protein that inhibits the activity of the normal allele. In 50% of oesophageal
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cancers, the p53 gene is abnormal (Meltzer et al., 1991), and point mutations are involved. 
The missence type mutation is the most common found in oesophageal cancer although 
nonsense mutations have been described (Huang et al., 1993; Imazeki et al., 1992). 
Mutations on p53 that are associated with the oesophagus can be caused by genotoxic 
factors such as aflatoxin B l, benzopyrene, nitrosamines and infection by human papiloma 
virus (HPV) of the oesophagus. In Barrett’s oesophagus the frequency of p53 mutation 
increases with the grade of dysplasia (Blount et al., 1991). Suppressor p53 mutations in 
Barrett’s oesophagus have a clonal origin. An early p53 mutation could result in functional 
loss of other tumour suppressor genes such as the rb gene, the MCC gene and the APC 
gene, found mutated in colon cancer (Younes et al., 1993). Allelic deletions involving 
tumour suppressor genes are important in formation and progression of oesophageal 
cancers. Oncogenes and growth factors are now known to be involved in Barrett’s 
oesophagus development. Oncogenes encode for growth factors (GF), their receptors and 
other molecules involved in the signal transduction system mediated by a tyrosine kinase 
pathway. An abnormality in oncogene expression leads to over expression of GF and their 
receptors, contributing to abnormal cell proliferation and cancer (Gousting et al., 1986). 
Oncogenes and GFs are also involved in angiogenesis. Angiogenesis is a process of blood 
vessel development, important for tumour growth. There is a correlation between EGFR 
and the degree of dysplasia. The TGFa that is a homologue protein of the EGF and the EGF 
ligands of the EGFR tumour cells have been reported over expressed in Barrett’s 
oesophagus (Al-Kasspooles et al., 1993) and in adenocarcinomas (Filipe et al., 1993). Al- 
Kasspooles et al., has also reported that EGFR is co-amplified with erbB2 proto-oncogene. 
The erbB2 proto-oncogene encodes for a transmembrane tyrosine kinase receptor highly 
homologous with EGFR, which probably explains the co-amplification. TGFa has been 
found to play a role in the development of adenocarcinoma of the oesophagus. An increase 
in TGFa and EGFR expression occurs through the progression of non-metaplastic
epithelium, to dysplastic and finally the development of carcinomas (Filipe et al., 1993).
15
Such studies indicate the wide spectrum of genes involved and the complexity of the 
oesophageal carcinomas. Other oncogenes such as the H-ras are also known to be involved 
in Barrett’s dysplastic mucosa, and adenocarcinoma, but are not found in nondysplastic 
Barrett’s metaplasia (Abdelatif et al, 1991).
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4. GASTRIC CANCER
Gastric cancer is a major world problem, despite advances in early diagnosis and 
treatment. Since 1930 there has been a significant decline in its incidence but it still 
remains the second most frequent cancer but not in UK (Correa & Chen, 1994). The 
events involved in transformation of gastric mucosa and progression are poorly understood. 
Epidemiological studies have identified many factors possibly related to the development 
of gastric cancer. Factors that may be related are Helicobacter pylori infection, diet, 
insufficient intake of vitamins A, C, E and flavinoids, environmental toxins, geographic 
location, tobacco, alcohol, Ebsten-Barr Virus (EBV) infection, atrophic gastritis, intestinal 
mataplasia, presence of post surgical gastric remnant and genetic predisposition. Gastric 
carcinoma is divided into two general clinicopathological patterns (Lauren, 1965).
a) Intestinal type, or well differentiated carcinoma
b) Diffuse or poorly differentiated carcinoma
Over 95% of the gastric cancers are adenocarcinomas derived from the epithelium
of the stomach. The intestinal-type lesions follow a progressive sequence of steps from
chronic gastritis to gastric atrophy, then to intestinal metaplasia, progressing to dysplasia,
then to early carcinoma and then finally to invasive carcinoma that leads to metastasis.
Metastasis of gastric cancer is often accompanied by lymph node metastasis. According to
studies by Yasuda et al., (1999) the tumour size and depth of submucosal invasion serve as
a simple and useful indicator of lymph node metastasis in the early stages of gastric
carcinoma. However, over the past decades the major decline in gastric cancer mortality
has been mostly due to a reduction into the number of cases of well-differentiated type,
while poorly differentiated cancers are still a major problem, probably due to lack of
precursor changes seen in the epidemic intestinal-type (Morris & Bruckner, 1997). The
molecular events that lead to these two forms appear to be different. The transformation of
normal gastric epithelial cells to cancer cells is complex and associated with abnormalities
in oncogenes, cellular growth factors and their receptors, tumour suppressor genes and
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adhesion molecules and DNA repair genes that will be discussed later. As in all other 
cancers, differences in molecular pathogenesis depend on the histological type of gastric 
cancers (Wright et al, 1993).
CHROMOSOMAL ABNORMALITIES
Karyotypic analysis has shown that complex chromosomal abnormalities exist in
both gastric adenocarcinoma and sarcoma. Granberg first did karyotypic analysis for gastric
cancer in 1973 (Morris & Bruckner, 1997). Chromosomal abnormalities have been shown
that include tetraploidy, triploidy and hyperploidy. An example of a chromosomal
abnormality would be translocation on ALL-1 gene at 1 lp23. This has been observed in
gastric cancer cell lines. (Van Dekken et al, 1999). This translocation is not the only one
observed in gastric cancer, as the tpr-met translocation described previously also has been
identified (Soman et al, 1991). In addition, deletions of gene regions have been seen in
gastric cancer but not always are strongly associated. It has been found that the loss of
14q31-32.1 on chromosome 14 occurred significantly more frequently in Barrett’s related
adenocarcinomas of the distal oesophagus than in gastric cardia cancers (P=0.02) as
reported by (Van Dekken et al, 1999). Diffuse-type tumours with loss of Y and X
chromosome disomy in male, and uni-parental X chromosome disomy in female patients
have also been seen (Saal et al, 1993). The intestinal type of cancer presents aneuploid
karyotypes with frequent structural abnormalities (Saal et al, 1993). However, other
chromosomal abnormalities such as loss of heterozygosity (LOH) have been reported on
other chromosomes such as chromosome 7. (LOH) on chromosome 7q and especially for
marker D7S95 is correlated with metastasis and poor prognosis was observed (Kuniyasu et
al, 1994). The incidence in well-differentiated gastric carcinomas was 53% but in poorly
differentiated and scirrhous gastric carcinomas were 33% (Kuniyasu et al, 1994). This
study lead to the conclusion that this may be a site of a tumour / metastasis suppressor
gene. Similar studies have revealed the involvement of the APC gene and (the closely
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linked MCC gene), the DCC gene, the k-ras gene, the p53 gene, the tpr-met gene, playing 
essential roles in the progression of gastric neoplasia probably due to telomeric instability 
(Tahara et al, 1994).
Recent studies have focused upon telomers, the terminal end of chromosomes. The 
telomers consist of specific nucleotide repeats that are responsible for the stability of 
chromosomes. In cancer telomerase is turned on and this prevents the shortening of the 
telomers, which is probably seen in an ageing cell. Immortality is therefore conferred on 
the cancer cell. It has been demonstrated that reduction of telomers occurs in gastric cancer 
(Hiyama et al, 1995). Most of the tumours with telomerase activity are large and are of 
advanced stages including metastasis. Patients with tumours with telomerase activity have 
shorter survival rate than those without (Hiyama et al, 1995).
For the purpose of this project the investigation of genetic markers located 
telomerically of chromosome 6 was necessary. The genetic markers utilised were HLA- 
BQB1 within the HLA class II region, the HSP-70 and the D6S273 marker within the HLA 
class IV region.
TUMOUR SUPPRESOR GENES, ONCOGENES AND GASTRIC CANCER
The most commonly observed genetic abnormalities in gastric cancer are mutations
and deletions of tumour suppressor genes. Most frequently the p53 gene has been
identified to be abnormal in many cancers. The p53 protein acts as a DNA binding factor,
regulating transcription and the control of cell entry to S  -  phase of the cellular cycle. It is
also involved in apoptosis and terminal differentiation. Such events are important for the
molecular onset of gastric cancer. In histological subtypes of gastric cancer progression
towards (i.e. intestinal mataplasia, gastric adenomas, low grade dysplasia, high grade
dysplasia and carcinoma) p53 mutations have been identified with increased frequency in
the late stages (Rugge et al., 1992). Nonsense mutations (alteration of a coding sequence
for an amino acid into a termination codon), frame shifts (a mutation resulting from
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insertion or deletion of a group of nucleotides that is not multiple of three and therefore 
changes the frame in which the altered gene is translated) and (LOH) (loss of one or two 
distinguishable alleles at heterozygous locus) are abnormalities that are commonly seen.
Other genes such as the APC gene that is located on chromosome 5q have been
reported to be mutated in gastric cancer (Horii et al, 1994). The most frequent mutations
of the APC gene are nonsense mutations. The 10% of APC gene mutations are somatic
mutations of hyperplastic gastric polyps, whereas 25% are adenomas. The APC gene
exhibits a histologic specificity. In 60% of well-differentiated gastric carcinomas, the APC
gene is mutated or completely lost, making it the most frequent alteration in this type of
carcinoma. The function of the product of APC is uncertain although suspected to be
involved in cell adhesion and signal transduction by binding to cell surface molecules such
as E-cadherin and B-catenin. E-cadherin is mutated in 50% of diffuse type gastric cancers
suggesting that it confers metastatic properties (Henning et al., 1995). On chromosome 5q
there is a second locus, MCC. The MCC (mutated in colon carcinoma) gene is closely
linked with the APC gene and it has found to be deleted or mutated in gastric cancer (Ryu
et al, 1994). In contrast with the APC gene the MCC gene is found to be deleted or
mutated far more in poorly differentiated cancers (23.5%) and rarely if at all in
differentiated cases (Hsieh et al, 1995). LOH at APC / MCC gene loci has been found in
both differentiated and undifferentiated types in both early and advanced stages. Thus,
LOH at MCC / APC is considered an essential genetic alteration in human gastric cancer
(Tamura et al, 1996). A study in a British population failed to report frequent LOH of
the MCC / APC genes in gastric cancers, suggesting that tumour suppressor genes in other
chromosomes may play a more significant role (Sud et al, 1996). Therefore it can be
concluded from this evidence that the mutational pattern of APC / MCC and p53 presents a
discordance, suggesting that such cancers have a multi-centric genetic origin. Allelic loss
has also been reported on 18q chromosomal site. The DCC (deleted in colon cancer) locus
on chromosome 18q codes for protein homologues to neuronal adhesion molecules of the
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Ig gene super family and is believed to contribute to cell adhesion and signalling. In well- 
differentiated gastric cancers, the DCC gene is deleted (Barleta et al, 1993). Therefore the 
overall pattern of allele loss in gastric cancer has many similarities with the colon cancer 
with losses at 5q, 18q, and 17p.
Apart from tumour suppressor genes, several oncogenes may also be implicated in 
gastric cancer. Mutations and overexpression of the ras family have been observed. A 
significant correlation between ras oncogene types and geographic variations has been 
seen. There is a low frequency of K-ras mutations in western European countries, Japan 
and more prevalent in Italy and China where more point mutations take place (Hongyo et 
al., 1995). K-ras expression is an early event in the progression of diffuse type and well- 
differentiated gastric cancers. K-ras is correlated with depth of invasion, metastasis and 
shortened survival. K-ras is probably not an indicator of neoplasia. Overexpression of K- 
ras has been observed in gastritis, benign ulcers, atypia, and dysplasia and in normal gastric 
epithelium near to tumour lesion. Other oncogenes, such as the K-sam II proto-oncogene is 
frequently amplified in poorly differentiated tumours and scirrhous gastric carcinomas 
(Yokozaki et al., 1994). K-sam II is a member of the fibroblast growth factor receptor 
family (FGF). Basic fibroblast growth factor-2 (bFGF-2) is overexpressed in scirrhous 
carcinomas (Yokozaki et al., 1994) where both FGF and bFGF correlates with large 
tumours, poorly differentiated, deep invasion and increased metastasis to lymph nodes. In 
scirrhous type stomach cancer frequent amplification of c-met gene has also been seen 
(Kuniyasu et al., 1992). There is a correlation between c-met amplification and clinical 
stage. In well-differentiated adenocarcinomas c-met behave as a suppressor gene (Kuniyasu 
et al., 1992). A rearrangement of c-met and tpr oncogene to produce a 65 KDa tpr-met 
fusion onco-protein has been reported in gastric cancer (Soman et al, 1991) as described 
previously.
Expression of c-erbB2 gene has also been reported in gastric cancers. c-erbB2
linked with large primary serosal tumours and lymphatic invasion and distant metastasis.
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c-erbB2 is overexpressed in metaplastic lesions with microsatellite instability more often 
(64.3%) than in primary tumours without (28.6% , p<0.05) (Lin et al, 1995). Blockage of 
apoptosis leads to immortalisation of cells, a phenomenon seen in cancer. The bcl-2 gene is 
associated with blockage of apoptosis where increased expression has been seen in colonic 
polyps and carcinomas and more recently in gastric epithelial dysplasia but not in normal 
gastric mucosa. Bcl-2 expression has not been found in Barrett’s oesophagus even when 
severe dysplasia occurs. Overexpression of bcl-2 has been seen in poorly differentiated and 
scirrhous gastric carcinomas and believed to act as a dominant oncogene. In addition bcl-2 
expression has been noted in gastric epithelial dysplasia as well as in chronic atrophic 
gastritis with intestinal metaplasia (Lauwers et al, 1994). This leads to the conclusion that 
extensive cell survival due to inhibition of apoptosis is essential in addition to increased 
cellular proliferation in altered cells towards progression of gastric carcinogenesis. Other 
factors such as platelet-derived growth factor (PDGF), CD44 adhesion molecules, basic 
fibroblast growth factor (b-FGF), and insulin like growth factor (IGF- II), musin proteins 
(MUC1), hepatocyte growth factor (HGF) and IL-la are all found expressed in various 
types of gastric cancer all acting as regulators of cell growth (Yokozaki et al, 1994).
INFECTIONS RESULTING IN GASTRIC CANCER
Epstein Barr Virus (EBV) infection has shown to be a cause for the onset of small
number of lymphomas. Studies have shown that of the pathologic material from gastric
cancer patients EBV was found to be present in 12 % of the cases. It was found to be in
large numbers of the stomach lesions that are composed of malignant epithelium and in
dysplastic gastric epithelium (Gulley et al, 1996). It has been suggested that EBV infects
gastric epithelial cells through a reaction with T-lymphocytes carrying EBV.
Immunohistochemical analysis of such lesions has shown accumulation of p53 protein but
it found to be similar to EBV negative specimen. This lead to the conclusion that EBV
infection does not correlate with p53 mutations during carcinogenesis. Similarly bcl-2
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expresion was tested but no correlation was detected with EBV accumulation. Therefore, it 
is not clear yet if EBV is involved in the onset of gastric cancer (Gulley et al, 1996). 
Helicobacter pylori bacterial infection is recognised as a risk factor for acute inflammatory 
gastritis, peptic ulceration, and lead to gastric cancer in western countries. Infection with 
Helicobacter pylori in childhood increases the risk of developing gastric cancer. 
Helicobacter pylori is not found in normal stomach but frequently found in chronic 
gastritis (Farthing, 1998). The correlation between Helicobacter pylori and gastric cancer 
is complex.
5. Helicobacter pylori
Helicobacter pylori is a gram-negative bacterium, with features such as sheathed 
flagella, external glycocalyx, and a G and C base content of chromosomal DNA, that 
enables it to be considered in the genus Helicobacter. Seven species are known to be 
associated with gastric mucosa in a variety of mammalian species and ten with intestinal 
mucosa. Helicobacter pylori has a circular genome with more than 1.6 million bp and 
1,590 coding sequences. Helicobacter pylori has the ability to mimic the human molecular 
immunological structure that probably explains the ability to avoid immunological defence 
mechanisms and therefore the involvement in gastritis (Farthing, 1998).
EPIDEMIOLOGY OF Helicobacter pylori
Humans are the main host of Helicobacter pylori infections. The average incidence 
of infection is 40%-50% in the Western countries while in developing countries this 
increases to 90%. It is believed that in Western countries the incidence is now decreasing, 
significantly. The ratio for men and women developing gastric cancer, due to Helicobacter 
pylori infection has been shown to be 2:1 (Forman, 1998). The route of transmission is not 
yet clear. It was believed that one possible route is through an infected water supply.
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Another possible route could be endoscopy. Oral-oral, gastro-oral and faecal-oral routes are 
other possible routes. Some studies have shown frequent isolation of strains from oral 
cavities but other studies found this less frequent as indicated by Rowland and Drum, 1998. 
Thus, water or dental sanitation cannot be considered as the main source of Helicobacter 
pylori infection but may contribute. The main route of transmission nowadays is by direct 
person-to-person contact (Feldman et al., 1998). The age of acquisition of Helicobacter 
pylori shows geographical variation. The most frequently acquisitions occur in persons 15 
years of age or younger. In adults is only 1% to 3% per annum. The overall prevalence is 
30%-40% in developed countries but can be 30% to 40% in children from low socio­
economic groups. In developing countries the range is from 80% to 100%. Infection in 
early age is essential for development of gastric cancer (Rowland & Drum, 1998).
VIRULENCE ASSOSIATED GENES
Among people with Helicobacter pylori infection not all develop disease. The main
disorders that arise are duodenal and gastric ulceration. Helicobacter pylori is considered a
major risk factor in the development of adenocarcinoma and mucosal associated lymphoma
(MALT). Of those infected, the virulence of the Helicobacter pylori strain appears to be a
major factor in determining, who will develop disease (Atherton, 1998). Whether all
strains can cause peptic ulceration or gastric carcinoma is unclear. Certain strains with
specific characteristics have been linked with disease. These characteristics are the
“Vacuolating cytotoxin” (Vac) production and specific types of VacA gene alleles, the
“Cytotoxin associated gene” product A (CagA) and genes within the (Cag) “Pathogenicity
Island” and the ability to strongly and rapidly stimulate neutrophil degranulation. Host
susceptibility may be relevant to onset of disease. There is growing evidence that the host’s
HLA type, and its expression are important as genetic factors of susceptibility to disease.
The HLA class II gene BQpi *0301 has been reported to be associated with
gastroesophageal adenocarcinoma in positive Helicobacter pylori patients (Lee et al.,
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1996). The fact that Helicobacter pylori produces a protein that induces vacuolation in a
variety of cultured epithelial cells first was first shown by (Leunk et al., 1988). Strains
producing Vacuolating cytotoxic activity were more commonly isolated from patients with
peptic ulcers than without. The gene Vac A (encoding the toxin) varies especially in its
signal activity between different Helicobacter pylori strains. Cytotoxic activity and signal
sequence type influenced by Vac A genes type, is closely associated with peptic ulceration.
Strains possessing the CagA are more commonly found in people with peptic ulceration
and gastric adenocarcinoma than without. CagA is probably a marker for Cag
“Pathogenicity Island” (Atherton, 1998). This includes genes responsible for increased
inflammation induced by pathogenic strains. The ability of Cag A to induce inflammation
can be explained by the fact that sequencing around CagA has shown, that to be of a cluster
of 40 genes usually present or absent as a group. Any disruption in one gene reduces the
ability of Cag A+ strains to induce IL-8 production that acts as chemotactic factor for T-
cells, neutrophils, and basophiles. Activated neutrophils release lysosomal enzymes and
induce adhesion of neutrophils to endothelial cells. Also cytokines such as GRO-a,
RANTES, and EMPI-a are released (Kassai et al., 1999; Farthing, 1998). Cag A+ strains
usually have the VacA si or B genotype and they are often toxicogenic, whereas CagA'
unusually has VacA s2 genotype and are not toxicogenic. The detection of Cag A+ strains
in patient’s serum could be a good practical test for detection of onset of inflammatory
diseases. However the interrelationship of such factors is poorly understood making it
difficult to estimate their relevance (Atherton, 1998). Despite the fact that Helicobacter
pylori strains appear to be a well known factor in the development of gastric cancer, in our
study testing for positivity and / or negativity of the results obtained against Helicobacter
pylori specific strains was not possible. This was due to the fact that such strain specific
data was difficult to be obtained for the test populations tested, the experimental time
within the laboratory was limited as was the range of subjects with Gastroesophagial
cancers at GRI, whose DNA samples were obtained for testing. Therefore, if split in to
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groups of positive or negative for specific strains this is not a fair representation of entire 
population for statistical purposes. However, it was necessary to mention at this point the 
involvement of Helicobacter pylori because it plays an important role in gastric 
carcinogenesis.
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6. INFLAMMATION AND GASTRIC CANCER
The potential signs of inflammation have arisen since the first century of Common 
Era, when Cornelius Celsus (30bc-38ad) was describing the typical reaction of tissue to 
microbes. Redness, swelling, heat and pain -'rubor et tumor cum calore et dolor ” are the 
four common signs of inflammation. Human hosts and animals have an invisible extensive 
defence mechanism ready to oppose to anything-foreign otherwise known as “antigen”. If 
the hosts defence mechanism fails to eliminate the antigen, infection occurs. If the hosts
♦ • • • • +umanage to eliminate the antigen, then immunity occurs. Until the 19 century there was no
thknowledge about inflammation. By the first decade of the 19 century, scientists were 
using microscopes to identify bacteria as the cause of infection and found that when 
introduced into the host, infection resulted (Weismann, 1992).
Inflammation, which may be acute or chronic, can be defined as the body’s
response to injury. Microscopically, it involves events such as dilation of arterioles, of
capillaries and veins increase permeability to blood flow, exudation of fluids and plasma
proteins and leukocyte migration into the inflamed area. Accumulation of leucocytes in
inflamed tissue is a common event while deficiency of inflammation leads to compromised
host. Recognition of host tissue as “foreign” leads to inflammatory autoimmune diseases.
The characteristics of inflammation are amplified or propagated in acute and chronic
inflammation, depending on recruitment of various cellular components of the immune
system. Recognition occurs by specific or non-specific means. Specific recognition is
mediated by immunoglobulin i.e. antibodies and/or T-lymphocyte receptors that bind to
specific epitopes. Non-specific recognition involves denaturation of proteins or endotoxins
that can be mediated directly by phagocytes. Binding of an antigen to a recognition
component of the immune system leads to an amplification system activation and release of
pro-inflammatory substances that creates the four signs that characterise inflammation.
Leukocyte adherence to vascular walls increases vascular permeability, and migration to
infected tissues, where leucocytes are stimulated to destroy the antigen. Finally,
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macrophages, Kupffer cells, and type-A synovial lining cells can mediate the destruction of 
antigens. Destruction outside the phagocyte and related cell system takes place in tissue 
spaces and is mediated by neutrophils migrating from peripheral blood. In most cases the 
antigen is eliminated without clinically detectable inflammation. When clinical 
inflammation is observed this would suggest that the antigen was of a high dose or in an 
unusual location or difficult to digest. (Gallin et al, 1992).
Inflammation is implicated to be involved in the pathogenesis of gastric cancer
(Ernst, 1999). Evidence from studies in humans and animal models suggest that chronic
inflammation of gastric mucosa is associated with Helicobacter pylori infection and
especially with CagA+ strains (Perez-Perez et al, 1999). Helicobacter pylori produce an
enzyme known as urease, which contribute to changes in mucosal permeability and
facilitate the generation of chronic immune responses. Production of ammonia not only
protects the organism from gastric acid but also has toxic effects on the gastric epithelium,
inducing proinflammatory cytokines (Tanahasi et al, 2000). Helicobacter pylori associated
chronic gastritis, induces gastric mucosal inflammation that is characterised by surface
epithelial degeneration and infiltration of the mucosa by chronic inflammatory cells such as
lymphocytes, plasma cells, neutrophils and occasionally eosinophils (Dixon et al, 1996).
Inflammation has been implicated in development of intestinal mataplasia and mutations in
oncogenes that proceed to the development of gastric cancer. Two mechanisms of
induction of gastric inflammation are known. First the organism may interact with surface
epithelial cells, producing direct cell damage or the liberation of proinflammatory
mediators (chemokines) and secondly Helicobacter pylori derived products may enter the
underlining mucosa, thereby directly stimulating immune response involving cytokines.
Chemokines such as GROa, IL-8, RANTES, M IP-la and cytokines such as TNFa, IL-12,
IL-13, IL-16 GM-CSF, IFNy, IL -la/($, IL-18, IL-6, IL-7, PGE2 and IL10, are induced
during infection and activate T-cells, B-cells, neutrophils and macrophages. Chemokines
have marked target cell specificity. IL-8 and GROa have specific chemotactic activity for
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neutrophils where RANTES and M IP-la have effects on monocytes and lymphocytes 
(Baggiolini et al, 1994). Bacterial induction of epithelial chemokines involves protein 
tyrosine kinase pathways e.g. Mitogen-activated protein kinase (MAPK) and NF-kB 
activation (Aihara et al, 1997). A number of transcription factor families involved in such 
pathways have been described recently in literature to be involved in inflammation. 
Activator protein 1 (AP-1), activating transcription factor 2 (ATF2), nuclear factor kB (NF- 
kB), nuclear factor of activated T-cell (NF-AT), signal transducer and activator of 
transcription STAT, and p53 are critical regulators of gene expresion in setting of 
inflammation (Firestain et al., 1999).
Cytokine production is a balance between inflammatory (IL-1, IL-2, IL-6, IL-8, IL- 
18, TNFa, IFNy) and anti-inflammatory (IL-1RA, IL-4, IL-10, IL-13, IL-16, TNF(3 and 
PGE2) products. Proinflammatory cytokines are induced in many infections, where anti­
inflammatory cytokines are induced to maintain the balance. In inflammatory response due 
to Helicobacter pylori infection all the above pro-inflammatory cytokines are induced 
(Firestain et al., 1999). However the balance tips towards the onset of inflammation. That 
is probably due to insufficient anti-inflammatory cytokine response or could be due to a 
number of genetically aberrant cytokines (e.g. TNFa, IL-1, IL-6) and aberrant transcription 
factors that are involved in protein tyrosine kinase signal transduction pathways that 
regulate gene expresion in inflammatory conditions (Firestain et al., 1999). The bacteria 
reside in the lumen of stomach where most of the immune material resides, at the same site 
and thus a specialised immune response is expected to take place. This does not happen. 
Thus, the genetic level of such interactions must have a specific role in the induction of 
gastric inflammation. Inflammation due to Helicobacter pylori is still a mystery. Most 
individuals play host to Helicobacter pylori throughout their lives, but have never obtained 
protective immunity. It has been found that epithelial cells are capable of transducing the 
signal of infection to host so receptors of the epithelium can stimulate production of IL-8
and in turn activation of neutrophils, macrophages, stem cells and cells involved in
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adaptive immune response such as B cells, T-cells and plasma cells. Molecular analysis of 
gastric mRNA has produced evidence that infection with cag+ strains is associated with 
increased transcription of IL-8 (Yamaoka et al, 1996). This evidence shows that IL-8, a 
potent neutrophil chemokine, may be particularly important in gastric inflammation. Also 
the cag+ bacterial infection may reflect strain specific mucosal cytokine and chemokine 
responses. Mononuclear phagocytes serve as an important source of immune response to 
pro-inflammatory mediators and as antigen presenting cells involved initiation of specific 
immunity. It has been shown in vitro, that Helicobacter pylori soluble proteins will 
activate peripheral blood monocytes leading to increased expresion of HLA-DR and IL-2 
receptors and the production of IL-1 and TNFa (Mai eta  I., 1991). In addition endoscopic 
antral biopsies in vitro have shown increased secretion of IL-1 p, TNFa and IL-6 in infected 
subjects with Helicobacter pylori. All three cytokines are predominantly derived form 
macrophages and have inflammatory actions and are involved in leukocyte activation 
(Noach et al., 1994; Crabtree et al, 1991). The inflammatory cells when activated produce 
inflammatory mediators to induce oxidative stress in the vicinity of the gastric epithelium. 
Oxidative stress can be neutralised by antioxidants such as vitamin C. However the level of 
antioxidants during infection is low in gastric juice. Elevated levels of antioxidants due to 
reactive oxygen (RO) produced by Helicobacter pylori in gastric epithelium can cause 
abnormalities to many genes and induce DNA damage (Ernst et al, 1999).
Epithelial cell turnover is affected by inflammatory response to Helicobacter
pylori. Increased epithelial cell proliferation as well as cell death by apoptosis has been
described in literature. Apoptosis is a regulated process of cell death that is initiated by
inflammatory mediators such as TNF, INFy and Helicobacter pylori. Immunohistochemical
studies have shown elevated accumulation of CD4+ T- cells in gastric mucosa during
infection. T- helper cells are classified into two types depending on the types of cytokine
they produce. Thl and Th2. Thl lymphocytes secrete IL-2 and IFNy and mediate cellular
immune responses where Th2 produce IL-4, IL-5 and IL-10 which help in B-cell activation
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and antibody production e.g. IgA (Seder, 1994). The IFNy -Thl cells are mainly seen in 
gastric mucosa (Karttunen et al, 1995) and increased mucosal mRNA expression of IFNy 
and IL-12 suggesting that Thl response is predominant (D’Elios et al, 1997). Thl-cells 
can cause problems because they are pro-inflammatory. IFNy can cause an increase of 
expression of MHC and accessory molecules, important in anchoring and activating 
immune inflammatory cells. IL-8 production may be increased from gastric epithelium 
resulting in elevated recruitment of neutrophils. Studies have identified materials that 
adhere to Helicobacter pylori and are identical in size to HLA class II molecules. The 
expression HLA class II molecules as potential receptors for Helicobacter pylori correlates 
with the binding of Helicobacter pylori to gastric epithelium and it is suggested that the 
Helicobacter pylori -  HLA class II complex is responsible for apoptosis induction by 
Helicobacter pylori. Increase of IFNy release can cause increase of HLA class II expresion. 
IFNy -Thl cells are known to be elevated in gastritis. If HLA class II are potential receptors 
for Helicobacter pylori this could facilitate colonisation, modulate signalling from 
bacterium to host via IL-8 and contribute to expression of epithelial damage. If this occurs 
then fibrosis and metaplastic tissue will be formed, leading to gastric cancer. However 
there is no clear evidence to suggest that these events are specifically involved in the 
development of gastric cancer (Fan et al, 1998). This kind of cycle of immunological 
events can contribute to mucosal damage. It is believed that there are many precursors that 
can cause abnormal turnover on the lining of the digestive tract including the oesophagus.
The complex cytokine network involved in inflammatory response could include 
regulatory cytokines such as IL-10, which may serve as a suppressor of inflammation, 
keeping the balance between various proinflammatory cytokines. Various cells produce IL- 
10, notably mononuclear phagocytes. IL-10 acts as an inhibitor of phagocytes and 
lymphocyte responses. Increased levels of IL-10 (secreted protein and mRNA) have been 
reported in Helicobacter pylori infected gastric mucosa with levels of IL-10 increasing
with the severity of gastritis (Bodger et al, 1997).
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7. GENERAL ASPECTS OF THE MHC MOLECULES
Major Histocompatibility Complex (MHC) is a general name describing genes 
encoding antigens that were first discovered in graft compatibility studies. Such antigens 
are known as Histocompatibility antigens. In many species the MHC has different names. 
In humans it is named as Human Leukocyte Antigens (HLA), where as in mice it is named 
H-2.
The HLA system is composed of genes that control a variety of immune functions 
and influence the susceptibility of more than 40 diseases, including cancer. In normal 
human cells over 50 genes have been identified that determine recognition of foreign 
proteins by T-cells. These genes have been identified mainly through their role in coding 
for proteins involved in tissue transplantation, sometimes referred as transplantation 
antigens (Rigas, 1996).
The MHC antigens are cell membrane glycoproteins that are classified into class-I 
and class-II. The major loci of HLA within the class-I region are HLA-A, HLA-B, and 
HLA-C and within class-II are DP, DQ and DR. Between DQ and DP are loci coding for 
transporter protein such as (TAP) that participate in selection of peptides available for 
binding (Fig 3).
There are other genes among class-I loci that are named non-classical class-I loci. 
These are, HLA-E, HLA-F, and HLA-G. Pseudogenes (HLA-H and HLA-J) that do not 
lead to protein are incorporated within Class-I. Pseudogenes have been identified in class-II 
(Rigas, 1996). There are some other genes between the class-II locus and class-I locus 
composing the class-III locus. Class-Ill locus and class-II locus will be discussed in detail 
later due to its complexity and importance to this work.
MHC occupies a segment of approximately 4 Mbp on the short arm of chromosome
6 and contains the highly polymorphic class-II genes, and class-I genes. These genes
encode for polymorphic cell surface proteins that are involved in presentation of antigens
(Ags) in immune responses. In man these two clusters are separated by 1100Kb of DNA,
32
termed HLA class-III. Among them the TNF, lymphotoxin a  and lymphotoxin p, the HSP 
genes, the C2, C4A, C4B, complement factors, and the two steroid 21-hydroxylase (21- 
OhaseA and 21-OhaseB) genes with immune related functions are forming the HLA class- 
III locus as shown in (Fig 3) (Roit et al., 1996; Carroll et al., 1987).
The HLA genes are located in a 3600Kb region of chromosome 6. Both HLA 
class-I and HLA class-II molecules are heterodimeres. HLA class-I consists of a 45-Kda
transmembrane a  chain, which is associated non-covalently with p2-microglobulin. The 
gene encoding p2-microglobulin is located on chromosome 15. HLA Class-I molecules
function in antigen presentation to CD8+ lymphocytes and are involved primarily in cell- 
mediated cytotoxicity. HLA Class-II molecules are composed of a pair of non-covalently 
linked a  and p chains. Chain a  is ~ 32 Kda whereas chain p is 28 Kda. Both chains of the 
class-II heterodimer are inserted into the cell membrane whereas in class-I only chain a  is 
inserted (Fig 4). HLA molecules are members of the immunoglobulin Ig gene family. Both 
chains of the HLA class-II contain two external domains -90-95 amino acid long. The 
membrane domains a2 and P2 are homologous to Ig constant region domains and present a 
disulfide loop similar to that in Ig. The N-terminal (a l and pi domains) is the major site of 
variation between the different HLA class-II alleles were the a l  and P2 domains show little 
variability between alleles (Fig 4). Another difference between HLA class II and HLA 
class-I is that in HLA class-I the membrane distal domains are encoded by one chain a  
were in HLA class II separate a  and p chains are present (Roit et al., 1996; Gregersen, 
1989).
Some of these genes as in (Fig. 3) with immune related function are believed to be 
relevant to diseases such as gastric cancer (Lee et al., 1996) and maybe Barrett’s 
oesophagus. This research project focused on the DQB1 locus in the HLA Class II region, 
the HSP-70 locus and the D6S273 marker within the HLA Class III region to investigate 
the development of gastric cancer and Barrett’s oesophagus.
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Fig 3. Genetic organizations of human MHC class I, class II, and class III and related loci 
telomeric on chromosome 6. The map presents a subset of loci o f interest (red 
colour) in the region. The map is not to scale. The approximate distances are given 
in kilobases.
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Fig 4. Schematic descriptions of the human HLA class I and class II binding domains as 
adopted from (Gregersen, 1989).
The T cell receptor is generally composed of an “a ” and a “(3” polypeptide chain.
Each chain is about 280 amino acids long and has a large extracellular part that is
folded into two Ig-like domains, forming the binding domain that has significant
structural differences between the two classes.
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THE MHC CLASS II GENES
The HLA-D region encodes for at least six a  and ten (3 chain genes for MHC class II as 
demonstrated in (Fig 5). The major expressed products of the human class II are encoded 
by the three loci: DR, DQ and DP. The DR family comprises a single a  gene (DRa) and up
to nine p genes (pi-9) including pseudogenes e.g. \\rp (Fig 5). The DQ and DP families, 
each have one expressed gene for a  and p, and an additional pair of genes, which may not 
be functional. The DQ subregion contains a set of genes designated DXa and DXp that are 
not pseudogenes but have not been found to be expressed (Jonssosn et al., 1987). Non­
functional pseudogenes are also included in the DP subregion designated as ij/a and v|/p 
(Fig 5). Additionally between the DQ and the DP subregion the DZa and DOp genes are 
located. The DR, DQ, DP, a  chains associated in the cell primarily with P chains of their
own loci. For example the DQA1 and DQB1 encode the HLA-DQ antigens. Several gene 
arrangements occur within the DR locus and it is believed to be more polymorphic than the 
DQ and DP loci (Gregersen, 1989). In the class II region, the various heterodimeres 
molecules are encoded in the same genetic region that contrast to other molecules such as T 
cell receptor, haemoglobin or Class-I molecules that each chain is encoded in different 
chromosomes. The functional significance of the localization of a  and p chains to the same 
genetic region rather than to a different genetic region is not known. However, the 
localization of class II a  and p chains correlated with the structure and function of the 
molecules formed. Sequencing of the MHC has revealed that the p chain genes of DR 
subregion are more closely related to each other than the P chain genes of the DQ 
subregion. The DRpl and DRp3 coding regions are over 90% similar (Curtsinger et al., 
1987) whereas DRpi and DQP chains have 70% sequence similarity (Custafsson et al., 
1987). This leads to the conclusion that there is a restricted ability of p chains to form a  / p
heterodimeres with a  chains encoded in the same subregion.
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Fig 5. Schematic description of the HLA D region on Chromosome 6.
The three major polymorphic allelic series are: DR1-14, DRw52, DRw53 and 
DQwl-DQw4. The less polymorphic sub-regions of DP locus are also shown. 
Pseudogenes are designated with the letter \\j (Gregersen, 1989).
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The DRa chain is identical with minor exceptions to all individuals and thus does 
not contribute to allelic variability of the DR molecules (Trowsdale et al., 1985). Although 
the DQ a  and p chain genes that encode the DQ series, are variable in sequence and it is 
believed that thep chain is responsible for polymorphism within DQw2, DQw3 and DQw4 
(Trowsdale et a l, 1985).
MHC polymorphism is concentrated in the peptide-binding cleft. The major 
function of MHC molecules is the presentation of antigens that is characterised by an 
extreme degree of polymorphism of the molecules encoded within it. Polymorphism is not 
thought to be spread evenly throughout the MHC but is focused more within class-II 
molecules rather than class-I, where the extent of variability depends on the sub-region and
on the polypeptide chain. For example, most polymorphisms occur in DRp rather than in 
DQp chains, while DPp chains are even less polymorphic. DQ a  is polymorphic whereas
D Ra chains are invariant. Thus the structural diversity in the expressed molecule increases
significantly. Most of the polymorphic amino acids in class-I and class-II antigens are 
clustered on top of the molecule in the large groove (Fig 4) that acts as the peptide-binding 
site (Roit et al., 1996).
The implication is that this polymorphism determines which antigen-derived 
peptides will be presented to the cell via their T cell receptors. Those T cells that recognise 
the HLA / peptide complex will become activated. This polymorphism, combined with the 
main role of HLA class II in regulating the immune response, is the heart of the association 
between HLA and diseases.
HLA alleles have been identified by serological typing and designated by a letter 
denoting the locus followed by a number e.g. HLA-B27. The polymerase chain reaction 
was applied later to reveal a greater polymorphism based on allele DNA sequence. Since 
then a more specific terminology is used e.g. DQB1*0301.
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Another feature of the HLA is the linkage disequilibrium (non-random association) 
between certain pairs of alleles at different loci. If a given combination of two alleles 
occurs much more frequently than each one alone, then they are in linkage disequilebrium. 
The physical meaning is that two genes pass from generation to generation together, thus 
preventing the equilibrium in their frequencies that would occur if they had travelled 
separately through successive generations. The linkage disequilebrium can be created 
naturally by a strong selection effect or migration and mixture of two populations. HLA 
association with a disease (e.g. gastric cancer) may imply that the frequency of the allele(s) 
is different in the patient population than in the ethnically matched control population. The 
implication of such large polymorphisms on T-cell antigen recognition has a great impact 
on scientific trials, to identify which genes are involved in diseases and especially in the 
case of gastric cancer (Rigas, 1996).
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D0B1 LOCUS AND DISEASE
The HLA DQB1 locus maps 110 kb centromeric to HLA DR locus and is 
comprised of a polymorphic HLA DQB1 gene encoding at least 22 alleles and an HLA 
DQBA1 gene encoding at least 12 alleles (Bodmer, 1995). The HLA DQB1 and HLA 
DQA1 gene products define the serological antigen families designated DQwl, DQw2, 
DQw3 and DQw4 (Petersdorf et al., 1996). Linkage disequilebrium of the HLA DQB1, 
DQA1 and DRB1 alleles in defined populations can produce extended haplotypes 
(Petersdorf et al., 1996). For example, the patterns of linkage disequilebrium found 
commonly in Caucasian population can be seen in (Fig 6). As shown serologically defined 
alleles encoded within the DQ subregion are in linkage disequilebrium with the DR 
subregion. The DR series is encoded by the DRpl locus and the DRw52 and DRw53 
alleles by the DRp3 locus (Fig 5). The DQw3 is almost always associated with the DR4, 
DR9, DR5 and the DQw2 is almost always associated with the DR7, DR3. Similarly 
DQwl is almost always associated with the DRw6, DR1, DR2 and DRwlO (Gregersen,
1989). Therefore, these patterns of linkage disequilebrium between DQ series, DR series 
and their DRW53, DRw52 associated genes (Fig. 6) reflect a characteristic relationship 
among these haplotypes. However these DQ / DR associations may differ in non-caucasian 
populations such as American Blacks (Hurley et al., 1988). Polymorphism in the DQ 
subregion is present in both DQa and DQp chain genes. The degree of variation in DQa 
and DQp chains is less than that seen in DRp chains in terms of the number of alleles 
involved and in the degree of variation at the particular residues. However, possible 
combinations of the variable DQa and DQp chains will increase the DQ polymorphism 
further. Additionally combinations of a  and p chain alleles will lead to an additional 
diversity that is characterising heterozygous individuals. The principle of this 
combinatorial diversity is the formation of hybrid DQ molecules through trans association
of DQa and DQP chains encoded in different haplotypes (Charron et a l, 1984).
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DQw3 --------------- DR4
DQw2 --------------  DR7 ---------- — 2 DRw53
DQw3 ---------------  DR9
DQw2 ----------------- DR3
DQw3 ----------------- DR5 ----------- — ^DRw52
DQwl ----------------- DRw6
DQwl ----------------- DR1
DQwl ----------------- DR2
DQwl ----------------- DRwlO
Fig 6. To show the patterns of linkage disequilebrium that is commonly found on HLA 
class II haplotypes in Caucasian populations (Gregersen, 1989).
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DQB1 sequence variability in the upstream regulatory region of HLA class-II has 
been described as an additional mechanism of diversity. Twelve HLA DQB1 upstream 
regulatory region variants have been identified approximately 600bp immediately upstream 
of the first exon of the DQB1 gene (Reichstetter et al., 1996). This study demonstrated a 
distribution of promoter sequence variability within DQB1 alleles coding region to be in 
strong linkage disequilebrium with exon 2 of the DQB1 in a Caucasian population. The 
DQB1 / QBP1 (DQB1 promoter) promoter haplotype presented a ratio of 75.9% for all 
DQB1 *0501 positive haplotypes alleles. Between DQB1 *0603 positive haplotypes,
DQB1 *0603/QBP 1-6.3 was present at 96.4% and 95.2% of the DQB1 *0604 positive 
haplotypes carried QBP16.2. Such studies indicate that these allelic polymorphisms may 
associate with differences in both transcription and affinity for DNA binding proteins. 
Functionally, such polymorphisms are related to the ability of HLA to bind and present 
peptides to T-cells. Thus, allelic polymorphism and promoter variability may contribute to 
the polymorphism of these heterodimeric molecules. Moreover, disease susceptibility may 
be influenced by variability in regulatory regions of genes (Haas et al., 1995).
Many population-based studies have focused on HLA class II alleles previously, 
trying to identify association or predisposition to diseases. Basal cell carcinoma is a 
common skin cancer. In Swedish population its incidence has increased. A study by 
Emtestam et al., (1996) demonstrated that DR1 frequency was the same in controls and 
patients but all the DR1 positive patients and controls carried the DQA1 *01101 and 
DQB 1*0501 alleles. This study showed that within HLA class II, there is a linkage 
between alleles coding regions but unfortunately they do not always contribute to aetiology 
of disease. However in Danish pregnant women it has been shown that HLA DR 
allogenotypes DR1/ DQ5 and/or DR3 are closely associated with predisposition in 
recurrent spontaneous abortions (Christiansen et al., 1996).
In cutaneous malignant melanoma (CMM) the DQB1 *0301 allele has been
suspected to have a strong association with tumour progression in US patients according to
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Lee et al., (1994). Patients with the *0301 allele showed increased frequency of malignant 
disease considering stages of progression (56% CMM Vs 27% control; P=0.003). The 
*0301 allele is associated with advanced disease and thicker primary tumours. Lee et al, 
(1996) also show that *0301 allele carriers have an increased risk of developing recurrent 
CMM (49%) compared with stage-matched patients who lack the *0301 allele (22%). In 
this study of Lee et al., (1996) the HLA DQB1 *0301 allele is reported as the most 
important allele associated with CMM. In a similar study by Bateman et al., (1997) within
the British population, the HLA DQB*0303 allele was found to be associated more with 
CMM patients than a control population (19.2% vs 5.8%; P=0.003; RR=3.9) where DQB1 
*0301 was found to be associated with more advanced tumours and poorer prognosis. Thus 
in the British population *0301 and *0303 alleles may play a prognostic role in CMM 
where in the US population only the *0301 allele has been shown to be a prognostic 
indicator. A similar study in an Italian population by Lombardi, (1998) revealed the 
association of DQB1 *0501allele with melanoma (patients 25% Vs 14.7% controls; 
P=0.038) where the *0301 allele was found in similar numbers (62.8% patients Vs 54.9 % 
controls; P=0.136). Because DQB1 *0301 and DQB1 *0501 are strongly associated with 
DRB1 *01 and DRB * 11 both alleles DRB1 *01 and DRB * 11 in the above study were 
found to be increased. In the British population (Bateman et al., 1997) and in the US 
population (Lee et al., 1996) such alleles show no association with melanoma. Such studies 
and many others within the literature, (examples as in Table 1) in different populations and 
diseases indicate the involvement of HLA molecules in onset and progression of diseases.
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Table 1. To show examples of studies in different populations and diseases that the 
involvement of the HLA molecules was studied.
Disease Author Year Population Studv conclusion
Cervical cancer Gregoire, et al 1994 African-American Association
Cervical cancer Helland, et al 1994 Norwegian Association
Cervical cancer Nawa, et al 1995 Japanese Association
Cervical cancer Odunsi, et al 1995 S England Association
Cervical cancer Odunsi, et al 1996 British Association
Cervical cancer Sanjeevi, et al 1996 Swedish Association
Cervical cancer Montoya, et al 1998 Spanish Association
Cervical cancer Helland, et al 1998 Norwegian Association
Cervical cancer Ferrera, et al 1999 Honduran Association
Leukaemia Dearden, et al 1996 British Association
Leukaemia Taylor, et al 1997 British Association
Leukaemia Manns, et al 1998 African Association
Celiac Disease Martin, et al 1995 British Association
Ulcerative colitis Reinsagen, et al 1995 German Association
Ulcerative colitis Roussomoustakaki 1997 British Association
Laryngeal papillomatosis Aaltonen, et al 1999 Finland Association
Bowel Disease Bouma, et al 1996 Dutch Association
Hepatitis C Asti, et al 1999 Italian Contribution
Hepatitis C Aikawa, et al 1996 Japanese Contribution
Rheumatoid Arthritis Irene, et al 1999 American Association
Lung cancer Hiraki, et al 1999 Japanese Association
T cell lymphoma Jackow, et al 1996 American Association
Non Hodgkin’s Lymphoma Nathalang, et al. 1997 Japanese Contribution
Pemphigus Lee, et al 1998 Korean Association
Tuberculosis Goldfeld, et al 1998 Cambodian Association
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In the case of gastric cancer onset in the Caucasian population the HLA genes are 
believed to have an association. A resent study by Lee et al, (1996) in Caucasian patients 
with gastric, colorectal and pancreatic adenocarcinoma revealed that the DQB1 *0301 
allele is strongly associated with gastric adenocarcinoma 54% versus controls of 27%.
After Bonferoni correction the data showed a P=0.003 by chi square test (odds ratio 3.2). 
No other HLA DQB1 allele and HLA DQA1, or TAP 2 alleles were found to be associated. 
The association of HLA DQB1, with Helicobacter pylori infection was investigated by Lee 
et al. (1996). Serological evidence for Helicobacter pylori in DQB1 *0301 positive patients 
with adenocarcinoma, compared with DQB1 *0301 negative patient population presented a 
lower frequency of DQB1 in positive 52% Vs negative 88% patient population (Fisher’s 
Exact Test P=0.007). Such results lead to the conclusion that the DQB1 *0301 allele is 
more common in Caucasian patients with adenocarcinoma than controls and the 
mechanism linking the DQB1 *0301 allele with gastric adenocarcinoma is not likely 
through increased susceptibility to Helicobacter pylori infection. In the other types of 
cancer tested no association was found for any of the DQB1 alleles. However, Ohmori et 
al., (1997) in the Japanese population revealed no statistical significance of any HLA 
DQB1 alleles or haplotypes in patients with gastric cancer (P< 0.05) compared with 
controls (P< 0.05). It is believed that in the Japanese population the environmental factors 
such as diet contribute more to gastric cancer than the genetic factor (Ohmori et al., 1997). 
Such comparison of studies confirmed that gastric cancer is a multifactorial disease.
Having such studies in mind, in this project DNA typing was performed using samples 
from West of Scotland-Glasgow population, looking for reproducible results such that of 
Lee et al., (1996).
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THE MHC CLASS III GENES
Many genes are located within the HLA class III including TNF, the HSP genes, 
complement factors and markers such as D6S273 (Fig 3). Among the HLA class III, TNF 
is a very important molecule involved in inflammatory responses. It is believed that it has a 
specific role in tumour pathology and more importantly in invasion of cancers. MHC class
III region is the region where TNF genes exist coding for TNF-a. This region also includes 
the lymphotoxin a  and p genes. The close relationship between TNF-a and lymphotoxin 
a  was not known until 1984 when cloning of the cDNAs of Human TNF and lymphotoxin 
revealed that they are 30 % homologues at amino acid level (Gray et al., 1984; Pennica et 
al., 1984). TNF-a and lymphotoxin a  bind to the same cell surface receptors and they are 
very similar in the spectra of their activities (Aggarwal et al., 1985). The TNF locus is 12 
Kb in length. The TNF locus is highly polymorphic. Within this locus five microsatellites 
have been identified, TNFa to TNFe (Nedospasov et al., 1991). TNFa consists of fourteen 
alleles TNFa 1-14. TNFa is an inducible cytokine with a broad range of proinflammatory, 
catabolic and immunostimulatory actions. These include induction of IL-1, IL-6, IL-8, and 
TNFa itself, stimulation of prostaglandin E2, nitric oxide synthase and collagenase 
production, and increased B and T cell proliferation and immunoglobulin synthesis. TNF is 
produced mainly by activated macrophages but expression also occurs in T and B- 
lymphocytes, natural killer cells, and keratinocytes. TNF is involved in inflammation by 
enhancing the cellular migration of monocytes and macrophages (Beutler et al., 1989). The 
gene encoding TNFa microsatellite lies within the MHC class III region, approximately 
350Kb telomeric of the complement cluster and 320 Kb centromeric of the HLA-B locus as 
shown in Fig 7. The discovery of microsatellites and the location of TNF within the MHC 
has prompted much speculation about the role of TNF alleles in the aetiology of MHC- 
linked diseases, in particular those with an inflammatory or autoimmune component.
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Fig 7. To present a schematic description of the TNF region.
The TNF gene locus, the lymphotoxin gene loci and microsatellite loci are shown in 
light blue colours. The map is not to scale.
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In the case of Helicobacter Pylori infection and gastric cancer it is believed that 
TNF increases the production of gastrin due to TNF over-expression where an increase in 
acid secretion initiates ulceration. Chronic inflammation at the site may results in gastric 
cancer. The actual relation of Helicobacter Pylori and gastrin releasing hormone and TNF 
gene expression is not well known. A possible mechanism could be that the Helicobacter 
Pylori infection causes inflammation and increased regulation of TNF that results in up 
regulation of G-cell function resulting in increased release of gastrin, whereas development 
of chronic ulceration and inflammation will lead eventually to gastric cancer (Beales et al.,
1996). TNF genes and TNF microsatellites have been found to be involved in other 
diseases such as, coeliac disease (McManus et al., 1995), colorectal cancer (Gallagher et 
al., 1997), IDDM (Moghaddam et al., 1997) and SLE (Tarasi et al., 1997; Rood et al., 
2000).
In 1995, McManus et al., reported that the TNFb3 microsatellite allele is 
significantly associated with coeliac disease (CD), which found in 86% of CD patients 
versus 24.5% of controls, with allele frequencies of 0.5392 and 0.1290, respectively (P <
0.001). Additionally the TNFa2 allele that was examined, presented frequency of 0.6122 
in CD patients and 0.2627 in controls (P < 0.001), with phenotype of 87% for CD patients 
versus 50 % for controls. TNFb3 showed maximal level of linkage disequilebrium with 
HLA class IIDQB1 *0201 in CD patients. However, while the HLA class IIDQB1 *0201 / 
TNFa2 haplotype was strongly associated with CD, HLA class IIDQB1 *0201 was not 
significantly found in linkage disequilebrium with TNFa2, suggesting that TNFa2 is 
independently associated with CD. This association may have functional significance as 
TNFa2 has been correlated with high TNF production (McManus et al., 1995).
In 1997, Gallagher et al., reported strong association of TNFa2 allele with
colorectal cancer in two different populations. In a Glasgow (British) population studied,
the distribution of TNFa2 microsatellite out of the TNFa 1-14 microsatellites that were
examined, presented a phenotypic frequency of 62 (36.9 %) in colorectal cancer patients
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(n=84) versus 37(20.33 %) of controls (n=91with significance of (P=0.0008) after 
Bonferoni’s correction (Pc=0.0104). In an Essen (German) population that the study 
involved, the distribution of TNFa2 microsatellite out of the TNFa 1-14 microsatellites 
that examined, presented phenotypic frequency of 47 (20.1 %) in colorectal cancer patients 
(n=47) versus 33(35.1%) of controls (n=l 17) with significance of (P=0.0066). This dual­
population study shows clearly, that TNFa2 allele has a positive association with colorectal 
cancer (Gallagher et al., 1997).
The hypothesis that TNF genes and / or TNF microsatellites, may be in linkage due 
to their position and function, with other loci on chromosome 6 (e.g. MHC), has trigger the 
curiosity of many research groups to proceed to further studies. In 1997, Moghaddam et al., 
investigated the relationship between different microsatellites and HLA-DQ loci in insulin 
dependent diabetes mellitus (IDDM). IDDM is a genetically controlled autoimmune 
disease. It has been demonstrated that the HLA DQA1*0501-DQB1*0201/ DQA1*0301- 
DQB1 * 0302 genotype is the most prevalent genotype in Caucasian IDDM patients (She et 
al., 1996; Moghaddam et al., 1997). Additionally it has been reported that DRB 1*0403 
protects against IDDM in Caucasian patients with genotype DR3- DQ2 / DR4 -DQ8 (Van 
der Auwera, 1995; Moghaddam et al., 1997). To define additional markers for genetic 
susceptibility or protection in the HLA DQ high-risk genotype IDDM patients and controls 
(all having the HLA DQA1*0501-DQB1*0201/ DQA1*0301-DQB1* 0302 genotype), 
Moghaddam et al., 1997, examined eight-microsatellite loci (HLA F, D6S273, TNFa 
D6S265, D6S1014, DQcar, TAPI, and D6S291) spanning the entire MHC region. The 
results presented no significant difference between the frequencies and homozygosity of 
the alleles. However, TNFa displayed a significant deference between diabetic patients and 
controls. For TNFa 47% of the control subjects and only 23% of the diabetic patients were 
homozygous (odds ratio 0.32; 95% Cl 0.17-0.60; P <0.0003). Within the TNFa, marker 
allele *99 displayed a significant deference between diabetic patients and control subjects.
Heterozygosity for allele *99 was observed in 62% of the patients and in 35% of the
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controls with (P<0.0005). Linkage disequilibrium analyses revealed strong linkage 
disequilibrium of TNFa *99 and DRB 1*0301 in both patients and controls but absence of 
TNFa *99 from other haplotypes (e.g. DQ8-DR4) in patients is associated with 
susceptibility to IDDM. The results suggested that two or more susceptibility loci in the 
MHC correlated with increase susceptibility to IDDM and that TNFa *99 /
DRB 1 *0301 could be an additional marker for susceptibility to IDDM (Moghaddam et al.,
1997).
Other studies such as that of Tarasi et al., (1997) in a Greek SLE population 
suggested that TNF polymorphism may be related to renal complications of SLE patients 
but this relationship was closely linked between DRB1 *1501 and *1601 and *0701. 
Linkage disequilebrium described between DRB1 *1501, TNFa 11 and DR3 and TNFa2, 
b3, d2 but a significant association was not reported. A recent study by Rood, et al., 2000, 
reported that TNF -308 and HLA-DRB 1*0301 alleles contribute independently to 
susceptibility to SLE. The results presented TNF-308A or DRB1*0301 alleles to be more 
prevalent among SLE patients than control population with odd ratios of 0.5 and 4.4 
respectively. The hypothesis that an association between TNF-308A and DRB1*0301 
might cause DRB 1*0301 to act as a confounder in the relationship between TNF -308A 
and SLE was tested. The results show that DRB 1*0301 was significantly associated with 
TNF -308A (P < 0.0001). However, further analysis in that study revealed that TNF -  
308A and DRB 1*0301 alleles are independent susceptibility factors for SLE (Rood, et al, 
2000).
The identification of several allelic polymorphisms in very close physical linkage to 
the TNF locus has opened the way to a systematic study of associations between TNF 
alleles and the development of MHC linked diseases. Our study produced DQB1 allelic 
data from patients with gastric cancer and patients with Barrett’s oesophagus that 
compared with a pre-existing TNFa microsatellite-allelic data from the same patients in 
order to discover any allelic relations.
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8. MICROSATELLITES OVERVIEW
Microsatellites form a significant proportion of repetitive DNA sequences that 
widely incorporated in the human genome. Microsatellites are non-coding DNA 
sequences. Non-coding regions of DNA may play a functional role in the genome’s 
function, either directly via a role in gene regulation (Hamada et al, 1984; Koreth et al, 
1996) or indirectly as hot spots for recombination (Sligthon et al, 1980; Koreth et al, 
1996). Non-coding regions could be located within genes or between genes and are called 
“introns”. They are embedded in unique sequence and they can be amplified in vitro by the 
polymerase chain reaction (PCR). Tremendous genetic diversity has been allowed to 
develop in these regions. Much of this non-coding DNA consists of highly repetitive 
segments of DNA, consisting of several alterations of specific sequence known as “DNA- 
repeats”. Microsatellites display considerable polymorphism due to variation in the 
number of “repeats” (Heame et al, 1992). Therefore they are ideal markers for 
constructing high-resolution genetic maps in order to identify susceptibility loci involved in 
genetic deceases.
DNA repeats can occur as a tandem array but not always. Such sequences are called 
variable number tandem repeats (VNTRs). One such class of sequences in humans consist 
of simple tandem repeat (STRs) often a dinucleotide sometimes a tri -  tetra repeat 
consisting of CA (Adenosine-Cytosine) on one DNA strand and GT (Thymine-Guanine) 
on the other and / or CT (Cytosine- Thymine) on one DNA strand and GA (Guanine- 
Thymine) on the other. Such repeats of 2-5 nucleotide segments are known as 
microsatellite DNA and usually are repeat 15-30 times. A single pair of PCR 
oligonucleotide primers that surround such sequences can produce variable sized DNA 
fragments depending upon the number of repeats (Koreth et al, 1996).
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Such repetitive sequences have been classified as follows.
1. Satellite sequences: arrays with repeat sizes ranging from 5-100 bp organised in clusters 
up to 100Mb. These are located in heterochromatin near chromosomal centromers and 
telomers and are not variable in size within populations.
2. Minisatellites: arrays with repeat sizes of 15-70 bp, which range from 0.5 to 30 kb. 
Minisatellites are found in enchromatic regions of the genome and are highly variable in 
repeat size within populations
3. Minosatellite sequences: arrays with a repeat size 2-6 bp variables in size varying 
around lOObp.
The human genome contains large number of microsatellite repeats, each of which
can exhibit a high degree of polymorphisms and are inherited with a Mendelian fashion,
making them useful genetic markers. The human genome contains 50,000-100,000
interspersed microsatellite repeats of CA (Adenosine-Cytosine) occurring every 30-60Kb
in enchromatic regions of DNA. Their function is largely unknown but it has been
proposed that they may play a role in recombination and gene regulation (Martin et al,
1998; Heame et al, 1992).
Within and flanking the MHC, approximately 50 microsatellites have been typed,
most of which are CA repeats. Some of these were used in studies involving the MHC to
map genes thought to be responsible for diseases, such as the haemochromatosis gene,
which is located telomeric to HLA-A (Feder et al, 1996). Recent laboratory findings
suggested that microsatellites might be useful markers for mapping regions of disease
(Martin et al, 1998). A paradigm of some microsatellite markers across the HLA region
can be seen in (Fig 3).
The possibility of the involvement of cytokines in the genetic predisposition to
diseases has been proposed by a large variety of studies. Production of cytokines is
genetically regulated in the sense that the capacity to respond to stimuli is determined by
the genetic make up of individuals (Jacob et al, 1993). Deregulated cytokine production
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has shown to be implicated in various immune deficiencies, autoimmune and anti­
inflammatory (Jacob et al, 1993). For example, variation of TNF-a has been seen in 
human diseases such as autoimmune lupus nephritis (Jacob & McDevitt et al, 1988), SLE 
(Jacob et al, 1990) and in rodent models (Haranaka, et al, 1984). In this frame the main 
idea was to consider HLA associated diseases where one HLA component is sufficiently 
well known and where the direct involvement of HLA pathophysiology of disease, is 
certain or highly probable. Various disease populations and control populations selectively 
matched for HLA markers that are known to be involved in a disease, and typed for 
microsatellites in order to detect additional susceptibility markers.
This area of application of microsatellite HLA typing is broad and the interest in 
HLA microsatellite is still increasing. Many HLA region polymorphism studies in different 
populations have taken place (Foissac & Cambon-Thomsen, 1998). The HLA DQ region 
has been characterised as important for such analysis because it presents high level of 
linkage disequilibrium with HLA DR region that often results in complex patterns of class 
II allelic associations. For example in coeliac disease trans complementation of HLA 
DQA1-DQB1 alleles suggest a specific role of the DQ heterodimer in disease 
susceptibility. In the HLA region recently a microsatellite marker located 1-1.5 Kb 
centromeric to HLA DQB1 has been characterised. This is the DQ CAR (Lin et al, 1997). 
However, many other microsatellite markers have been described with HLA, too many to 
describe (Foissac & Cambon-Thomsen, 1998).
Instability in micro satellite repeats could cause genetic abnormalities that may lead
to carcinogenesis. Microsatellite instability recently has been suggested to result in
development of neoplasia. Microsatellite instability can be defined as the condition of
novel microsatellite alleles in tumours. It is believed that mutations in the mismatch repair
genes are responsible for development of some tumours, which exhibit microsatellite
instability. A paradigm would be the discovery of microsatellite instability in hereditary
nonpolyposis colon cancer (HNPCC) an autonomic dominant syndrome with
53
predisposition to colorectal and endometrial cancers (Lynch, et al., 1991). The first clue 
came from the observation of a previously unrecognised phenomenon in HNPCC, new 
microsatellite alleles “ T ” DNA compared to non-neoplastic “ N ” DNA. In HNPCC 
microsatellite instability was discovered to be due to germline mutations in genes that 
encode the components of DNA proofreading complex (Kunkel, 1993). In HNPCC linkage 
to the marker D2S123 on chromosome 2p was reported and it was noted that instability of 
microsatellite repeat number was present in microsatellites through out the genome 
(Peltomaki et al., 1993; Aaltonen et al., 1993). Candidate genes in the region of linkage on 
chromosome 2p were screened and the hMSH2 gene was identified by sequence homology 
to the yeast MSH2 gene and its protein product was shown to be a DNA mismatch binding 
protein (Leach et al., 1993; Fishel et al., 1993). Additional mismatch repair genes where 
shown to be involved in HNPCC such as hMLHl, hPMSl and hPMS2 that are 
homologues to bacterial mz^-HLS (Bronner et al., 1994; Nicolaides et al., 1994). 
Microsatellite instability has been identified in a high range of tumours such as sporadic 
colon carcinomas as well as endometrial carcinoma and gastric cancer with multiple 
replication errors as in HNPCC cases (Woostrer et al., 1994; Peltomaki et al., 1993). In 
contrast with other sporadic tumours such as lung, breast, testis, CNS tumours and soft 
tissue sarcomas, micro satellite instability is present but has been described as a rare event, 
only affecting a single microsatellite loci (Woostrer et al., 1994; Peltomaki et al., 1993).
The contribution of such genomic instability to carcinogenesis is not clear as yet. 
What is unclear is whether a mutation targeting specific sequence repeats or that the 
genomic instability has general effects, non-specifically activating oncogenes and / or 
inactivating tumour suppressor genes. Markowits et al., (1995) reported that TGF-p 
receptor gene (a tumour suppressor gene) is inactivated specifically in colon cancer cell 
lines favours the former feasibility.
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HEAT SHOCK PROTEIN 70 FAMILY AND (HSP-70-2) MARKER
Heat shock proteins (HSPs) are present in both prokaryotic and eukaryotic cells. 
Their highly complex structure suggests that they play a role in intracellular processes. 
Heat shock proteins are synthesised in response to stress. Rapid induction of heat shock 
proteins accompanies, a decrease in transcription and translation of other genes and gene 
products. HSPs are present in the cytosol, mitochondria, endoplasmic reticulum and 
nucleus. They have a relatively long half-life of 48 hours in human epidermoid cells. The 
complete function of these proteins is not clear as yet. There is substantial evidence 
linking heat shock proteins with a protective mechanism during and following cellular 
stress. The protection is probably mediated by the HSP’s capacity to function as molecular 
chaperones to prevent inappropriate protein aggregation and to mediate transport of 
immune proteins to the target organelles for final packaging, degradation or repair (Kiang 
et al, 1998). Furthermore, there is a close relationship between heat shock protein 
expresion and malignant transformation in mammalian cells (Harrison et al, 1987).
The locus encoding for the major heat shock protein (HSP-70) is located between
the complement and the TNF genes (Fig 8). The HSP 70 loci are 12 Kb apart and lie 92 Kb
telomeric of C2 genes (Milner & Campbell, 1990). HSP 70 proteins have a protective role
during and after cellular stress (Sargent et al, 1989). Nucleotide sequence analysis of the
two introless genes HSP 70-1 and HSP 70-2 has shown that these genes encode an
identical product of 641 amino acids long (Milner & Campbell, 1990; Hunt & Morimoto,
1985). A third introless gene HSP 70-Hom exists in the HSP70 region and located 4 Kb
telomeric to HSP 70-1 gene. This encodes for a basic protein of 641 amino acids long,
which have be found to have 90% sequence similarly with HSP 70-1 (Milner & Campbell,
1990). The HSP-Hom appears to be constantly expressed but the levels of mRNA are not
increased following heat shock (Milner & Campbell, 1990). The fact that two closely
linked loci both express an identical protein is surprising. A possible explanation could be
that the range of stress factors that induce HSP 70 expresion is too high for the promotor
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sequence of a single gene to recognise them all. Thus, two genes HSP70-1 and HSP70-2 
are required to provide adequate response. Expression of HSP 70 is related to endothelial 
cell activation through adhesion molecules such as ICAM-1, VCAM-1 and release of IL-8, 
which has been found being increased in alograft presentation studies and related 
endothelial injury studies (Eberl et al, 1999). However, expression of HSP 70 is related to 
age according to Rao et al., (1999). Rao et al, (1999) demonstrated that there is an age 
related reduced expresion of HSP 70 in human peripheral lymphocytes. Low expresion of 
HSPs may correlate with decreased resistance to infections and increased mortality in the 
elderly. It is noteworthy in this respect, that lymphocyte activity induced by interleukins 
and mitogens also induces the synthesis of HSPs at the transcriptional and translational 
level. Moreover, HSPs associated with processing of protein antigens that associated with 
human diseases such as malaria and leishmaniasis for example (Rao et al., 1999). In many 
bacterial and parasitic infections the HSP 70s are the immunodominant antigens of the 
infecting organisms (Kiang et al., 1998). HSPs are present only intracellularly. How the T- 
cells recognise the bacterial or parasitic HSPs is not clear yet. It is believed that the 
bacterial produced protein GroEL is secreted or present on the surface membrane and 
allows T cells to bind to the GroEL antigen. Another possibility is that cytolysis of 
infected cells releases pathogenic HSPs to the extracellular space where they are detected 
by host immune cells. Macrophages respond to infection by releasing cytokines, oxygen 
free radicals and nitric oxide, which are involved in killing the infected cells (Snyder et al., 
1992). On the other hand the synthesis of HSPs in macrophages increased by the release of 
cytokines, oxygen free radicals and nitric oxide (Matnney et al., 1992). However, increase 
in HSPs in macrophages in turn inhibits cytokines, oxygen free radicals and nitric oxide 
production leading to ineffective immune responses (Shigetada et al, 1996). Thus, Increase 
expresion of HSPs may not benefit the host.
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Fig 8. Molecular map of the MHC class III region, showing the position of the HSP 70 loci 
(green colour) in relation to other genes identified in this region. HSP 70 loci lie 92 
Kb telomeric to the C2 gene. HSP 70-1 and the locus of interest HSP 70-2 (violet 
colour) are 12Kb apart. The position of the cognate gene HSC 70 is also shown. The 
map is not to scale.
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HSP 70 is involved in bacterial infections as mentioned previously. Surface- 
associated HSP 70 mediates Helicobacter Pylori attachment to epithelial cells. The 
increase expresion of heat shock proteins following acid shock correlates with association 
with inflammation of gastric mucosa (Hoffman & Gurdano, 1999). Thus, heat shock 
proteins may play an important role in the colonisation of bacteria in the stomach and 
mucosal infection and promoting inflammation (Hoffman & Gurdano, 1999). This finding 
is a very important reason that has driven us to investigate the HSP 70 in this study. Also 
liberated HSPs may play a prominent role in promoting inflammation since it has been 
demonstrated that HSPs induce the production of INF-y and TNF- a  in mouse gastric tissue 
infected by Helicobacter Pylori (Hoffman & Gurdano, 1999). HSP 70 plays an important 
role in cytoprotection against TNF mediated cytotoxicity (Nishimura et al, 1997). HSP 70 
acts as protector against macrophage TNF induced cell death (Jaattela, 1999). This 
mechanism has been demonstrated previously in macrophages infected by bacteria such as 
Salmonella (Nishimura et al, 1997). Although in other infections from protozoa such as 
Leismania donovani TNF plays an integral role in host response (Salotra et al, 1995).
TNF is essential for expression of cytotoxic levels of nitric oxide, which mediates 
intracellular killing of Leismania donovani. Furthermore TNF may itself produce proteins 
that protect cells from TNF mediated cytotolysis essential in macrophage survival (Wong 
et al, 1989). However, induction of heat shock proteins by TNF has been demonstrated 
only in bacteria (Nishimura et al, 1997).
Studies such that of Salotra et al, (1995) and Ahn et al, (1998) have demonstrated
the role of HSP 70 in apoptosis. Heat shock proteins are involved in cell death. HSP 70
induces infiltrate of T-cells, macrophages and dendritic cells into tumours as well as Thl
cytokine expresion of IFNy, TNFa and IL-12 where it enhances immunogenisity via a T-
cell mediated mechanism. HSP 70 protection is both tumour and cell specific. HSP 70
acts as a chaperone and is involved in direct chaperoning into dendritic cells (Todryk et al,
1999). Mutations of P53 gene are known to result in the generation of mutant proteins and
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in tumourogenesis. HSP 70 in most cases binds mutant P53 proteins and presents them to 
leucocytes for elimination (Fourier et al, 1997). Induction of heat shock proteins in many 
tumour cells renders them resistant to cytotoxicity mediated by TNF (Salotra et al., 1995; 
Kusher et al, 1990). Wei et al., (1995) showed that HSP 70 gene overexpression in 
tumour cells inhibits cell proliferation. The induction of apoptosis that takes place suggests 
that HSP 70 is required for tumour cell proliferation and survival. Ahn et al, (1998) 
demonstrated resistance to apoptosis by utilising a prostaglandin and c-myc mRNA 
expresion model. Decrease in prostaglandin (known to act as anti-proliferative) was 
related to the amount of c-myc expresion. Induction of c-myc regulated the elevation of 
HSP 70, resulting in decrease of intracellular apoptosis. Therefore tumour immunogenisity 
is determined by the mechanism of cell death via HSP 70s expresion. Research groups are 
now focusing on the utilisation of gene transfer to tumour cells in order to stimulate an 
anti-tumour immune response (Melcher et al, 1998).
Several genes with anti apoptotic activity have been determined in studies such that
of Mussarella et al, (1998) in an avian blastodermal cell model derived from fertile
chicken eggs. In that study genes including the bcl-2, bcl-X L , HSP 70, grp 78 and
glutathionine S-transferase were expressed as early as in stage 1 in embryo of the newly
oviposide egg. Significant levels of HSP 70 mRNA found when such genes were
expressed. However the whole mechanism of induction of resistance to apoptosis is not
clear yet. Many other proteins are probably involved. One example is the BAG-1
(Takayama et al, 1998). Human BAG-1 proteins have 3 isoforms BAG-1, BAG-1M and
BAG-1L. BAG-1 proteins have the ability to bind to HSP 70 and HSC 70, a HSP 70
cognate gene (Fig 8), which is constitutively expressed and shares 82 % similarity in its
amino acid sequence with HSP 70 (Dwomiczak & Mirault, 1987). The BAG-1 protein has
been identified as a novel regulator of apoptosis. Its ability to bind to Bcl-2 results in
increased levels of BAG-1. This has been seen in correlation with increased levels of Bcl-2
suppressing apoptosis via CD95 (fas/apo-1) in tumour cell lines from leukaemia, breast
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cancer, prostate cancer and colon cancer that examined by (Takayama et al, 1998). IL-2 
and IL-3, up regulate the expresion of BAG-1 significantly for cell survival and enhances 
independent cell growth (Adachi et al., 1996). In gastric cancer, the complex HSP 70 -  
Bel 2 probably promotes cells survival where BAG-1 accelerates cell motility (Takayama 
et al, 1998). Naishiro et al., (1999), provided evidence that gene transfer mediated the 
over-expression of BAG-1. The result of this gene transfer was a remarkable increase in 
the motility of human gastric cancer cells but without any alterations in cell morphology or 
adhesion capacity. Heat shock proteins are directly expressed in human gastrointestinal 
cancers. HSP 70 and HSP 27 mRNA levels found to be differentially expressed in 
gastrointestinal cancers (Ehrenfield et al., 1995). Similarly the results in pancreatic cancer 
and colon cancer in the same study suggested that deferential expresion of HSP 70 occurs 
but not as strongly as in gastric cancers. In other cases such that of squamus cell carcinoma 
of the oesophagus, the expresion of HSP 70 and HSP 27 was found to be frequently 
reduced, suggesting that HSP 70 and HSP 27 are independent prognostic factors 
(Kawanishi et al., 1998).
The possibility that HSP 70 may be involved in various aspect of the immune 
system has risen. The specific location of HSP70 gene complex between the classical 
transplantation antigens and the TNF locus makes the nature of these proteins and genes 
obviously vital in different diseases involving bacterial infections as described above and 
cancer. Additionally, proof exists that HSP 70 is involved in bacterial colonisation, 
infection and inhibition of apoptotic cascades in cancers including gastrointestinal cancers. 
Taken into consideration all those facts, it was deemed important to investigate the role of 
HSP 70 locus in this project. The primer sequences for the HSP 70-2 microsatellite 
analysis that utilised in this study are described in the method and materials section.
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The D6S273 MICROSATELLITE MARKER
The microsatellite marker D6S273 has a range of 126-142 bp in size. It is located 
between the HSP70 locus, BAT 2 and the TNF locus within the MHC III (Fig 3). The 
MHC class III region remains among the most gene- rich regions of the human genome 
with on average, one gene per 10 Kb of DNA. Because of its location near HSP-70 that is 
known to be involved in carcinogenesis and inflammation, and near TNF another factor 
that is involved in carcinogenesis and regulation of inflammation, and also because of its 
positive involvement with diseases that described below, D6S273 was the best possible site 
to investigate next.
A 30Kb segment of the MHC class III region lying between the heat shock protein 
HSP-70 and TNF genes has been recently sequenced by Ribas et al., (1999). The 
sequencing revealed the localization of seven genes whose precise position and order is 
cen-G7-G6-G6A-G6B-G6C-G6D-G6E-tel. These genes belong to the Ly-6 superfamily. It 
is believed that the Ly-6 superfamily of genes, are involved in leukocyte maturation. The 
microsatellite marker D6S273 was contained within this sequence. In different population 
studies, D6S273 microsatellite alleles and TNFa microsatellite alleles presented a variation 
in their distribution. This variability of expression may result in the variability of onset of 
diseases including cancer. In studies such as that of Gubric et al., (1999) in a Croatian 
population this kind of variation-irregularity in specific microsatellite alleles in different 
populations were confirmed, compared with studies in other populations such as in Dutch, 
Italian, Greek, Basques and Danish. Then most frequent alleles at D6S273 locus were 
D6S273 134bp and 136bp while at TNF locus two most frequent alleles were TNFa 117bp 
and 99bp. In that study it was concluded that the irregularity in distribution of 
microsatellite alleles in different populations with the predominance of two or three alleles 
on these two investigated microsatellite loci was present.
Different studies have observed possible association of D6S273 microsatellite
alleles with diseases. Marker D6S273 has now been reported to be strongly associated
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with autoimmune diseases such as Ankylosing Spondylitis (AS), as reported by Brown et 
al, (1998) in the British population and probably it is in linkage with other genes within 
the HLA class III region, such as the HSP 70 that is found not to be independently 
associated with (AS) by Fraile et al, (1998).
Another example that indicates the association of D6S273 marker with disease is 
that of IDDM1. IDDM1 is a genetically controlled disease resulting from the destruction 
of p-cells in the pancreas. D6S273 microsatellite alleles are found to contribute to the 
genetic risk, especially the alleles 136 and 140. However a recombination linkage between 
DQ and TNFa was reported as an additional contributory factor in IDDM1 (Moghaddam et 
al., (1998). In contrast, the HLA-DR and TNFp markers have been reported by Haines et 
al., (1998) to have strong genetic linkage with D6S273 marker and the onset of Multiple 
Sclerosis (MS). In other diseases such that of Rheumatoid arthritis (RA) D6S273 is now 
believed to have an association. Rheumatoid arthritis (RA) is a chronic inflammatory 
disease that is associated with the HLA-DRB1 genes. A resent study by Signal, D.P. (1998) 
revealed that two D6S273 microsatellite alleles 132 and 138 were significantly associated 
in Canadian patients with RA. Such studies suggest that D6S273 has not an independent 
association with diseases but probably are in strong linkage with other markers.
D6S273 marker now believed to be linked with some types of cancer. However not 
many studies have utilised this marker to investigate cancer and the literature lacks a 
significant amount of information regarding the cancer issue. One example of the few 
cancer studies that utilized the D6S273 marker is that of Mazurenko et al., (1999) 
regarding cervical cancer where demonstrated that deletion of alleles in chromosome 6 
leads to LOH and microsatellite instability MIN. In the study curried out by Mazurenko et 
al., (1999) it was reported that the highest LOH was observed in the HLA region within the 
markers D6S273 and D6S276 where MIN was found in 3 out of 62 cases. Such results 
suggest that several regions in chromosome 6 might harbour potential tumour suppressor 
genes important in cervical cancer.
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Taken together such studies and the lack of extensive information in literature 
regarding D6S273 and cancer, good reasons existed to lead us in the investigation of the 
distribution of D6S273 alleles in a West of Scotland (Glasgow) population and tried to 
estimate association of any of the D6S273 microsatellite alleles with gastric and 
oesophageal cancer.
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AIMS OF THE PROJECT
The genetic control of inflammation must be an important factor in pre-malignant 
cases of Barrett’s oesophagus and gastric cancer. The location and expresion of certain 
genetic loci such as DQpl, HSP 70 and polymorphic sites such as TNFa and D6S273 
within chromosome 6 suggests their importance in this control. The fact that TNF locus has 
already been implicated in malignant progression through its ability to promote the 
invasive properties of tumour cells in gastrointestinal cancers, further fuels the hypothesis. 
Taking into account the information already known linking genotype expresion of such 
markers and disease several aims were drawn up.
First to carry out a thorough allelotype and genotype analysis of the sites around 
TNF locus on human chromosome 6 in a Barrett’s oesophagus population and in a gastric 
cancer population. In doing so, to optimise the reaction conditions for the detection of the 
alleles was necessary.
Second to determine whether the normal populations present similarities or 
differences to pre-malignant and malignant populations where certain alleles may present 
overexpression.
Third to compare the data obtained from the loci investigated in this study with that 
previously collected within the group regarding TNFa in Barrett’s oesophagus and gastric 
cancer. This would allow the detection of any differences and / or similarities between the 
populations to be noted, with a possible suggestion as to whether genotype expresion 
patterns were a feature of these pre-malignant and malignant conditions.
Fourth to attempt to draw conclusions about the role of TNF, either as an 
independent factor or in conjunction with the other three loci that were examined.
There are no previous attempts at this project but a small number of similar studies in 
different diseases including some other various types of cancer, have utilised similar and / 
or the same genetic markers concluding to positive results. The whole experimental
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process was then carried out within a laboratory at the Lister Department of Surgery at the 
North Glasgow Hospitals University Trust.
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MA TERIALS & 
METHODS
MATERIALS AND METHODS
DNA - EXTRACTION
Genomic DNA was used from a panel of stock samples that already existed in the 
laboratory. Extraction of this genomic DNA, had previously been carried out by others 
using the Dynal® DNA extraction Kit (Tissue Typing-Dynal SSP, Technical Handbook, 
First edition, 1996) from whole blood lymphocytes, from malignant Barrett’s oesophagus, 
gastric cancer and normal populations whereas the benign population DNA was extracted 
from a panel of histological materials (Slides) using the method as described by (Wright 
D.K., Manos M. M. “Sample preparation from paraffin-embedded tissues” In Innis, M., 
Gelfand, D. H., Sninsky J. J., White, T., eds. PCR Protocols: “A guide to method and 
applications”. San Diego academic press, 1990; 153-158). The tumor location of the 
gastric cancer samples obtained was various, 11 were proximal gastric, 3 distal 1/3 
oesophagus, 33 antrum, 16 corpus of stomach, 5 whole stomach and 2 gastro-jejeunostomy 
stoma.
The concentration of samples ranged from 5 ng /pi to 10 ng /pi for the benign DNA 
samples from patients with Barrett’s oesophagus, whereas the malignant DNA samples 
from patients with Barrett’s oesophagus, and DNA samples from patients with gastric 
cancer ranged between 50 ng /pi to 100 ng /pi. The normal DNA needed to be diluted to 
50 ng /pi to be effective.
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PART 1. DOB1 -Typing
Study subjects
DNA samples from 101 disease free Caucasian unrelated subjects, from 51 
Caucasian unrelated patients with Barrett’s adenocarcinoma oesophagus, from 37 
Caucasian unrelated patients with benign Barrett’s oesophagus and from 44 Caucasian 
unrelated patients with gastric adenocarcinoma were investigated. The patient and control 
population originated from the West of Scotland. The control population data was obtained 
from the west of Scotland tissue typing laboratory, Glasgow Royal Infirmary.
Polymerase chain reaction (PCR)
Dynal ^4//set™ SSP DQ “Low resolution sets” were used. The protocol is based on 
(Aldener-Canava & Olerup, 1994; Olerup, et al., 1993). Each PCR-SSP 8-tube reaction per 
person mixture was consisted of lOpl of each genomic DNA sample (lp l per reaction), 
lxAdvanced Biotechnologies PCR buffer (200mM (NFL^ SO^ 750 mM Tris-HCl, pH 
(8.8) at 25 °C, 0.1% (v/v) Tween® 20), 1.5 mM MgCl2, 200pM each of (dATP, dCTP, 
dGTP and dTTP), 0.5 units / reaction Ampli -Taq ™ DNA polymerase (Advanced 
Biotechnologies 5 units/pl), 10 % (v/v) glycerol, and Cresol Red, sodium salt (100 pg/ml) 
resulting to final volume of lOOpl DNA-PCR solution-Ampli-Taq mixture. The PCR 
reaction micro-tubes and master mix tubes were always kept on ice during preparation. Ten 
microlitre of the DNA-PCR solution-Ampli-Taq mixture was dispensed into each of 8- 
microtube set (Fig. 9), pre-coated with the allele and group specific primer mixes and 
control primers matching non-allelic sequences. The allelic and serological relationship of 
DQp 1 is shown on (Table 2).
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Fig 9. Tray lay out.
The tubes are pre-coated with the allele and group specific primer mixes and 
control primers matching non-allelic sequences. The coloured shaded areas 
represent the coated portion of the tubes.
68
Table 2. To show the allelic and serological relationship of DQB1 alleles, (Dynal yl/Zset™) 
SSP “DQ low resolution”
Tube number Product 
size bp
Alleles DQ Serology
1 2 2 0 DQB1 *0501 -DQB1 *0504 5
2 2 2 0 DQB1 *06011-DQB1*0613 6
3 205 DQB1 *0201- DQB1*0203 2
4
130,145
DQB 1*0201, DQB 1*0202, 
DQB 1*0302, DQB1*0301- 
DQB 1*0307, DQB 1*0308
2, 8,3
5 125 DQB1 *0301, DQB1*0304 7
6 125,140 DQB1 *0302, DQB1 *03032, DQB1 
*0305- DQB1 *0307
8 , 9,3
7 125 DQB1*0203, DQB1*0301 DQB1 
*03032, DQB1*0306
2, 7, 9, 3
8 130 DQB1 *0401, DQB 1*0402 4
Adopted from the Dynal ^4//set™ “ DQ low resolution” literature.
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PCR Cycling parameters
PCR amplification was carried out in a PTC-225 DNA Engine, Tetrad, (Version 
0.3), 96-well plate thermal cycler. After an initial denaturation at 94 °C for 2 minutes the 
DNAs were amplified by 30 amplification cycles. The first 10 cycles consisted of 
denaturation at 94 °C for 10 seconds and a combined annealing and extension step at 65 °C 
for 60 seconds. The following 20 cycles consisted of denaturation at 94 °C for 10 seconds, 
annealing at 61 °C for 50 seconds and an extension at 72 °C for 30 seconds.
Visualisation of amplifications
The visualisation of the amplified DNA was performed by agarose gel 
electrophoresis. The whole PCR reaction products were directly electrophorised on 2 % 
agarose (SEA KEM LE™) or Ultra Pure agarose (GIBCO™) pre-stained with ethidium 
bromide (0.25pg/ml). The gels electrophorised for 20 minutes at 150 mAmps/cm in lxTBE 
buffer solution consisted of (34 mM Tris-base, 34 mM boric acid, 4mM EDTA, pH 8.0) 
and visualised under ultra violet illumination. The PCR product obtained was dependent to 
the specific primer amplification taken place each time and the control PCR product was a 
standard of 425 base pair of the human growth factor as indicated in the manual of the 
Dynal Allset™ SSP set (October 1998). The <|)xl74-RF DNA / Hae III sequencing ladder 
(GIBO™. BRL.UK) or the hyperLadder-I™ (Bioline Ltd) was used to determine the 
fragments length.
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PART 2. HSP 70-2 restriction fragment length polymorphism marker
Study subjects
DNA samples from 111 disease free Caucasian unrelated subjects, from 30 
Caucasian unrelated patients with Barrett’s adenocarcinoma oesophagus, from 26 
Caucasian unrelated patients with benign Barrett’s oesophagus and from 42 Caucasian 
unrelated patients with gastric adenocarcinoma were investigated. The patient and control 
population was originated from the West of Scotland.
Polymerase chain reaction (PCR)
In order to explore the possibility that HSP 70-2 gene locus may be involved in 
determining the susceptibility to Barrett’s oesophagus and gastric carcinoma, the HSP 70-2 
restriction fragment length polymorphism (RFLPs) was investigated by PCR. The coding 
sequence of the HSP 70-2 gene was amplified, using sequence specific oligonucleotide 
primers and considering the polymorphic Pst-I restriction site at position 1267 of these 
alleles. (Nucleotide 1267 of structural HSP 70-2 gene) The 5'-primer: 5'- CAT CGA CTT 
CTA CAC GT CCA -3' was used in combination with the 3'-primer: 5'- CAA AGT CCT 
TGA GTC CAA AC -3' (MWG Biotech AG, UK). The PCR reaction mixture consisted of 
50 ng/pl genomic DNA, 200pM each of (dATP, dCTP, dGTP and dTTP), 2 mM MgCU, 
lxAdvanced Biotechnologies PCR buffer (2 0 0 mM(NH4)2 SC>45 750 mM Tris-HCl, pH 
(8 .8 ) at 25 °C, 0.1% (v/v) Tween® 20), ImM of each primer, 0.5 units Ampli-Taq™ DNA 
polymerase (Advanced Biotechnologies 5 units/pl), and two drops of liquid paraffin, in a 
total of 25 pi reaction volume.
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PCR Cycling parameters
PCR amplifications were carried out in a Biometra Uno-thermoblock™ thermal 
cycler (Biometra™ USA) that did not have a heated lid. Amplification was accomplished 
by an initial denaturation at 94 °C for 5 minutes, followed by 30-35 cycles (depending to 
Sample origin and concentration) each consisted of further denaturation at 94 °C for 30 
seconds, annealing at 56 °C for 30 seconds, extension at 72 °C for 30 seconds and a final 
extension at 72 °C for 5 minutes.
Visualisation of amplifications
The visualisation of the amplified DNA was performed by agarose gel 
electrophoresis. Five microlitre of PCR reaction products were mixed with 5pl orange-G 
and electrophorised on 2 % Ultra Pure agarose (GIBCO™) pre-stained with ethidium 
bromide (0.25pg/ml). The gels electrophorised for 40 minutes at 80 mAmps/cm in lxTBE 
buffer solution consisted of (34 mM Tris-base, 34 mM boric acid, 4mM EDTA, pH 8.0) 
and visualised under ultra violet illumination. The (|)xl74-RF DNA / Hae III sequencing 
ladder (GIBCO™. BRL UK) or the hyperLadder-I™ (Bioline Ltd) was used to determine 
the fragments length.
PCR -product digestion (RFLPs)
To assess the polymorphism (RFLP) of the HSP 70-2 at position 1267 the 
corresponding PCR products were digested with Pst-1 restriction digest enzyme 5'- 
CTGCA -3' and 3'- GACGTC -5' (Stratagene, USA). The digestion mixture were consisted 
of 1 xUniversal buffer (1 M koAc, 250 mM Tris acetate, pH 7.6, 100 mM MgoAc, 5 mM 
B-mercaptoethanol, 100 pg / ml BSA), 5 units of Pst-I restriction digest enzyme, sterile 
H2O and lOpl of PCR product template. The mixture was incubated for 3 hours in order 
the digestion to take place.
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Visualisation of RFLP products
The visualisation of the amplified DNA was performed by agarose gel 
electrophoresis. The PCR digested products were mixed with 5pi orange-G and 
electrophorised on 2 % Ultra Pure agarose (GIBCO™) pre-stained with ethidium bromide 
(0.25pg/ml). The gels electrophorised for 40 minutes at 80 mAmps/cm in lxTBE buffer 
solution consisted of (34 mM Tris-base, 34 mM boric acid, 4mM EDTA, pH 8.0) and 
visualised under ultra violet illumination. The (j)xl74-RF DNA / Hae III sequencing ladder 
(GIBCO™BRL.UK) or the hyperLadder-I™ (Bioline Ltd) was used to determine the 
(RFLP) fragments length of (1117 bp) and (936 bp).
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PART 3. D6S273 restriction polymorphism microsatellite marker
Study subjects
DNA samples from 105 disease free Caucasian unrelated subjects, from 32 
Caucasian unrelated patients with Barrett’s adenocarcinoma oesophagus, from 13 
Caucasian unrelated patients with benign Barrett’s oesophagus and from 37 Caucasian 
unrelated patients with gastric adenocarcinoma were investigated. The patient and control 
population originated from the West of Scotland.
Polymerase chain reaction (PCR)
In order to explore the possibility that D6S273 marker may be involved in 
determining the susceptibility to Barrett’s oesophagus and gastric carcinoma, amplification 
of microsatellite locus D6S273 was performed in a total reaction volume of 10p,l 
containing 50 ng of genomic DNA. The PCR reaction mixture also consisted of lxBioline 
™ reaction buffer (160mM (NH4)2S0 4, 670 mM Tris-HCl (pH 8 . 8  at 25 °C), 0.1 % Tween- 
20), 2 mM MgCl2, 0.5 units Biotaq™ DNA polymerase(Bioline, Ltd, UK), 0.5pM of 
each primer, 200pM of each (dATP, GTP, TTP), and 1:10 of dCTP. The sequences of the 
D6S273 primers used for amplification were D6S273-1= 5'- GCA ACTT TTC TGT CAA 
TCCA -3' and D6S273 -2  = 5'- AC CAA ACT TCA AAT TTT CGG -3' (MWG Biotech 
AG, UK). The primer D6S273-1 was 5'-end labelled with [r32 P] d-CTP (370 MBq / ml-10 
Ci / ml) purchased from Amersam Pharmacia biotech Ltd, UK.
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PCR Cycling parameters
PCR amplifications were carried out in a Biometra Uno-thermoblock™ thermal 
cycler (Biometra™ USA) without heated lid. Amplification was accomplished by initial 
denaturation at 94 °C for 5 minutes, followed by 34 cycles each consisted of further 
denaturation at 94 °C for 30 seconds, annealing at 48 °C for 30 seconds, extension at 72 °C 
for 30 seconds and a final extension at 72 °C for 30 seconds.
Preparation of 6%  polyacrylamide gel
The 6 % polyacrylamide gels were prepared by mixing 15 ml of 40% acrylamide 
solution with 20 ml of 5xTBE and with 7 M Urea. The final volume of 100 ml was 
adjusted with the addition of distilled deionised H2O. The mixture was let to dissolve for 
about 1 hour. Finally 50pl of TEMED (C6 H16 N2) and 750 pi of 10% ammonium 
persulphate was added for the polymerisation to take place. The solution was poured 
between a set of glass plates, separated with 1mm plastic spacers using a 50 ml syringe, 
where a sequencing comb was inserted to form a well. The gel was always left overnight 
in order the polymerisation to take place.
Visualisation of amplifications
The PCR amplified DNA was analysed following electrophoresis on a 6 % 
denaturing polyacrylamide gel. Prior of loading the 6 % polyacrylamide gel with the 
amplified DNA, 4 pi of denaturing enzyme formamide (GIBCO™BRL.UK) was added in 
each of the PCR amplified products and then placed in a Biometra Uno-thermoblock™ 
thermal cycler (Biometra™ USA) for 10 minutes at 80 °C for the denaturation to take 
place. The gels electrophorised for 3 hours at 75 mAmps/cm in lxTBE buffer solution 
consisted of (34 mM Tris-base, 34 mM boric acid, 4 mM EDTA, pH 8.0). The 
polyacrylamide-sequencing gels were dried and autoradiographed overnight using
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radiographic intensifying screens. The D6S273 alleles were identified by the size of the 
amplified fragments (126 bp, 128 bp, 130 bp, 132 bp, 134 bp, 136 bp, 138 bp) on a 
lightbox.
Optimisation of the protocols for determining genotype at the three loci
Attempts were made to optimise the PCR reactions and gel conditions of the 
individual three loci. For the optimisation of PCR reactions standard cell line DNA 
(Bristol, UK) was utilised. The optimisation of the PCR reactions was performed following 
some simple steps. The annealing temperature was first calculated by taking into 
consideration the melting temperature (Tm) of the primers from the manufactures 
documentation. After an initial PCR the annealing temperature was adjusted if it was 
necessary. An MgCE titration was then performed in order to identify the best possible 
concentration of MgCE that the certain PCR would produce appropriate results. This was 
varied from 0.5 mM to 2.0 mM in increments of 0.5 mM. The primer concentration was 
titrated in some instances. This was varied from 0.5pM to 1.5pM in increments of 0.5pM. 
A touchdown PCR program of cycling was tried as an alternative to the original decided. 
Sometimes the extension time was needed to adjust in order to avoid miss-amplifications 
that may interfere with the expected fragments. Although there were situations, in which 
Taq polymerase was tested from Ampli -Taq ™ DNA polymerase (Advanced 
Biotechnologies, UK), Biotaq™ DNA Polymerase (Bioline Ltd, UK) and Primezyme Taq™ 
in order to identify the most appropriate for the specific PCR to work with. In all cases the 
enzyme was supplied with a PCR Buffer and Mg CI2 buffer. Both were tried during the 
optimisation process. All the PCR reactions in this investigation were standardised in the 
same way. Genotype determination was tested on a 2 % Ultra Pure agarose (GIBCO™) or 
(SEA KEM LE™) pre-stained with ethidium bromide (0.25pg/ml) or on a 6  % denaturing 
polyacrylamide gel respectively. The complete optimised protocols are detailed above.
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PREPARATION OF STOCK SOLUTIONS
Preparation of 40 %  acrylamide stock solution
The 40% acrylamide (19:1) stock solution used, was prepared by mixing 38gr of 
acrylamide (CH2: CH.NH2) with 2 gr Bis-Acrylamide (CH2: CH.CO.NH) 2CH2). The 
mixture was dissolved in a total volume of 100ml solution (pH 7.0) with the addition of 
distilled deionised H20. The mixture was deionised over night with 0.2 volume of 
monobed resin, followed by filtration through Whatman No.l paper. Deionisation was 
necessary as acrylamide (CH2: CH.NH2) and Bis-Acrylamide (CH2: CH.CO.NH) 2CH2) are 
often contaminated with metal ions during the manufacturing process.
Preparation of 5xTBE stock solution per litre
5 x TBE stock solution was prepared by mixing 54 g Tris base with 27.5 g boric 
acid (H3 BO3) and 20 ml EDTA (0.5 M) pH 8.0. The mixture was dissolved in a total 
volume of 1 litre with distilled deionised H20 .
Preparation of 10% Ammonium Persulphate Stock solution
10% Ammonium Persulfate was prepared by dissolving lgr ammonium persulphate 
(NH4)2S20 g in a total volume of 10ml H20. The stock solution was dispensed in 1.5 ml 
vials and stored in -20 °C.
Preparation of EDTA (0.5 M) solution
EDTA (0.5 M) prepared by dissolving 18.6 g EDTA and 21 pellets of sodium hydroxide in 
100ml of distilled deionised H20 . The solution was adjusted to pH 8.0
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RESULTS
RESULTS
DOB1 results methodology
The protocol employed for this type of experiment was a standard yf/ZSet™ SSP 
“Low resolution” tissue typing procedure for DQpityping, purchased as a kit from Dynal 
Ltd, UK. The allelic specificity for each serotype is presented in Table 2. Based on 
sequence similarities, the allelotype DQp*0305 and DQP*0307 will type serologically as 
DQ 8  (DQP*0302) and that DQP*0306 will type serologically as DQ 9 (DQP*03032).
The serotype DQ 7 incorporating the allelotypes DQp*0301, DQp*0304, the 
serotype DQ 8  incorporating the allelotype DQp*0302 and the serotype DQ 9 
incorporating the allelotype DQp*03032 will type serologically as DQ 3 that is incorporate 
the allelotypes DQp*0301 to DQP*0307 (Table 2). Therefore, any probable DQ 7, DQ 8 , 
DQ 9 predicted serotype results will be accounted as serotype DQ 3, the reason being that it 
is impossible to identity specific allelotypes for these three former serotypes utilising an 
^//Set™ SSP “Low resolution” DQpi typing kit. Additionally, all the serotypes incorporate 
a group of alleles (see Table 2). Thus, it is impossible to determine precisely specific 
DQpi allelotypes. Therefore, all the DQpi data obtained will be presented as a serotype 
with correspondence to the allelotypes in Table 2. If such specificity was to be determined 
specifically an yf/ZSet™ SSP “High resolution” DQpityping protocol must have been 
employed but it is very expensive to do so.
The DQB1 locus
The results at this locus are presented in Table 3. Among the entire test populations 
and the control population the serotype DQ 2 * 3 in benign Barrett’s (32.4 %) presents the 
highest expresion in frequency. The results show that the serotype DQ 2 * 3 is by far the 
most commonly expressed in control population (20.7%) and also in the three test
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populations gastric cancer (22.7%), benign Barrett’s (32.4%) and malignant Barrett’s 
(19.6%). However, no significant association is present. Within the control population the 
serotypes DQ 2 * 6  (13.9%) and DQ 3 * 6  (13.9%) are the second most frequently 
expressed. In benign Barrett’s population the serotype DQ 2 * 6  is the second most 
frequently expressed serotype (16.2%) where in the other two test populations gastric 
cancer and malignant Barrett’s the expresion is lower (6 .8 %) and (9.8%) respectively. 
However, DQ 2 * 6  serotype in benign Barrett’s population present higher expresion 
(16.2%) than it is in control population (13.9%). Although, significant association was not 
found. The serotype DQ 3 * 6  in the control population (13.9%) compared with the gastric 
cancer population (13.6%) presents very similar expresion. The other two-test populations 
for the former serotype show much lower expresion and no significance is present. The 
homozygous serotype DQ 3 * 3 in the gastric cancer population (15.9%) is the second most 
frequently expressed when compared with the control population and the other two test 
populations presents higher expresion. However the homozygous serotype DQ 3 * 3 is the 
second most frequently expressed serotype in malignant Barrett’s population (13.7%) but if 
compared with the control, the gastric and the benign Barrett’s population the difference is 
very low and no significance is present.
This expression pattern is also reflected in the allelotype expression pattern 
presented in Table 4. The allelotype expression at this locus shows that the serotype DQ 3 
in the gastric cancer population (39.8%) to be the most commonly expressed among all the 
other serotypes and among all types of population tested. The DQ 3 serotype expresion in 
the benign Barrett’s population and in the malignant Barrett’s population presents lower 
frequencies of (33.8%) and (33.3%) compared with the gastric cancer and the control 
population. However, in the control population the serotype DQ 3 presents the lowest 
frequency of (28.5%) if compared with all three-test populations where significant
•y
association is present between the control and gastric cancer population (Ch =4.133,
P=0.0421). No other associations were found among the rest of the populations. The
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frequency of DQ 2 serotype in the benign Barrett’s population (36.5%) is the second most 
frequently expressed serotype among the all the test populations. With regards to DQ 2 
serotype expresion in the malignant Barrett’s population (32.3%) and in gastric cancer 
population (28.4%), the results show that malignant Barrett’s population presents slightly 
higher expresion. Comparing the serotype DQ 2 in the control population (30.5%) with the 
former two test populations, the malignant Barrett’s population (32.3%) presents a slightly 
higher expresion than the control population where the gastric cancer population (28.4%) 
presents a slightly lower expresion than the control population for the serotype DQ 2. 
However, significant associations were not found. Additionally the serotype DQ 6  in the 
control population (26.0 %) presents higher expresion than in the three test populations, 
gastric cancer population (20.4%), benign Barrett’s population (16.2%) and malignant 
Barrett’s population (16.7%). Among the three test populations, gastric cancer population 
has the highest DQ 6  serotype expresion (20.4%) whereas benign Barrett’s population and 
malignant Barrett’s population if compared with each other, present no significant 
difference or association. Representative gel pictures of HLA-DQpl genotyping by DQ 
“low resolution” PCR-SSP (Dynal AllSet ™) are illustrated in Fig 10.
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TABLE 3. Distribution and relative frequency (%) of DQpi genotypes in normal
individuals and three test populations.
Predicted DQp 1
serotype** Distribution and Relative frequency (%)
Control* Gastric Benign Malignan
cancer Barrett’s Barrett’s
n (%) n (%) n (%) n(% )
2 * 2 8  (7.9) 4(9.1) 3(8.1) 6 (1 1 .8 )
2 * 3 21 (20.7) 10(22.7) 12(32.4) 10(19.6)
2 * 4 2  (2 .0 ) 1 (2.3) 0  (0 .0 ) 0  (0 .0 )
2 * 5 8  (7.9) 3 (6 .8 ) 3 (8.1) 6 ( 1 1 .8 )
2 * 6 14(13.9) 3 (6 .8 ) 6(16.2) 5 (9.8)
3 * 3 9 (8.9) 7(15.9) 3(8.1) 7(13.7)
3 * 4 1 ( 1 .0 ) 0  (0 .0 ) 1 (2.7) 1 (2 .0 )
3 * 5 3 (3.0) 5(11.4) 4(10.8) 6 (1 1 .8 )
3 * 6 14(13.9) 6(13.6) 2 (5.4) 3 (5.9)
4 * 5 2  (2 .0 ) 0  (0 .0 ) 0  (0 .0 ) 0  (0 .0 )
4 * 6 0  (0 .0 ) 1 (2.3) 0  (0 .0 ) 0  (0 .0 )
5 * 5 3 (3.0) 0  (0 .0 ) 0  (0 .0 ) 1 (2 .0 )
5 * 6 7 (6.9) 0  (0 .0 ) 2 (5.4) 3 (5.8)
6 * 6 9 (8.9) 4(9.1) 1 (2.7) 3 (5.8)
n= number of subjects
* Obtained from the west of Scotland tissue typing laboratory, Glasgow Royal Infirmary. 
**The DQpi genotype and serological relationship is presented in Table 2.
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TABLE 4. Total distribution and relative frequency (%) of DQpi genotypes in normal
individuals and three test populations.
Predicted DQpi
serotype** Total genotypic distribution and relative frequency (%)
Control* Gastric Benign Malignant
cancer Barrett’s Barrett’s
n (%) n (%) n (%) n (%)
2 61 (30.5) 25 (28.4) 27 (36.5) 33 (32.3)
3 56 (28.5)* 35 (39.8)* 25 (33.8) 34 (33.3)
4 5 (2.0) 2 (2.3) 1 (1.3) 1 ( 1 .0 )
5 26(13.0) 8  (9.1) 9(12.2) 17(16.7)
6 53 (26.0) 18(20.4) 12(16.2) 17(16.7)
n= number of alleles
* Obtained from the west of Scotland tissue typing laboratory, Glasgow Royal Infirmary. 
**The DQpi genotype and serological relationship is presented in Table 2.
*  Significant difference between test group and controls (P < 0.05)
(Ch2 =4.133, P=0.0421)
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Panel A
Panel B
Fig 10. Illustration of typical HLA-DQB1 genotyping by DQ ‘‘low resolution” PCR-SSP 
(Dynal AllSet ™). The direction of electrophoretic migration is downward. The 
internal positive control primer pair amplifies a 429bp segment of the human 
growth hormone gene in all lanes 1-8. In the presence of a specific amplification, 
the intensity of the control band often decreases. Alleles are assigned by the 
presence of PCR product. The PCR product sizes (see table 2) may also be helpful 
in the interpretation of DQB1 typing. Lane M indicates molecular weight marker 
in base pair (lOObp).
Panel A: Positive lanes: 3, 4, and 8. Genotype: DQB1 *0201-*0203, DQB1 *0201, 
DQB1 *0401, *0402. Serotype: DQ 2, DQ 4.
Panel B: Positive lanes: 1, 5, and 7. Genotype: DQB1 *0501-*0504, DQB1 *0301, 
*0304. DQB 1*0301. Serotype: DQ 5, DQ 7.
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The HSP 70-2 locus
The results at this locus are presented in Table 5. Among the entire test populations 
and the control population the heterozygous genotype 1 * 2  in gastric cancer population 
(61.9 %) presents the highest expresion. However, the results show that the heterozygous 
genotype 1 * 2  is not the only most commonly expressed, in gastric cancer population 
(61.9%) but also in the other two test populations benign Barrett’s (57.7%), malignant 
Barrett’s (30.0%) and in the control population (54.1%). The malignant Barrett’s 
population (30.0%) presents much lower frequency than the control population (54.1%), 
where significant association was found (Ch = 5.468, P= 0.0194) between these two. 
Comparing the benign Barrett’s and gastric cancer populations with the control population 
for the heterozygous genotype 1 * 2  their frequencies are slightly higher. Additionally the 
malignant Barrett’s population (30.0%) presents much lower expresion compared with the 
gastric cancer population (61.4%) with difference of (31.9%) but significant association 
was not found.
The homozygous genotype 2 * 2 is the second most expressed genotype among all 
the other genotypes. The homozygous genotype 2 * 2 in malignant Barrett’s population 
(43.3%) presents the highest expresion compared with the two other test populations, 
benign Barrett’s (26.9%), gastric cancer (33.3%) and in the control population (34.2%).
The difference between the benign Barrett’s (26.9%) and the gastric cancer (33.3%) is not 
significant. Similarly the difference of those two former test populations compared with the 
control population is not significant regarding the homozygous genotype 2 * 2 .  The 
difference in frequency between the benign Barrett’s (26.9%) and the malignant Barrett’s 
population (43.3%) is also not significant.
This expression pattern is also reflected in the allelotype expression pattern
presented in Table 6 . The allelotype expression at this locus shows that the allelotype 2* =
936bp is the most commonly expressed in all types of population tested. Specifically the
allelotype 2* = 936bp in gastric cancer population (64.3%) presents the highest expresion
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compared with the other two test populations benign Barrett’s (55.8%), malignant Barrett’s 
(58.34%) and the control population (61.3%) but significant associations were not found. 
However, the allelotype 2* = 936bp presents higher expresion in the control population 
(61.3%) compared with the two test populations benign Barrett’s (55.8%), malignant 
Barrett’s (58.34%) but significant association was not found. Additionally the difference 
among the benign Barrett’s (55.8%), malignant Barrett’s (58.34%) and gastric cancer 
population (64.3%) regarding the allelotype 2* = 936bp is not great and significant 
associations were not found. A representative gel picture of amplified fragment length 
polymorphism of heat shock protein 70-2 (HSP70-2) gene is illustrated in Fig 11.
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TABLE 5. Distribution and relative frequency (%) of HSP 70-2 genotypes in normal
individuals and three test populations.
HSP 70-2
genotypes Distribution and Relative frequency (%)
Malignant 
Barrett’s 
n (%)
8 (26.7)
9 (30.0)* 
13 (43.3)
Allele 1* = 1117 bp 
Allele 2* = 936 bp 
n= number of subjects
4* Significant difference between test group and controls (P < 0.05) 
(Ch2 = 5.468, P= 0.0194)
Control Gastric Benign
cancer Barrett’s
n (%) n (%) n (%)
1*1 13(11.7) 2(4.8) 4(15.4)
1 * 2 60 (54.1)* 26 (61.9) 16 (57.7)
2 * 2 38 (34.2) 14(33.3) 7(26.9)
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TABLE 6. Total distribution and relative frequency (%) of HSP 70-2 allelotypes in
normal individuals and three test populations.
HSP 70-2 Total allelotypic distribution and relative frequency (%)
allelotypes ____________________________________________________
Control Gastric Benign Malignant
cancer Barrett’s Barrett’s
n r / o )  n r / o )  nr/o) n r / o
8 6  (38.7) 30 (35.7) 23 (44.2) 25 (41.66)
2* 136(61.3) 54 (64.3) 29 (55.8) 35 (58.34)
Allele 1* = 1117 bp 
Allele 2* = 936 bp 
n= number of alleles
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Allele 1 
Allele 2
Fig 11. Amplified fragment length polymorphism of heat shock protein 70-2 (FISP70-2)
gene. The (HSP70-2) polymerase chain reaction (PCR) products were digested with 
restriction digest enzyme PST-1 (5'- CTGCA -3' and (5'- GACGTC -3') and 
separated on a 2% ultra pure agarose gel. The HSP allele 1 corresponds to the 1117 
bp and the allele 2 to 936 bp. The identification analysis of RFLP repeats of all the 
samples performed in comparison with representative control fragments (cell line 
DNA); Lanes, A (H2 O), B (homozygote-1117 bp), C (homozygote-936 bp), D 
(heterozygote-1117 bp -  936 bp), and against molecular marker M (4>x 174 -RF 
DNA/ Hae III).
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The D6S273 locus
The results at this locus are presented in Table 7. Among the entire test populations 
and the control population the heterozygous microsatellite genotype 132-134 in malignant 
Barrett’s population (28.1 %) presents the highest expression of all. Additionally the 
results show that the heterozygous microsatellite genotype 132-134 is by far the most 
commonly expressed in malignant Barrett’s population (28.1%) and also in the gastric 
cancer population (24.3%) and in the control population (12.4%) among the rest of 
genotypes. In the benign Barrett’s population the frequency of the genotypic expresion is 
widely distributed among the heterozygous microsatellite genotypes 126-134, 130-132, 
130-134, 132-138, all with equal frequencies of (15.3%). The heterozygous microsatellite 
genotype 132-134 presents a small difference in frequency among the malignant Barrett’s 
population (28.1%) and the gastric cancer population (24.3%). However, the difference in 
frequency between the gastric cancer population (24.3%) and the control is high (11.9%) 
but a significant association was not found. The difference in frequency for the 
heterozygous microsatellite genotype 132-134, among the control population (12.4%) and 
the malignant Barrett’s population (28.1%) however is higher (15.7%) where significant 
association was found (Ch2 =4.510, P=0.0337).
This expression pattern is also reflected in the microsatellite allelotype expression 
pattern presented in Table 8 . The microsatellite allelotype expression at this locus shows 
that the microsatellite allelotype 134 is the most commonly expressed among all the other 
allelotypes in all populations tested. The microsatellite allelotype 134 in gastric cancer 
population (37.9%) presents slightly higher expresion than the other two test populations 
benign Barrett’s (34.6%), malignant Barrett’s (32.9%) and the control population (26.7%). 
However, the microsatellite allelotype 134 presents no significant differences in frequency 
and no significant association is present between the benign Barrett’s population (34.6%) 
and malignant Barrett’s (32.9%). However, these two-test populations present a slightly
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higher expresion if compared with the control population (26.7%) but significant 
association was not found.
In the control population the microsatellite allelotype 132 presents slightly higher 
frequency (28.1%) compared with the microsatellite allelotype 134 (26.7%). The 
microsatellite allelotype 132 in malignant Barrett’s population (29.7%) presents higher 
expresion compared with the benign Barrett’s population (19.2%), the gastric cancer 
population (18.9%) and but not if compared with the control population (28.1%) but 
significant associations were not found. Additionally, the microsatellite allelotype 132 
presents no significant differences in frequency between the benign Barrett’s population 
(19.2%) and the gastric cancer population (18.9%) but these two-test populations present 
lower expresion if compared with the control population (28.1%). However significant 
associations were not found among these. A representative autoradiograph of microsatellite 
typing at tested 6 p (D6S273) locus is illustrated in Fig 12.
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TABLE 7. Distribution and relative frequency (%) of D6S273 genotypes in normal
individuals and three test populations.
D6S273
genotypes
126-126
126-128
126-130
126-132
126-134
126-136
126-138
128-128
128-130
128-132
128-134
128-136
128-138
130-130
130-132
130-134
130-136
Distribution and Relative frequency (%)
Control
n(%)
2(1.9)
1(0.9)
3 (2.9)
3 (2.9) 
2(1.9) 
1(0.9)
0 (0.0)
3 (2.9)
5 (4.8)
3 (2.9)
0 (0.0)
0 (0 .0)
0 (0 .0)
3 (2.9)
3 (2.9) 
6(5.7)
3 (2.9)
Gastric 
cancer 
n (%)
1(2.7)
0 (0.0) 
0 (0 .0) 
0 (0.0) 
2(5.4) 
0 (0 .0) 
0 (0.0) 
0 (0.0) 
0 (0.0)
1 (2.7) 
3(8.1) 
0 (0.0)
1 (2.7) 
0 (0 .0)
1 (2.7) 
3(8.1) 
0 (0 .0)
Benign 
Barrett’s 
n (%)
0 (0.0)
0 (0.0)
0 (0 .0)
0 (0.0) 
2(15.3) 
0 (0.0)
0 (0.0)
0 (0 .0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0 .0)
2(15.3)
2(15.3)
0 (0 .0)
Malignant 
Barrett’s 
n (%)
1 (3.1)
0 (0.0)
0 (0.0)
0 (0 .0)
1 (3.1)
0 (0 .0)
1 (3.1)
0 (0.0)
0 (0.0)
1 (3.1)
1 (3.1)
1 (3.1)
0 (0.0)
1 (3.1)
2 (6.2)
3 (9.4)
0 (0.0)
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132-132 12(11.4) 0  (0 .0 ) 0  (0 .0 ) 2  (6 .2 )
132-134 13 (12.4)* 9 (24.3) 0  (0 .0 ) 9(28.1)
132-136 4 (3.8) 0  (0 .0 ) 1 (7.8) 0  (0 .0 )
132-138 9 (8 .6 ) 3(8.1) 2(15.3) 3 (9.4)
134-134 10(9.5) 4(10.8) 1 (7.8) 3 (9.4)
134-136 5 (4.8) 1 (2.7) 1 (7.8) 1 (3.1)
134-138 10(9.5) 2 (5.4) 2(15.3) 0  (0 .0 )
136-136 2(1.9) 2 (5.4) 0  (0 .0 ) 0  (0 .0 )
136-138 2(1.9) 2 (5.4) 0  (0 .0 ) 1 (3.1)
138-138 0  (0 .0 ) 2(5.4) 0  (0 .0 ) 1 (3.1)
n = number of subjects
*  Significant difference between test group and controls (P < 0.05) 
(Ch2 =4.510, P=0.0337)
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TABLE 8. Total distribution and relative frequency (%) of D6S273 allelotypes in normal
individuals and three test populations.
D6S273 Total allelotypic distribution and relative frequency (%)
allelotypes -------------------------------------------------------------------------------
Control Gastric Benign Malignant
cancer Barrett’s Barrett’s
n (%) n (%) n (%) n (%)
126 14 (6.7) 4(5.4) 2 (7.7) 4 (6.2)
128 15(7.1) 5 (6 .8 ) 0  (0 .0 ) 3 (4.7)
130 26 (12.4) 4(5.4) 4(15.4) 7(10.9)
132 59 (28.1) 14(18.9) 5 (19.2) 19(29.7)
134 56 (26.7) 28 (37.9) 9 (34.6) 21 (32.9)
136 19(9.0) 7(9.4) 2 (7.7) 3 (4.7)
138 2 1  (1 0 .0 ) 12(16.2) 4(15.4) 7(10.9)
n = number of alleles
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1 2 3 4 5 6 7 8 9 10 ! 1 12 13 14 15 16 17 18 19 20 21 22 23 24 25 A B C D E F
Fig 12. Representative autoradiograph of microsatellite typing at tested 6p (D6S273) 
locus. The identification analysis of microsatellite repeats of all the samples 
performed in comparison with representative control fragments (cell line DNA); 
Lanes, A (H2 O), B (heterozygote-134 -138), C (heterozygote-126 -136), D 
(heterozygote-128 -130), E (heterozygote-132 -138), F (homozygote-130).
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DOB1 predicted serotypes in comparison with TNFa 1-14 microsatellites
It would be interesting to examine the relationship between various TNFa 1-14 
microsatellite alleles with DQpi predicted serotypes (genotypes are given in Table 2), 
looking for linkage between them in the three test populations benign Barrett’s, malignant 
Barrett’s and gastric cancer population. (I would like to thank Hasan Kasem for the 
provision of the TNFa data on which I did this analysis).
Since these two polymorphic sites lie within a close distance of each other, 
telomeric of the short arm on Chromosome 6  in region 2, band 1, sub-band 3, it was 
deemed reasonable to examine whether, in any of the three test populations, patterns 
pertaining to disease specificity could be observed and to investigate for linkage between 
DQpipredicted serotypes and TNFa microsatellite allelotypes at the three test sites.
The results are presented in Tables 9 to 11. The data obtained in those Tables 9 to 
11, generally indicates that there is a wide distribution of DQpipredicted serotypes and 
microsatellite allelotypes. However the results in Table 9 present a higher frequency for 
DQ 2 -  TNFa2 in benign Barrett’s population (15.7%) compared with the rest of the 
DQpipredicted serotypes and TNFa microsatellite alleles in this population. Similarly, the 
results in Table 10 present a higher frequency for DQ 2 -  TNFa2 in malignant Barrett’s 
population (16.8%) compared with the rest of the DQpipredicted serotypes and TNFa 
microsatellite alleles in this population. Again the results in Table 11 present a higher 
frequency for DQ 2 -  TNFa2 in gastric cancer population (11.6 %) compared with the rest 
of the DQpipredicted serotypes and TNFa micro satellite alleles in this population.
Comparing the DQ 2 -  TNFa2 results among the benign Barrett’s population 
(15.7%) and malignant Barrett’s population (16.8%) not significant difference in 
frequencies is present and significant association was not found. However, the DQ 2 -  
TNFa2 results for the benign Barrett’s population (15.7%) and the malignant Barrett’s 
population (16.8%) if compared with the gastric cancer population (1 1 .6 %), present higher
95
frequencies with differences of (4.1%) and (5.2%) respectively but again significant 
association was not found. These two differences are not major among the last three 
former test populations that were tested.
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HSP 70-2 allelotypes in comparison with TNFa 1-14 microsatellites
Additionally, it would be interesting to examine the relationship between various 
TNFa 1-14 micro satellite alleles with HSP 70-2 allelotypes, looking for linkage between 
them in the three test populations benign Barrett’s, malignant Barrett’s and gastric cancer 
population.
Since these two polymorphic sites lie within close distance of each other telomeric 
on the short arm of Chromosome 6 in region 2, band 1, sub-band 3, it was deemed 
reasonable to examine whether, in any of the three test populations, patterns pertaining to 
disease specificity could be observed and to investigate for linkage between HSP 70-2 
allelotypes and TNFa microsatellite allelotypes at the three test sites.
The results are presented in Tables 12 to 14. The results in Table 12 present a 
higher frequency for allele 1 *(1117bp) -  TNFa2 in benign Barrett’s population (23.1%) 
compared with the rest of the HSP 70-2 alleles and TNFa microsatellite alleles in this 
population. However the allele 2*(936 bp) -  TNFal 1 also presents an increased frequency 
of (15.4%) compared with the rest of the HSP 70-2 alleles and TNFa microsatellite alleles 
in this population but lower than allele 1 *(1117bp) -  TNFa2. Similarly, the results in 
Table 13 present a higher frequency for allele 1*(1117bp) -  TNFa2 in malignant Barrett’s 
population (21.7%) compared with the rest of the HSP 70-2 alleles and TNFa microsatellite 
alleles in this population. However the allele 2*(936 bp) -  TNFa2 presents an increased 
frequency of (20.0%) compared with the rest of the HSP 70-2 alleles and TNFa 
microsatellite alleles in this population but slightly lower than allele 1 *(1117bp) -  TNFa2. 
The results in Table 14 present a higher frequency for allele 1 *(1117bp) -  TNFa2 in gastric 
cancer population (20.0%) compared with the rest of the HSP 70-2 alleles and TNFa 
microsatellite alleles in this population. However the allele 2*(936 bp) -  TNFal 1 presents 
an increased frequency of (20.2%) compared with the rest of the HSP 70-2 alleles and 
TNFa microsatellite alleles in this population and with equal frequency with allele 
1*(1117bp) -  TNFa2.
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Comparing the allele 1 *(1117bp) -  TNFa2 results among the benign Barrett’s 
population (23.1%), malignant Barrett’s population (21.7%) and gastric cancer population 
(20.2%), no major difference in frequencies are present and significant association was not 
found. Again comparing the allele 2*(936bp) -  TNFal 1 results among the benign Barrett’s 
population (15.4%) and gastric cancer population (20.2%) a small difference of (4.8%) in 
frequencies are present but significant association was not found. Additionally the 
genotype, allele 2*(936bp) -  TNFa2 presents the highest frequency in malignant Barrett’s 
population (20.0%) compared with the benign Barrett’s population (9.6%) and with the 
gastric cancer population (14.2%) but again significant associations were not found. 
Additionally, there is a small difference in frequency among the benign Barrett’s 
population (9.6%) and the gastric cancer population (14.2%) but significant association 
was not found.
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HSP 70-2 alleloty pes in comparison with DOB1 predicted serotypes
Also it would be interesting to examine the relationship between various DQpi 
predicted serotypes with HSP 70-2 allelotypes, looking for linkage between them in the 
three test populations benign Barrett’s, malignant Barrett’s and gastric cancer population.
Since these two polymorphic sites lie within close proximity, among them telomeric 
on the short arm of Chromosome 6 in region 2, band 1, sub-band 3, it was deemed 
reasonable to examine whether, in any of the three test populations, patterns pertaining to 
disease specificity could be observed and to investigate for linkage between HSP 70-2 
allelotypes and various DQp 1 predicted serotypes at the three test sites.
The results are presented in Tables 15 to 17. The results in Table 15 present a 
higher frequency for allele 1*(1117bp) -  DQ2 in benign Barrett’s population (28.8%) 
compared with the rest of the HSP 70-2 alleles and DQp 1 predicted serotypes in this 
population. However the allele 2*(936 bp) -  DQ3 also presents an increased frequency of 
(25.0%) compared with the rest of the HSP 70-2 alleles and DQpi predicted serotypes in 
this population but lower than allele 1 *(1117bp) -  DQ2. Similarly, the results in Table 16 
present an increased frequency for allele 1*(1117bp) -  DQ2 in malignant Barrett’s 
population (15.0%) compared with the rest of the HSP 70-2 alleles and DQpi predicted 
serotypes where surprisingly the allele 2*(936 bp) -  DQ2 presents an equal frequency of 
(15.0%) in this population. However, the allele 2*(936 bp) -DQ3 presents the most 
increased frequency of (30.0%) compared with the rest of the HSP 70-2 alleles and DQpi 
predicted serotypes in malignant Barrett’s population, double the frequency of allele 
1 *(1117bp) -  DQ2 and 2*(936 bp) -  DQ2. The results in Table 17 present the highest 
frequency for the allele 2*(936 bp) -  DQ3 in gastric cancer population (30.6%) compared 
with the rest of the HSP 70-2 alleles and DQpi predicted serotypes in this population. 
However, the allele 1 *(1117bp) -  DQ2 presents an increased frequency of (22.2%)
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compared with the rest of the HSP 70-2 alleles and DQP 1 predicted serotypes in this
population.
Comparing the allele 2*(936 bp) - DQ3 results between the malignant Barrett’s 
population (30.0%) and gastric cancer population (30.6%), no major difference in 
frequencies is present and significant association was not found. Again comparing the 
allele 2*(936bp) -  DQ3 results among the benign Barrett’s population (25.0%), malignant 
Barrett’s population (30.0%) and gastric cancer population (30.6%) there is a small 
difference of (5.0%) and (5.6%) in frequencies present and significant association was not 
found. The allele 1 *(1117bp) -  DQ2 if compared among the three test populations 
presents the highest frequency in the benign Barrett’s population (28.8%) where the lowest 
frequency is present in malignant Barrett’s population (15.0%), less than half the benign 
Barrett’s frequency but significant association was not found. The frequency of allele 
1 *(1117bp) -  DQ2 in gastric cancer populations (22.2%) compared with the benign 
Barrett’s population (28.8) and malignant Barrett’s population (15.0%) presents a small 
difference and significant association was not found. However, a big difference in 
frequencies is present among the 2*(936bp) -  DQ2 malignant Barrett’s population (15.0%) 
and 2*(936bp) -  DQ2 gastric cancer population (2.7%) where significant association was 
found between them (Ch2 = 3.884, P= 0.0487).
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DOB1 predicted serotypes in comparison with D6S273 microsatellites
Again it would be interesting to examine the relationship between various D6S273 
microsatellite alleles with DQP 1 predicted serotypes (genotypes are given in Table 2), 
looking for linkage between them in the three test populations benign Barrett’s, malignant 
Barrett’s and gastric cancer population.
Since these two polymorphic sites lie within a very close distance among them 
telomeric on the short arm of Chromosome 6 in region 2, band 1, sub-band 3, it was 
deemed reasonable to examine whether, in any of the three test populations, patterns 
pertaining to disease specificity could be observed and to investigate for linkage between 
DQP 1 predicted serotypes and D6S273 microsatellite allelotypes at the three test sites.
The results are presented in Tables 18 to 20. The results in Table 18 present a 
higher frequency for DQ 2 -  134 in benign Barrett’s population (15.4%) compared with the 
rest of the DQpi predicted serotypes and D6S273 microsatellite alleles in this population. 
The results in Table 19 present a higher frequency for DQ 3 -  134 in malignant Barrett’s 
population (15.6%) compared with the rest of the DQplpredicted serotypes and D6S273 
microsatellite alleles in this population. Additionally, there is an increased frequency for 
DQ 2 -  132 in malignant Barrett’s population (12.5%) something not seen in benign 
Barrett’s population. The results in Table 20 present a higher frequency for DQ 3 -  134 in 
gastric cancer population (18.7%) compared with the rest of the DQplpredicted serotypes 
and D6S273 microsatellite alleles in this population. Additionally there is an increased 
frequency for DQ 3 -  138 in gastric cancer population (12.5%) and equally for DQ 6 -  136 
in gastric cancer population (12.5%), something not seen in the other two test populations.
Comparing the allele 132 - DQ2 results among the benign Barrett’s population 
(7.7%), the malignant Barrett’s population (12.5%) and gastric cancer population (3.1%), a 
major difference in frequencies is present between malignant Barrett’s population (12.5%) 
and the gastric cancer population (3.1%) but significant association was not found. Now
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comparing the allele 134 -  DQ2 results among the benign Barrett’s population (15.4%), the 
malignant Barrett’s population (4.7%) and gastric cancer population (3.1%), a major 
difference in frequencies is present between benign Barrett’s population (15.4%) and the 
gastric cancer population (3.1%) but significant association was not found. Comparing the 
allele 134 -  DQ3 results among the benign Barrett’s population (3.8%), the malignant 
Barrett’s population (15.6%) and gastric cancer population (18.7%), again a major 
difference in frequencies is present between the benign Barrett’s population (3.8%) and the 
gastric cancer population (18.7%) but significant association was not found.
Comparing the allele 138 -  DQ3 results among the benign Barrett’s population 
(3.8%), the malignant Barrett’s population (4.7%) and gastric cancer population (12.5%), 
again a major difference in frequencies is present between the benign Barrett’s population 
(3.8%) and the gastric cancer population (12.5%) but significant association was not found.
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HSP 70-2 allelotypes in comparison with D6S273 microsatellites
The relationship between various D6S273 microsatellite alleles with HSP 70-2 
allelotypes was examined looking for linkage in the three test populations benign Barrett’s, 
malignant Barrett’s, gastric cancer population and the control population.
Again these two polymorphic sites lie within a few base pairs (bp) distance of each 
other telomeric on the short arm of Chromosome 6 in region 2, band 1, sub-band 3, it 
seemed reasonable to examine whether, in any of the three test populations, patterns 
pertaining to disease specificity could be observed and to investigate for linkage between 
HSP 70-2 allelotypes and D6S273 microsatellite allelotypes at the three test sites.
The results are presented in Tables 21 to 24. The results in Table 21 show that the
highest frequency occurs for allele 2*(936bp)-134 genotype in benign Barrett’s population
(27.3%) compared with the rest of the HSP 70-2 alleles and D6S273 microsatellite alleles
in this population. However the allele 2*(936 bp)-130 genotype also presents an increased
frequency of (9.1%) compared with the rest of the HSP 70-2 alleles and D6S273
microsatellite alleles in this population. The same frequency is present for the alleles
1 *(1117bp)-130, l*(1117bp)-132, 1 *(1117bp)-138 genotypes indicating an equal
distribution. The results in Table 22 show that the highest frequency occurs again for allele
2*(936bp)-134 genotype in the malignant Barrett’s population (26.8%) compared with the
rest of the HSP 70-2 alleles and D6S273 microsatellite alleles in this population. However,
the allele 2*(936 bp)-130 genotype also presents an increased frequency of (17.9%)
compared with the rest of the HSP 70-2 alleles and D6S273 microsatellite alleles in this
population. The results in Table 23 show that the highest frequency occurs again for
allele 2*(936bp)-134 genotype in the gastric cancer population (28.1%) compared with all
the rest of the HSP 70-2 alleles and D6S273 microsatellite alleles in this population.
However, the allele 2*(936 bp)-130 also presents an increased frequency of (10.9%)
compared with the rest of the HSP 70-2 alleles and D6S273 microsatellite alleles in this
population. The results in Table 24 show that the highest frequency occurs for allele
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2*(936bp)-132 genotype in control population (19.2%) compared with the rest of the HSP 
70-2 alleles and D6S273 microsatellite alleles in this population. The allele 2*(936 bp)- 
134 genotype also presents an increased frequency of (17.6%) compared with the rest of 
the HSP 70-2 alleles and D6S273 microsatellite alleles in this population.
Comparing the allele 2*(936 bp)-130 genotype results among the benign Barrett’s 
population (9.1%), malignant Barrett’s population (5.4%) the gastric cancer population 
(1.6%) and the controls (7.1%) the highest difference in frequencies is present between the 
benign Barrett’s population and gastric cancer population but significant associations were 
not found. Comparing the allele 2*(936bp)-132 genotype results among the benign 
Barrett’s population (4.5%), the malignant Barrett’s population (17.9%), the gastric cancer 
population (10.9%)and the controls (19.2%), a major difference in frequency of (14.7%) is 
present between the controls (19.2%) and the benign Barrett’s population (4.5%) but 
significant association was not found between these two and between the controls and the 
rest. Finally the frequencies for 2*(936bp)-134 among the benign Barrett’s population 
(27.3%), malignant Barrett’s population (26.8%) the gastric cancer population (28.1%) and 
the controls (17.6%) present no significant differences in frequency and significant 
associations were not found.
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Comparison of the DQPI predicted serotypes in total Barrett’s oesophagus patient
population with the control population
The results at this locus are presented in Table 25. Among the entire Barrett’s 
population the serotype DQ 2 * 6 (1 2 .5 % ) presents the highest expresion. The results show 
that the serotype DQ 2 * 3 is by far the most commonly expressed in control population 
(20.7%). Comparing the serotype DQ 2 * 6  (12.5 %) in Barrett’s population with the 
serotype DQ 2 * 6 (13.9) in the control population the difference in frequency is very small 
and significant association was not found. However, comparing the serotype DQ 2 * 3 in 
control population (20.7%) with the serotype DQ 2 * 3 in Barrett’s population (11.4%) the 
data reveals a difference in frequency of (9.3%) but significant association was not found. 
Similarly the data reveals a difference in frequency of (8.4%) among the serotype DQ 3 * 5  
in control population (3.0%) compared with the serotype DQ 3 * 5 in Barrett’s population 
(11.4%) but significant association was not found. Additionally, a similar difference in 
frequency of (8.2%) exists between the serotype DQ 3 * 6 in control population (13.9%) 
compared with the serotype DQ 3 * 6 in Barrett’s population (5.7%) but significant 
association was not found.
A similar expression pattern is also reflected in the allelotype expression pattern 
presented in Table 26. The allelotype expression at this locus shows that the serotype DQ 
2 in Barrett’s population (34.1%) and the serotype DQ 3 in Barrett’s population (33.5%) to 
be the most commonly expressed from all the other serotypes and from all types of 
population tested. However, comparing the serotype DQ 2 in Barrett’s population (34.1%) 
and DQ 3 in Barrett’s population (33.5%) with the serotype DQ 2 (30.5%) and DQ 3 
(28.5%) in the control population the difference in frequency is very low and significant 
association was not found. The serotype DQ 6 in Barrett’s population (16.5%) compared 
with the serotype DQ 6 in the control population (26.0%) presents a difference in frequency 
of (9.5%) and significant association was found between these two (Ch = 5.2740, 
P=0.0252).
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TABLE 25. Distribution and relative frequency (%) of DQP 1 genotypes in normal
individuals and in total Barrett’s oesophagus individuals.
Predicted DQP 1
serotype** Distribution and Relative frequency (%)
Control*
population
Total Barrett’s 
oesophagus
n (%) n (%)
2 * 2 8 (7.9) 9(10.2)
2 * 3 21 (20.7) 22(11.4)
2 * 4 2 (2.0) 0 (0.0)
2 * 5 8 (7.9) 9(10.2)
2 * 6 14(13.9) 11 (12.5)
3 * 3 9 (8.9) 10(11.4)
3 * 4 1(1.0) 2 (2.3)
3 * 5 3 (3.0) 10(11.4)
3 * 6 14(13.9) 5 (5.7)
4 * 5 2 (2.0) 0 (0.0)
4 * 6 0 (0.0) 0 (0.0)
5 * 5 3 (3.0) 1(1.1)
5 * 6 7 (6.9) 5 (5.7)
6 * 6 9 (8.9) 4 (4.5)
n= number of subjects 
Total Barrett’s n = 88
* Obtained from the west of Scotland tissue typing laboratory, Glasgow Royal Infirmary. 
**The DQpi genotype and serological relationship is presented in Table 2.
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TABLE 26. Total distribution and relative frequency (%) of DQP 1 genotypes in normal
individuals and in total Barrett’s oesophagus individuals.
Predicted DQpi
serotype** Total genotypic distribution and relative frequency (%)
Control* Total Barrett’s
population oesophagus
n (%) n (%)
2 61 (30.5) 60(34.1)
3 56 (28.5) 59 (33.5)
4 5(2.0) 2(1.1)
5 26(13.0) 26(14.8)
6 53 (26.0)* 29 (16.5)*
n= number of alleles 
Total Barrett’s n = 176
* Obtained from the west of Scotland tissue typing laboratory, Glasgow Royal Infirmary. 
**The DQpi genotype and serological relationship is presented in Table 2.
*  Significant difference between test group and controls (P < 0.05)
(Ch2 = 5.2740, P=0.0252).
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Comparison of the HSP 70-2 genotypes in total Barrett’s oesophagus patient
population with the control population
The results at this locus are presented in Table 27. Among the entire Barrett’s 
population the heterozygous genotype 1 * 2  (44.6%) presents the highest expresion. Also 
the results show that the heterozygous genotype 1 * 2 is by far the most commonly 
expressed in the control population (54.1%).
Comparing the heterozygous genotype 1 * 2  (44.6%) in Barrett’s population with 
the heterozygous genotype 1 * 2 in the control population (54.1%) the difference in 
frequency is very small and significant association was not found. Additionally, comparing 
the homozygous genotype 1 * 1 in control population (11.7%) with the homozygous 
genotype 1 * 1 in Barrett’s population (21.4%) the data reveals a difference in frequency of 
(9.7%) but again significant association was not found.
Unfortunately, this expression pattern is reflected in the allelotype expression 
pattern presented in Table 28. The allelotype expression at this locus shows that the 
allelotype 2* (936bp) in control population (61.3%) to be the most commonly expressed 
from all the other allelotypes and from all types of population tested. Comparing the 
allelotypes 1 *(1117bp) in Barrett’s population (42.9%) and 2*(936bp) in Barrett’s 
population (57.1%) with the same allelotypes in the control population the difference in 
frequency is low and significant association was not found.
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TABLE 27. Distribution and relative frequency (%) of HSP 70-2 genotypes in normal
individuals and in total Barrett’s oesophagus individuals.
HSP 70-2
genotypes Distribution and Relative frequency (%)
Control Total Barrett’s
population oesophagus
nr/o nr/o
1*1  13(11.7) 12(21.4)
1 *2 60(54.1) 25 (44.6)
2 * 2 38 (34.2) 20 (35.7)
Allele 1* = 1117 bp 
Allele 2* = 936 bp 
n= number of subjects 
Total Barrett’s n =56
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TABLE 28. Total distribution and relative frequency (%) of HSP 70-2 allelotypes in
normal individuals and in total Barrett’s oesophagus individuals.
HSP 70-2 Total allelotypic distribution and relative frequency (%)
allelotypes ____________________________________________________
Control Total Barrett’s
population oesophagus
n r / o )  n ( y o
86 (38.7)
136(61.3)
48 (42.9)
64 (57.1)
Allele 1* = 1117 bp 
Allele 2* = 936 bp 
n= number of alleles 
Total Barrett’s n =112
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Comparison of the D6S273 microsatellite genotypes in total Barrett’s oesophagus
patient population with the control population
The results at this locus are presented in Table 29. Among the entire Barrett’s 
population the heterozygous genotype 132-134 (20%) presents the highest expresion. Also 
the results show that the heterozygous genotype 132-134 is by far the most commonly 
expressed in control population (12.4%).
Comparing the heterozygous genotype 132-134 (20%) in Barrett’s population with 
the heterozygous genotype 132-134 in the control population (12.4%) the difference in 
frequency is low (7.6%) and significant association was not found.
Similarly, comparing the homozygous genotype 132-132 in control population 
(11.4%) with the homozygous genotype 132-132 in Barrett’s population (4.4%) the data 
reveals a difference in frequency of (7%) and significant association was not found.
This expression pattern is reflected in the allelotype expression pattern presented as 
in Table 30. The allelotype expression at this locus shows that the allelotype 134 in 
Barrett’s population (33.3%) to be the most commonly expressed from all the other 
allelotypes and from all types of population tested. Additionally the allelotype 132 in the 
control population (28.1%) is the second most expressed between the two populations. 
Comparing the allelotype 132 in the control population (28.1%) with the allelotype 132 in 
the (26.7%) Barrett’s population no great difference in frequency is present and significant 
association was not found. Similarly the frequency of the allelotype 134 in the control 
population (26.7.1%) compared with the allelotype 134 in the (33.3%) Barrett’s population 
presents no great difference and significant association was not found. Additionally all the 
rest of the frequencies (Table 30) if compared with each other between the two 
populations, present similar or equal distribution and significant association were not 
found.
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TABLE 29. Distribution and relative frequency (%) of D6S273 genotypes in normal
individuals and in total Barrett’s oesophagus individuals.
genotypes _____________________________________________
Control Total Barrett’s
population oesophagus
n (%) n (%)
126-126 2(1.9) 1 (2.2)
126- 128 1(0.9) 0(0.0)
126- 130 3 (2.9) 0(0.0)
126- 132 3 (2.9) 0(0.0)
126- 134 2(1.9) 3 (6.7)
126- 136 1(0.9) 0(0.0)
126- 138 0(0.0) 1 (2.2)
128- 128 3 (2.9) 0(0.0)
128- 130 5 (4.8) 0(0.0)
128- 132 3 (2.9) 1 (2.2)
128- 134 0(0.0) 1 (2.2)
128-136 0(0.0) 1 (2.2)
128- 138 0(0.0) 0(0.0)
130- 130 3 (2.9) 1 (2.2)
130- 132 3 (2.9) 4(8.9)
130- 134 6(5.7) 5 (11.1)
130- 136 3 (2.9) 0(0.0)
128
132-132 12(11.4) 2 (4.4)
132-134 13(12.4) 9 (20.0)
132-136 4 (3.8) 1 (2.2)
132-138 9 (8.6) 5(11.1)
134-134 10(9.5) 4 (8.9)
134-136 5 (4.8) 2 (4.4)
134-138 10(9.5) 2 (4.4)
136-136 2(1.9) 0 (0.0)
136-138 2(1.9) 1 (2.2)
138-138 0 (0.0) 1 (2.2)
n = number of subjects 
Total Barrett’s n =45
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TABLE 30. Total distribution and relative frequency (%) of D6S273 allelotypes in normal
individuals and in total Barrett’s oesophagus individuals.
D6S273 Total allelotypic distribution and relative frequency (%)
allelotypes -------------------------------------------------------------------------------
Control Barrett’s
population oesophagus
n (%) n (%
126 14 (6.7) 6(6.7)
128 15(7.1) 3 (3.3)
130 26(12.4) 11 (12.2)
132 59 (28.1) 24 (26.7)
134 56 (26.7) 30 (33.3)
136 19(9.0) 5 (5.6)
138 21 (10.0) 11 (12.2)
n = number of alleles 
Total Barrett’s n =90
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DISCUSSION
DISCUSSION
Polymerase chain reaction (PCR) determination of DNA markers
The Polymerase chain reaction is a quick method of amplifying a region of DNA 
within which a RFLP and /or microsatellite site lie. The effectiveness of the technique is 
very much dependant upon the optimisation of the reaction conditions. However, standard 
PCR based commercial protocols are available for certain types of laboratory tests such as 
the Dynal A //set™ SSP DQ “Low resolution sets” for tissue typing that was employed for 
the initial marker (DQpl) in this study.
Value of RFLP and microsatellite markers analysis in studies involving immuno- 
relevant genes
In this study the restriction length polymorphism (RFLP), HSP 70-2 marker was 
also employed. The presence or absence of a restriction endonuclease cleavage site within a 
region of DNA gives rise, on digestion with that enzyme, to a possible biallelic pattern.
The haplotype tends to be inherited in a Mendelian fashion allowing the inheritance of 
genes to be monitored. However, the main disadvantage is the low degree of information 
from a biallelic site. This is where the use of microsatellite polymorphism has 
revolutionised the field of DNA analysis. Microsatellites involve the presence of 
dinucleotide or less frequently tri- nucleotide sequences, tandem arranged and each allele is 
defined by the variation of repetitions of the sequence. Their high abundance throughout 
the genome and the large amount of information that is possible to determine, makes them 
ideal candidates for studying allelic variation in genes or loci of interest such as the 
D6S273 locus in this study.
131
Genotype and allelotype (predicted serotypes) data at the DOB1 locus
In the recent past years tissue typing has started to be employed as a standard 
procedure in many types of diseases. Because of the localisation of the HLA DQP1 genes 
to within the MHC class-I and class- II genes and the biological roles of the gene products, 
it is worth considering the expression patterns of the HLA molecules in tumours. Although 
some attempts have been made in the past years to find an association of gastric cancer 
with HLA, only poor associations have been reported. Many of these attempts where 
serologically based, producing non-specific allelic data. Recently, it was mentioned that the 
HLA class II gene DQp 1*0301 was strongly associated with gastric cancer in Caucasians 
(Lee et al., 1996), which is not inconsistent with previous serological reports. However, 
similar recent molecular studies in Japan present no association of DQp 1*0301 with 
gastric cancer in Japanese (Ohmori et al, 1997). Additionally no attempts have been made 
to consider HLA DQ- typing in Barrett’s oesophagus condition in Caucasians and to 
compare such data with a gastric cancer data at the molecular level as we do in this study.
Because a DQpi “low resolution” protocol was employed it is more appropriate to 
present and discuss the results for this locus as a group of allelotypes i.e. predicted 
serotypes. The exact alleles incorporated in each serotype can be seen in Table 2. In our 
study the results for the DQp llocus generally suggest that the heterozygous DQ 2 * 3  
genotype is over expressed among all the test populations tested and the controls. This 
means that the heterozygous DQ 2 * 3  genotype may be of an importance. However, in the 
benign Barrett’s oesophagus population the DQ 2 * 3  presents the highest overexpression, 
where if compared with the control a (11.7%) difference in expresion is present but 
significant association was not found for this genotype. This means that DQ 2 * 3 is not 
involved in the initial stages for the transformation of the normal oesophageal epithelium 
towards pre-malignant conditions. Although a more specific analyses (DQ “High 
resolution” typing) is probably needed for this serotype in order to identify exact allelic
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specificities. Other serotypes such as the heterozygous DQ 3 * 6  and homozygous DQ 3 *
3 are present a secondary character of overexpression, which is means that such secondary 
serotypes could be supportive secondary elements in the transformation process from a 
normal to a pre-malignant condition in Barrett’s oesophagus. However significant 
association was not found. Therefore such genotypic results lead us to the conclusion that 
the DQ 2 * 3 ,  DQ 3 * 6  and DQ 3 * 3 are not significantly involved in Barrett’s 
oesophagus.
The allelotypic (single serotype) expression of this locus presents that the serotype 
DQ 3 is the most commonly expressed in gastric cancer where if compared with the 
controls a difference of (11.3%) is present where significant association was found (Ch2 
=4.133, P=0.0421) This means that this allelotype (single serotype) DQ 3 is probably a 
significant factor that may be involved in the process of gastric carcinogenesis. The 
serotype DQ 3 among to the all the alleles that incorporates (Table 2), it incorporates the 
allele *0301. This means that our results probably are reproducible to those of (Lee et a l, 
1996) but a certain prediction is not possible at this point unless a fine DQpl high 
resolution typing is performed specifically for the only allele *0301.
With regards to the serotype DQ 2 in benign Barrett’s population, the data presents 
that it is the second most expressed serotype among all. However, no significant difference 
is presented among the test populations and in controls and significant association was not 
found. This suggests that the serotype DQ 2 is not an important element in the early stages 
of development of Barrett’s oesophagus or gastric cancer. The serotype DQ 6 in the 
control population presents the highest expresion compared with the three test populations. 
This means that the serotype DQ 6 in Barrett’s oesophagus it may have protective 
properties to the host due to the fact that is probably mutated in the three test populations 
as the low difference in frequencies suggests. However, significant association was not 
found suggesting that this serotype probably is not involved in Barrett’s oesophagus at all.
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In summary our data for this locus suggests, that our results probably are 
reproducible of that of (Lee et al., 1996) regarding susceptibility of the allele *0301 in 
gastric cancer but a certain prediction is not possible at this point unless a fine DQP 1 
typing is performed specifically for the allele *0301. Additionally, that the genotypes 
(combination of serotypes) DQ 2 * 3 ,  DQ 3 * 6  and DQ 3 * 3 are not significantly 
associated with Barrett’s oesophagus at all. Also DQ 2 * 3 is not involved in the initial 
stages for the transformation of the normal oesophageal epithelium to pre-malignant. The 
heterozygous DQ 3 * 6  and homozygous DQ 3 * 3 are not secondary supportive elements 
in the transition from a normal to a pre-malignant condition in Barrett’s oesophagus. The 
DQ 6, alleles (*06011-*0613) does not play a protective part in the development of 
Barrett’s oesophagus whereas the precise identification of specific DQ 6 alleles is not 
possible with a DQ “low resolution” protocol. Finally the serotype DQ 2 present loss of 
expression among the malignant Barrett’s, gastric and control populations and is not 
involved in the initial stages in susceptibility to Barrett’s oesophagus or gastric cancer. It is 
unclear however whether the loss of HLA expresion is due to immune selection or a 
secondary event occurring during tumour progression.
Genotype and allelotype data at the HSP 70-2 locus
The interest in this locus stemmed from it’s positioning between HLA DQp 1 and
TNF loci and from its involvement in carcinogenesis. It is known that HSP expression
induced during the process of cell death. Induction of HSP 70 induces an infiltrate of T
cells, macrophages and predominately dendritic cells into the tumours as well as an
intratumoral profile of Thl cytokine expresion (INF-y, TNF-a, and IL-12) and enhances
immunogenicity via a T cell mediated mechanism. The protection conferred by HSP 70 is
both tumor and cell specific. Additionally HSP 70 targets immature APCs to make them
significantly more able to capture Ags (Todryk et al., 1999). The HSP 70/ HSc70 bind to
BAG-1 proteins that in turn interacts with the Bcl-2, Raf-1, and steroid hormone receptors,
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Shiah-1 and hepatocyte growth factor (HGF) all known to be involved in cell growth and 
cell migration (Naishiro et al., 1999). It has been demonstrated that the complex HSP 70/ 
HSc70 -BAG-1 has a novel function for cell migration in human gastric cancer cells 
possibly through cooperation with cytoskeletal proteins (Naishiro et al., 1999). Moreover 
BAG-1 modulates the activities of p53 proteins and p53-inducible factor Siah-1, and 
steroid hormone receptors (all promoting cell growth and survival) where the HSP 70 
family of molecular chaperones in most cases recognises and bound mutant p53 proteins 
(Fourie et al., 1997) thus acting as tumour development protector. Additionally HSP 70 
can deliver NF-kB, a key transcriptional regulator of inflammatory responses, by binding to 
the p50 subunit of NF-kB a direct to the cytoplasm and nucleus of cells. Then it can bind 
DNA specifically and activate IgK expresion and TNFa (Fujihara et al., 1999). Therefore 
HSP 70 can be used as a vehicle for intracytoplasmic and intranuclear delivery of proteins 
or DNA for modulation of gene expresion. The polymorphic site HSP 70-2 was examined 
in this study by RFLP technique. Further more little work has previously been done on this 
locus with regards to gastric cancer and Barrett’s oesophagus.
The results of the genotype data of this locus, presents the heterozygous genotype 1
* 2 (1117bp-936bp) to be the most commonly expressed among all the other genotypes in
all test populations and the control. This suggests in general terms that the heterozygous
genotype 1 * 2 (1117bp-936bp) may have some importance. More specifically, the
heterozygous genotype 1 * 2 (1117bp-936bp) presents a large difference in frequency of
(31.9%) between the malignant Barrett’s oesophagus and the gastric population but
significant association was not found and thus this genotype is not specifically involved in
either two types of cancer. A difference in frequency of (24.1%) is present between the
malignant Barrett’s oesophagus and the controls where significant association was found
between these two populations (Ch2 =5.468, P =0.0194). These suggest that the
heterozygous genotype 1 * 2 (1 1 17bp-936bp) is actually overexpressed gradually from
normal conditions towards malignancy and cancer. Therefore the protective action of the
135
HSP 70-2 proteins in individuals with this genotype, as described above, is present in 
Barrett’s oesophagus but not in gastric cancer.
With regards to all the homozygous genotypes, the most commonly expressed is the 
2 * 2 (936bp-936bp) among all other genotypes. This means that the homozygous genotype 
is probably important. The homozygous genotype 2 * 2 (936bp-936bp) presents a 
difference of (16.2%) between the malignant Barrett’s oesophagus and the benign Barrett’s 
oesophagus. However, significant association was not found. This means that this 
genotype is overexpressed progressively from pre-malignant conditions towards 
malignancy in Barrett’s oesophagus individuals but is not specifically involved in 
malignant Barrett’s oesophagus. This suggests that the HSP 70 genes are influenced by 
other factors in this case. This progressive overexpression is not seen in gastric cancer 
individuals (gastric cancer 33.3% Vs 34.2% controls) that suggest the HSP 70-2 alleles are 
probably mutated and the protective motif is lost. However significant association was not 
found, which suggests that again HSP 70 genes are influenced by other factors in this case 
too.
The allelotypic expression at this locus presents a similar pattern. The allelotype 2* 
(936bp) is the most commonly expressed in all types of population tested. However, the 
frequency of the allelotype 2* (936bp) in gastric cancer compared with the control is not 
great and significant association was not found. Similarly the difference in frequency of 
the allelotype 2* (936bp) between the two Barrett’s oesophagus and controls is not great 
and again significant association was not found. These findings suggests that the allelotype 
2* (936bp) alone is not associated with gastric cancer individuals and/or Barrett’s 
oesophagus individuals where the protective action of the HSP 70 proteins is probably lost.
In summary the heterozygous genotype 1 * 2 (1 1 17bp-936bp) is actually
overexpressed gradually from normal conditions towards malignancy and cancer.
Therefore the protective action of the HSP 70 proteins as described above is present in
Barrett’s oesophagus but not in gastric cancer. Similarly the homozygous genotype 2 * 2
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(936bp-936bp) is overexpressed progressively from a pre-malignant condition towards 
malignancy in Barrett’s oesophagus individuals but is not specifically involved in 
malignant Barrett’s oesophagus. This suggests that the HSP 70 genes are influenced by 
other factors in this case. This progressive overexpression is not seen in gastric cancer 
individuals that suggest the HSP 70-2 alleles are probably mutated and the protective motif 
is lost. However significant association was not found, which suggests that HSP 70 genes 
are influenced by other factors in this case too.
The allelotypic expression at this locus presents a similar pattern where the 
allelotype 2* (936bp) is not associated with gastric cancer individuals and/or Barrett’s 
oesophagus individuals where the protective action of the HSP 70 proteins is probably lost.
Genotype and allelotype data at the D6S273 microsatellite locus
The interest in this locus stemmed from it’s positioning between HLA DQp 1,HSP 
70 and TNF loci and from its involvement in different types of diseases, including 
autoimmune diseases. The marker D6S273 has been reported to strongly being associated 
with autoimmune diseases such as Ankylosing Spondylitis (AS), as reported by Brown et 
al, (1998) in the British population and in a Canadian population (Singal et al, 1998) and 
that this marker is probably in linkage with other genes within the HLA class III region, 
such as the HSP 70 and with other regions on chromosome 6 (6 p21.3). Microsatellite 
D6S273 and DQ region was found to be involved in susceptibility and protection to IDDM 
in a Belgian population (Moghaddam et al, 1998).
The results of the genotype data for this locus, presents the heterozygous genotype
132bp -  134 bp to be the most common expressed among all the other genotypes in all test
populations and the control. This suggests that this genotype might be important in this
study. The data demonstrates that the highest expresion of the heterozygous genotype
132bp -  134 bp is present in Barrett’s oesophagus. This suggests that this genotype may
have some responsibility for susceptibility to Barrett’s oesophagus. The difference in
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frequency between the malignant Barrett’s oesophagus population and the control 
populations is quite elevated (15.7%) where significant association was found between 
these two populations (Ch =4.510, P =0.0337) suggesting that this genotype presents 
susceptibility to the onset of malignant Barrett’s oesophagus. The difference in frequency 
between the gastric cancer population and the control population is quite elevated (11.9%) 
but significant association was not found, suggesting that this genotype does not present 
susceptibility to the onset of gastric cancer. Also this data suggests that in both cancerous 
populations the genotype 132-134 is overexpressed where in control and in benign (pre- 
malignant) populations this genotype presents low expresion. Therefore the genotype 132- 
134 must some how be involved in susceptibility cancer and specifically to malignant 
Barrett’s oesophagus.
This type of expresion pattern involving the alleles 132 and 134 is also reflected in 
the microsatellite allelotype expression. Generally the allelotype 134 is the most 
commonly expressed among all other types of allelotypes. This suggests that the allelotype 
134 is probably responsible for susceptibility to malignancy. The data obtained show that 
the allelotype 134 presents higher frequency in pre-malignant and malignant conditions 
than in controls. However, these differences are not significantly among all the test 
populations and controls. The most important difference is present between the control and 
the gastric cancer population (11.2%) but significant association was not found, suggesting 
that the allelotype 134 is not responsible for susceptibility to solid tumours and in this case 
gastric cancer.
The allelotype 132 presents higher expresion in malignant Barrett’s population if
compared with the benign Barrett’s population (difference 10.5%) and / or gastric cancer
population (difference 10.8%) but not with the controls. Significant association was not
found among the test populations and the control. This suggests that the allele 132 is
probably not responsible for susceptibility to solid tumours and in this case with malignant
Barrett’s carcinogenesis. The difference in frequency of the control population with the
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gastric cancer population is (9.1%) and significant association was not found. This 
suggests that this allele probably is not responsible for susceptibility to solid tumours and 
in this case with gastric carcinogenesis. Additionally it can be concluded from our data 
that the allele 132 is not involved in the late stages of tumourogenesis (solid tumour stage) 
in gastric and Barrett’s oesophageal cancer. Also according to the data obtained the 
difference in frequency between the control and benign Barrett’s populations (8.9%) 
suggests that the allele 132 is also not involved in the initial steps for the onset of such 
cancers.
In summary among all the allelotypes tested the allelotypes 132 and 134 appears not 
to be susceptible in gastric cancer. Additionally the data show that in both cancerous 
populations the genotype 132-134 is overexpressed where in control and in benign (pre- 
malignant) populations this genotype presents lower expresion. The genotype 132-134 was 
found to present significant association with malignant Barrett’s oesophagus (Ch =4.510,
P =0.0337) this finding leads to the conclusion that the heterozygous genotype 132-134 is 
associated with malignant Barrett’s oesophagus.
HLA DQB1 predicted serotype expresion is not associated with TNFa microsatellites
The localisation of the TNFa microsatellite locus between the MHC class-II and 
class-I genes and the importance of the biological roles of the gene products, is considered 
when looking at expression patterns of the HLA Class-II molecules in tumours and 
associations between these antigens and the TNFa alleles, in gastric cancer and in Barrett’s 
malignant and benign oesophagus conditions. HLA Class-II (DP, DR, DQ) molecules 
present a non-constitutive expresion in most cell types, but physiological inducers such as 
TNF and INFy can induce it. The patterns of expresion of such cell surface molecules 
changes in relation to cell function. A decrease or even complete lost of expresion are 
often associated with carcinogenesis. Furthermore, there seems to be a general lack of 
information available on this front.
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We were able to carry out HLA DQP 1 typing of the three test populations in this 
study. The HLA-B locus is near the TNFa locus and strong linkage would therefore be 
expected, although a wide distribution is present. This means that the HLA-B locus is not 
in linkage with the TNFa locus. The data presents the higher frequency among all of the 
HLA D Q pi- TNFa alleles to be concentrated at DQ2-TNFa2 genotype in all populations 
tested. However, the difference in the frequencies of DQ2-TNFa2 genotype among the test 
populations is extremely low and significant association was not found, indicating that no 
association is present with progression of tumourogenesis.
In summary the results at the HLA DQp 1-TNFa loci obtained indicate a wide 
distribution of the DQpl alleles compared with the TNFa alleles. This suggest that the 
DQpi locus is not in linkage with the TNFa locus and therefore the TNFa locus is an 
independent factor for susceptibility to Barrett’s oesophagus and in gastric cancer. These 
discoveries support the previously reported findings regarding TNFa from our research 
group in GIT carcinogenesis.
HSP 70-2 allelotype expresion is not associated with TNFa microsatellites
These two polymorphic sites are in close approximation to each other. The 
idea therefore to examine the possibility that alleles within these two loci may be in linkage 
was reasonable. Is known that induction of HSP 70 induces an infiltrate of T cells, into the 
tumours as well as an intratumoral profile of Thl cytokine expresion including TNF and 
enhances immunogenicity via a T cell mediated mechanism that leads to the protection 
against tumor development and progression to aggressive tumour stages. Further more, 
there seems to be a general lack of information available on this front.
The data for such comparisons presents that the highest frequencies are
concentrated in the allelotype combination 1*(1117bp)-TNFa2 (23.1%). However, the
difference in the frequencies of 1 *(1117bp)-TNFa2 genotype among the test populations is
extremely low (malignant Barrett’s 21.7% Vs gastric 20%) and significant association was
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not found, indicating that no association is present with progression of tumourogenesis. 
Similarly the data for such comparisons presents that the allelotype combination 
2*(936bp)-TNFal 1 is the second most expressed from all the other genotypes but again the 
difference in the frequencies of 2*(936bp)-TNFal 1 genotype among the test populations is 
extremely low and again significant association was not found, indicating that no 
association is present with progression of tumourogenesis. In addition the 2*(936bp)- 
TNFa2 genotype present an increased expresion in malignant Barrett’s oesophagus 
population (20.0%) compared with the other two test populations (benign Barrett’s 9.6%
Vs gastric 14.2%) but the difference in frequency is not significantly great and significant 
association was not found. These finding suggest that 2*(936bp)-TNFa2 genotype is not 
associated with tumour progression.
In summary the results at the HSP 70-2 -  TNFa loci obtained indicate a wide 
distribution of the HSP70-2 alleles compared with the TNFa alleles. It is well established 
that TNFa is in tight linkage disequilibrium with the HLA class II region - however they 
may have additive or separate effects on disease susceptibility. Again these discoveries 
support previously findings with regards to TNFa within our research group in GIT 
carcinogenesis.
HSP 70-2 allelotype expresion is associated with HLA DQB1 predicted serotype 
expresion
Similarly, these two polymorphic sites share close proximity. The idea 
therefore to examine the possibility that alleles within these two loci may be in linkage 
with each other was reasonable. The importance of the biological roles of the gene products 
of such molecules was to be studied to consider expression patterns of the HLA Class-II 
(DQPI) alleles in tumours and associations between these antigens and the HSP 70-2 
alleles in gastric cancer and in Barrett’s malignant and benign oesophagus conditions.
Again, there is little information available specifically on this subject.
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The data obtained indicates that the genotype of allele 2*(936bp)-DQ 3 presents the 
most common expresion from all the other genotypes and among all populations, which 
means that it might be associated with progression of tumourogenesis. However the results 
indicate that the differences in frequency among the three test populations for this genotype 
are low and significant association was not found, which is means that the genotype 
2*(936bp)-DQ 3 is not associated with any specific type of cancer tested in this study. 
Similarly our data indicates that although the expresion of 1 *(1117bp)-DQ2 genotype 
presents a secondary increased character the differences in frequencies among the three test 
populations are low and significant association was not found. This means that the 
genotype 1*(1117bp)-DQ2 is not associated with any specific type of cancer tested in this 
study. The only difference that is probably respectable is among 2*(936bp)-DQ 2 in 
malignant Barrett’s oesophagus and in gastric cancer (difference of 12.3%) where
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significant association was found (Ch =3.884, P=0.0487). This finding suggests that this 
genotype is associated with susceptibility to malignant Barrett’s oesophagus and / or gastric 
cancer.
In summary the results at the HSP 70-2-DQpi loci obtained indicate a wide 
distribution of the HSP70-2 alleles compared with the DQpi alleles. However, the only 
genotype that is associated with susceptibility to malignant Barrett’s oesophagus and / or 
gastric cancer is 2*(936bp)-DQ 2. This suggests that the HSP70-2 locus is in linkage with 
the DQp Hocus only for the former genotype.
D6S273 microsatellite expresion is not associated with HLA DOB1 predicted serotype 
expresion
These two polymorphic sites are in close proximity to each other. The idea therefore
to examine the possibility that alleles within these two loci may be in linkage was
reasonable. Although this marker it has been reported to be involved in different types of
diseases and to be in linkage with the DR locus. D6S273 microsatellite alleles were found
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to contribute to the genetic risk of IDDM-1, especially the alleles 136 and 140. However, a 
recombination linkage between DQ and TNFa was reported as an additional contributory 
factor in IDDM-1 (Moghaddam et al., (1998). Additionally, the HLA DR and TNFp 
markers have been reported by Haines et al., (1998) to have strong genetic linkage with 
D6S273 marker and the onset of Multiple Sclerosis (MS). In other diseases such that of 
Rheumatoid arthritis (RA) D6S273 is now believed to have an association. Rheumatoid 
arthritis (RA) is a chronic inflammatory disease that is associated with the HLA-DRB1 
genes. A resent study by Signal, D.P. (1998) revealed that two D6S273 microsatellite 
alleles 132 and 138 were significantly associated in Canadian patients with RA. Such 
studies suggest that D6S273 has not an independent association with diseases but probably 
are in strong linkage with other markers within the HLA. D6S273 marker now believed to 
be linked with some types of cancer. An example is that of Mazurenko et aL, (1999) in 
cervical cancer where demonstrated that LOH was observed in the HLA region within the 
marker D6S273 due to deletions of alleles.
The results obtained in our study indicate that the genotype DQ 2-132 in malignant
Barrett’s oesophagus (12.5%) present the highest expresion among the rest test populations
for this genotype (benign 7.7%, gastric 3.1%). However the difference in frequencies is
not great and significant association was not found. This suggests that this genotype do not
contribute to the genetic risk of malignant Barrett’s oesophagus. On the other hand the
genotype DQ 2-134 in benign Barrett’s oesophagus (15.4%) present the highest expresion
among the rest test populations for this genotype (malignant 4.7%, gastric 3.1%). A
difference in frequency of (12.3%) is present between the benign and the gastric population
but significant associations were not found. This suggests that this genotype do not
contribute to the genetic risk of benign Barrett’s oesophagus and that is probably not
involved at the initial stages of carcinogenesis. Additionally the results obtained in our
study indicate that the genotype DQ 3-134 in gastric cancer (18.7%) present the highest
expresion among the rest test populations for this genotype (benign 3.8% Vs malignant
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15.6%). A difference in frequency of (14.9%) is present between the benign and the gastric 
population but significant association was not found. This suggests that this genotype do 
not contribute to the genetic risk of gastric cancer. Also the results indicate that the 
genotype DQ 3-138 in gastric cancer (12.5%) present the highest expresion among the rest 
test populations for this genotype (benign 3.8%, malignant 4.7%). However, the difference 
in frequencies and the fact that significant associations were not found, suggests that this 
genotype do not contribute to the genetic risk of gastric cancer.
In summary the results at the D6S273-DQpl loci obtained indicate that the DQ 2- 
134 do not contribute to the genetic risk of malignant Barrett’s oesophagus. Also that the 
DQ 2-132 genotype do not contribute to the genetic risk of benign Barrett’s oesophagus 
and that is not involved at the initial stages of carcinogenesis. Also that the DQ 3-134 do 
not contribute to the genetic risk of gastric cancer and that the DQ 3-138 genotype do not 
contribute to the genetic risk of gastric cancer too. All these lead to the conclusion that the 
D6S273 locus is not in linkage with the DQP llocus.
HSP 70-2 allelotype expresion is not associated with D6S273 microsatellite expresion
As already mentioned, certain alleles present linkage within the MHC in 
chromosome 6. The two loci of interest at this point are the HSP 70-2 locus compared with 
the D6S273 microsatellite locus looking for linkage between them. Further more, there 
seems to be a general lack of information available on this front.
The data obtained indicates that the genotypes 2*(936bp)-130, 2*(936bp)-132
2*(936bp)-134 present the most reasonable differences among the three test populations
and the controls. More specifically the genotype 2*(936bp)-130 presents the highest
frequency (9.1%) in benign Barrett’s population when compared with the other two test
populations studied (malignant 5.4% Vs gastric 1.6%) and the control (7.1%) but the
difference in the frequencies are not significantly high among them and significant
association was not found. This means that this genotype do not contribute to the genetic
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risk of benign Barrett’s oesophagus and that is probably has a protective motif. On the 
other hand the genotype 2*(936bp)-132 presents higher frequency (17.9%) in malignant 
Barrett’s oesophagus where if compared with the benign Barrett’s (4.5%) the difference in 
frequency present is significantly high (13.4%) but not if compared with the controls 
(19.2%) where significant association was not found. This means that this genotype is not 
associated with malignant Barrett’s oesophagus. The difference in frequency between the 
benign Barrett’s (4.5%) and the controls (19.2%) is significantly elevated (14.1%) but 
significant association was not found. Despite the fact that no association was found, this 
means that the genotype 2*(936bp)-132 is probably mutated in benign Barrett’s 
oesophagus leading to low expresion and therefore the protective motif is lost. This also 
suggests that the genotype 2*(936bp)-132 is probably involved in the initial stages of the 
progression towards malignancy and cancer. Finally the genotype 2*(936bp)-134 presents 
no significantly high difference in frequency among the three populations studied and the 
control and significant association was not found. This means that this genotype does not 
contribute to the genetic susceptibility of any type of cancer tested in this study.
In summary, our findings suggest that none of the genotypes 2*(936bp)-130, 
2*(936bp)-132 and 2*(936bp)-134 contribute to the genetic susceptibility of any type of 
cancer tested.
HLA DOB1 predicted serotype expresion is associated with Barrett’s oesophagus in 
total patient population compared with the controls
In order to assess the possibility whether certain genotypes and allelotypes 
(predicted serotypes) for this locus, in Barrett’s population may present differences in 
frequency with the control population, a comparison was performed considering the two 
different types of Barrett’s population (benign and malignant) as one. The data obtained 
was then compared with the control population.
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The results obtained in our study indicate that the heterozygous genotype DQ 2 * 6  
(presented as serotype) is the most commonly expressed in Barrett’s population. However 
comparing this genotype with the same genotype in the control population the difference in 
frequency is not significantly different and significant association was not found. This 
finding suggests that this genotype is not involved in the genetic susceptibility to Barrett’s 
oesophagus development. Similarly the heterozygous genotype DQ 2 * 3  present high 
expression in control population. However, comparing this genotype with the same 
genotype in the Barrett’s population the difference in frequency is quiet high but not 
significantly different and significant association was not found. This finding suggests that 
this genotype is not involved in the genetic susceptibility to Barrett’s oesophagus 
development. Additionally the heterozygous genotype DQ 3 * 5  present high expression in 
control population. However comparing this genotype with the same genotype in the 
Barrett’s population the difference in frequency is quite high but not significantly different 
and again significant association was not found. This finding suggests that this genotype is 
not involved in the genetic susceptibility to Barrett’s oesophagus development. 
Additionally the heterozygous genotype DQ 3 * 6  present high expression in control 
population. However comparing this genotype with the same genotype in the Barrett’s 
population the difference in frequency is high but not significantly different and significant 
association was not found. This finding suggests that this genotype is not involved in the 
genetic susceptibility to Barrett’s oesophagus development.
A similar expresion pattern is reflected in the allelotype (presented as serotype) DQ
2 and DQ 3 where these are the most expressed allelotypes in Barrett’s population.
However when these allelotypes compared with the same allelotypes in the control
population the difference is not great and significant association was not found. This
means that neither of these two allelotypes is associated in the genetic susceptibility to
Barrett’s oesophagus. Finally the allelotype DQ 6 presents quite high expresion in
Barrett’s oesophagus but if compared with the control the difference in frequency is not
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high. Although significant association was found, (Ch = 5.2740, P=0.0252, this finding 
suggests that this genotype is associated with genetic susceptibility to Barrett’s oesophagus 
development.
In conclusion, our findings suggest that only one of the above allelotypes the DQ 6 
(presented as serotype) is associated with genetic susceptibility to Barrett’s oesophagus. 
Neither of the genotypes tested above are found to be associated with gastric cancer or 
Barrett’s oesophagus development.
HSP 70-2 genotype expresion is not associated with Barrett’s oesophagus in total 
patient population compared with the controls
Again in order to assess the possibility whether certain genotypes and 
allelotypes for this locus, in Barrett’s population may present differences in frequency with 
the control population, a comparison was performed considering the two different types of 
Barrett’s population (benign and malignant) as one. The data obtained was then compared 
with the control population.
The results obtained in our study indicate that the heterozygous genotype 1 * 2 is 
the most commonly expressed in Barrett’s population. However comparing this genotype 
with the same genotype in the control population the difference in frequency is not 
significantly different and significant association was not found. This finding suggests that 
this genotype does not involved in the genetic susceptibility to Barrett’s oesophagus 
development. Similarly the homozygous genotype 1 * 1 presents high expression in 
Barrett’s population. However, comparing this genotype with the same genotype in the 
control population the difference in frequency is quiet high but significant association was 
not found. This finding suggests that this genotype is not associated with the genetic 
susceptibility to Barrett’s oesophagus development.
This pattern is not reflected in the allelotype expresion. The most commonly
expressed among all is the allelotype 2*(936bp) in control population. However compared
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with the 2*(936bp) in Barrett’s population no significant difference was present and 
significant association was not found. This means that this allelotype is not associated with 
the genetic susceptibility to Barrett’s oesophagus development. The same pattern is 
present for the allelotype 1 *(1117bp) which is found not to be associated with Barrett’s 
oesophagus development.
In conclusion, our findings suggest that no one of the above genotypes and 
allelotypes tested associated with the genetic susceptibility of Barrett’s oesophagus.
D6S273 microsatellite expresion is not associated with Barrett’s oesophagus in total 
patient population compared with the controls
Finally in order to assess the possibility whether certain genotypes and 
allelotypes for this locus, in Barrett’s population may present differences in frequency with 
the control population, a comparison was performed considering the two different types of 
Barrett’s population (benign and malignant) as one. The data obtained was then compared 
with the control population.
The results obtained in our study indicate that the heterozygous genotype 132 * 134 
is the most commonly expressed in Barrett’s population. However comparing this 
genotype with the same genotype in the control population the difference in frequency is 
not significantly different and significant association was not found. This finding suggests 
that this genotype does not involved in the genetic susceptibility to Barrett’s oesophagus 
development. Similarly the homozygous genotype 132 * 132 presents high expression in 
control population. However, comparing this genotype with the same genotype in the 
Barrett’s population the difference in frequency is quite high but not significantly different 
and significant association was not found. This finding suggests that this genotype does not 
involved in the genetic susceptibility to Barrett’s oesophagus development.
A similar expresion pattern is reflected in the allelotype expresion where the
allelotypes 132 and 134 in between the two populations are the most expressed allelotypes
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among all. However when these allelotypes are compared with each other between the two 
populations, the difference in frequency is not great and significant association was not 
found. This means that neither of these two allelotypes is associated with the genetic 
susceptibility to Barrett’s oesophagus.
In conclusion, our findings suggest that no one of the above genotypes and 
allelotypes tested associated with the genetic susceptibility of Barrett’s oesophagus.
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Conclusions and prospects
Several points can be concluded from the work undertaken for this study.
Based on evidence suggesting involvement of genetic factors as risk factors for 
gastrointestinal cancers and that limited information is available regarding the precise role 
of various known genetic markers and genetic changes involved in gastrointestinal 
carcinogenesis, it is concluded that it was indeed very important to proceed in the 
determination whether the genetic alterations take place during gastric and oesophageal 
cancer development could be related with control of inflammation.
It can be concluded that allelotyping at the polymorphic sites DQpi, HSP70-2 and 
D6S273 is possible by employing the optimised PCR-based techniques determined in this 
study.
Despite the wide distribution of allelotypes and genotypes among the populations 
tested for each marker it is concluded that significant associations were demonstrated 
among certain genotypes and allelotypes such as in the DQP 1 locus for the DQ 3 serotype 
(gastric cancer Vs controls; P = 0.0421), in the HSP 70-2 locus genotype 1 * 2  (malignant 
Barrett’s Vs controls; P = 0.0194), in the D6S273 locus genotype 132-134 (malignant 
Barrett’s Vs controls; P =0.0337) and the allelotype (serotype) DQ 6 (total Barrett’s 
population Vs controls; P= 0.0252) suggesting their probable involvement in the control of 
inflammation in gastrointestinal cancers.
Also it can be concluded that significant association is present between certain 
allelotypes among certain loci where significant association was discovered between the 
DQpi locus and the HSP 70-2 locus (DQ 2 - HSP (936bp) alleles in gastric population Vs 
controls; P= 0.0487), suggesting their probable involvement in the control of inflammation 
in gastrointestinal cancers.
Additionally, it can be concluded that there is not a defined difference in genotype- 
allelotype distribution and no significant association was discovered among the three loci
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tested compared with the TNFa 1-14 microsatellites. Therefore TNF locus is a primary 
independent locus for susceptibility to Barrett’s oesophagus and probably gastric cancer.
Finally our study leads to the conclusion that the HLA-DQpi and HSP-70-2 loci are 
in linkage with each other for the genotype (DQ 2 - HSP (936bp) in gastric cancer.
The encouraging results that were obtained in this project could lead to the 
development of new immunogenetic therapeutic procedures for Barrett’s oesophagus 
and/or gastric cancer, based on these specific immunogenetic targets (i.e. HLA-DQpi, 
HSP-70-2, and D6S273) their protein products and relative cytokines. With further 
research it may be possible to use the data from this project to study such specific markers 
in greater depth. These results will assist the exploration of novel therapies in order to 
individualise treatment, in relation to specific histological types, depth of invasion of 
gastroesophagial cancers and probable reduction of inflammation. Combination of novel 
and new therapeutic modalities will assist to develop an accurate tailoring to the need of 
patients with gastroesophagial cancers and could minimise the side effects of current 
treatment. The fact that our markers are associated with gastrointestinal cancers, as 
supported by our data, could also encourage further study of other similar markers within 
close proximity to the loci investigated in our study. However, TNFa remains the main 
genetic component for such gastroesophagial cancers and the potential is there to use such 
multifactorial cytokines in the treatment of malignant diseases. Not only will it be possible 
to use this information for therapy but also within research in molecular diagnostics. In the 
future we will be able to diagnose specific cancers in the early stages, using diagnostic 
techniques based on such individual markers. Better treatment and obviously prognosis 
relies upon early and precise diagnosis and better understanding of the characterisation and 
progression of individual cancers.
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APENDIX
APENDIX-I
MATERIALS AND EQUIPMENT
Tris-base
Boric acid ( H 3  B O 3 )
Urea (NH2CO NH2)
Acrylamide (CH2; CH.NH2)
Bis-Acrylamide (CH2: CH.CO.NH) 2CH2) 
Ammonium Persulfate (NH4)2S20 s 
TEMED (C 6H i6H 2)
Acetic acid glacial
Dynal Allset™ SSP-DQ “Low resolution “ sets 
Ampli-Taq™
(lOx) Ampli-Taq Buffer 
Cresol Red (C2i Hi7 O 5  S Na)
Glycerol 
Liquid paraffin
PCT -  225 DNA Engine Tetrad, 96-well 
thermal cycler, Version 3.0
Life Technologies™, UK 
Life Technologies™, UK 
Life Technologies™, UK 
Life Technologies™, UK 
Life Technologies™, UK 
Sigma® Chem. Co.USA 
Sigma® Chem. Co.USA 
Fisher scientific Ltd, UK 
Dynal. Ltd, UK 
Adv. Biotechnologies,UK 
Adv. Biotechnologies, UK 
Sigma® Chem. Co.USA 
W. Ransom & son Plc.UK 
Pinewood Labs, Ltd. UK
MJ-Research. Inc. USA 
Uno-thermoblock™, 96-well thermal cycler (no heated lid) Biometra™ USA
Agarose SEA KEM LE™
Ultra Pure Agarose
Ethidium Bromide
TM
Orange-G (Ci6 H ]0 N2 O 7  S2 Na2) 
Pst-I Restriction Enzyme
FMC® Co. USA 
GIBCO™. BRL. UK 
Sigma® Chem. Co.USA 
Sigma® Chem. Co.USA 
Stratagene. Co. USA
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(lOx) Universal Buffer™
[a32- P] d-CTP (350 MBq / ml-lOmCi /ml) 
hyperLadder-I™
(|>xl74-RF DNA / Hae III 
Formamide (Ultra Pure™)
HSP-70 oligonucleotide primers 
D6S273 oligonucleotide primers 
100 bp DNA Ladder 
EDTA
Stratagene. Co. USA 
Amersam Pharmacia biotech Ltd, UK 
Bioline. Ltd., U.K. 
GIBCO™. BRL. UK 
GIBCO™. BRL. UK 
MWG-Biotech AG, UK 
MWG-Biotech AG, UK 
GIBCO™. BRL. UK 
anaLAR. Co.UK
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